id	sid	tid	token	lemma	pos
ajlm-2018	1	1	abstract	abstract	ADJ
ajlm-2018	1	2	introduction	introduction	NOUN
ajlm-2018	1	3	methods	method	NOUN
ajlm-2018	1	4	results	result	VERB
ajlm-2018	1	5	discussion	discussion	NOUN
ajlm-2018	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2018	1	7	references	reference	NOUN
ajlm-2018	1	8	about	about	ADP
ajlm-2018	1	9	the	the	DET
ajlm-2018	1	10	author(s	author(s	NOUN
ajlm-2018	1	11	)	)	PUNCT
ajlm-2018	1	12	mercy	mercy	NOUN
ajlm-2018	1	13	n.	n.	PROPN
ajlm-2018	1	14	okunorobo	okunorobo	PROPN
ajlm-2018	1	15	department	department	PROPN
ajlm-2018	1	16	of	of	ADP
ajlm-2018	1	17	medical	medical	ADJ
ajlm-2018	1	18	laboratory	laboratory	NOUN
ajlm-2018	1	19	science	science	NOUN
ajlm-2018	1	20	,	,	PUNCT
ajlm-2018	1	21	faculty	faculty	NOUN
ajlm-2018	1	22	of	of	ADP
ajlm-2018	1	23	health	health	NOUN
ajlm-2018	1	24	sciences	sciences	PROPN
ajlm-2018	1	25	and	and	CCONJ
ajlm-2018	1	26	technology	technology	NOUN
ajlm-2018	1	27	,	,	PUNCT
ajlm-2018	1	28	nnamdi	nnamdi	PROPN
ajlm-2018	1	29	azikiwe	azikiwe	PROPN
ajlm-2018	1	30	university	university	PROPN
ajlm-2018	1	31	,	,	PUNCT
ajlm-2018	1	32	awka	awka	NOUN
ajlm-2018	1	33	,	,	PUNCT
ajlm-2018	1	34	nigeria	nigeria	PROPN
ajlm-2018	1	35	nwakasi	nwakasi	PROPN
ajlm-2018	1	36	k.	k.	PROPN
ajlm-2018	1	37	nnamah	nnamah	PROPN
ajlm-2018	1	38	department	department	PROPN
ajlm-2018	1	39	of	of	ADP
ajlm-2018	1	40	chemical	chemical	PROPN
ajlm-2018	1	41	pathology	pathology	PROPN
ajlm-2018	1	42	,	,	PUNCT
ajlm-2018	1	43	faculty	faculty	NOUN
ajlm-2018	1	44	of	of	ADP
ajlm-2018	1	45	clinical	clinical	ADJ
ajlm-2018	1	46	medicine	medicine	NOUN
ajlm-2018	1	47	,	,	PUNCT
ajlm-2018	1	48	nnamdi	nnamdi	PROPN
ajlm-2018	1	49	azikiwe	azikiwe	PROPN
ajlm-2018	1	50	university	university	PROPN
ajlm-2018	1	51	,	,	PUNCT
ajlm-2018	1	52	awka	awka	NOUN
ajlm-2018	1	53	,	,	PUNCT
ajlm-2018	1	54	nigeria	nigeria	PROPN
ajlm-2018	1	55	ugomma	ugomma	PROPN
ajlm-2018	1	56	a.	a.	PROPN
ajlm-2018	1	57	ude	ude	PROPN
ajlm-2018	1	58	department	department	PROPN
ajlm-2018	1	59	of	of	ADP
ajlm-2018	1	60	medical	medical	ADJ
ajlm-2018	1	61	laboratory	laboratory	NOUN
ajlm-2018	1	62	science	science	NOUN
ajlm-2018	1	63	,	,	PUNCT
ajlm-2018	1	64	faculty	faculty	NOUN
ajlm-2018	1	65	of	of	ADP
ajlm-2018	1	66	health	health	NOUN
ajlm-2018	1	67	sciences	sciences	PROPN
ajlm-2018	1	68	and	and	CCONJ
ajlm-2018	1	69	technology	technology	NOUN
ajlm-2018	1	70	,	,	PUNCT
ajlm-2018	1	71	ebonyi	ebonyi	PROPN
ajlm-2018	1	72	state	state	PROPN
ajlm-2018	1	73	university	university	PROPN
ajlm-2018	1	74	,	,	PUNCT
ajlm-2018	1	75	abakaliki	abakaliki	ADJ
ajlm-2018	1	76	,	,	PUNCT
ajlm-2018	1	77	nigeria	nigeria	PROPN
ajlm-2018	1	78	enyioma	enyioma	PROPN
ajlm-2018	1	79	a.	a.	PROPN
ajlm-2018	1	80	ude	ude	PROPN
ajlm-2018	1	81	department	department	PROPN
ajlm-2018	1	82	of	of	ADP
ajlm-2018	1	83	medical	medical	ADJ
ajlm-2018	1	84	laboratory	laboratory	NOUN
ajlm-2018	1	85	science	science	NOUN
ajlm-2018	1	86	,	,	PUNCT
ajlm-2018	1	87	faculty	faculty	NOUN
ajlm-2018	1	88	of	of	ADP
ajlm-2018	1	89	health	health	NOUN
ajlm-2018	1	90	sciences	sciences	PROPN
ajlm-2018	1	91	and	and	CCONJ
ajlm-2018	1	92	technology	technology	NOUN
ajlm-2018	1	93	,	,	PUNCT
ajlm-2018	1	94	nnamdi	nnamdi	PROPN
ajlm-2018	1	95	azikiwe	azikiwe	PROPN
ajlm-2018	1	96	university	university	PROPN
ajlm-2018	1	97	,	,	PUNCT
ajlm-2018	1	98	awka	awka	NOUN
ajlm-2018	1	99	,	,	PUNCT
ajlm-2018	1	100	nigeria	nigeria	PROPN
ajlm-2018	1	101	citation	citation	PROPN
ajlm-2018	1	102	okunorobo	okunorobo	PROPN
ajlm-2018	1	103	mn	mn	PROPN
ajlm-2018	1	104	,	,	PUNCT
ajlm-2018	1	105	nnamah	nnamah	PROPN
ajlm-2018	1	106	nk	nk	PROPN
ajlm-2018	1	107	,	,	PUNCT
ajlm-2018	1	108	ude	ude	PROPN
ajlm-2018	1	109	ua	ua	PROPN
ajlm-2018	1	110	,	,	PUNCT
ajlm-2018	1	111	ude	ude	NOUN
ajlm-2018	1	112	ea	ea	NOUN
ajlm-2018	1	113	.	.	PUNCT
ajlm-2018	2	1	lipids	lipid	NOUN
ajlm-2018	2	2	and	and	CCONJ
ajlm-2018	2	3	apolipoproteins	apolipoprotein	VERB
ajlm-2018	2	4	c	c	PROPN
ajlm-2018	2	5	-	-	PUNCT
ajlm-2018	2	6	iii	iii	NOUN
ajlm-2018	2	7	and	and	CCONJ
ajlm-2018	2	8	e	e	X
ajlm-2018	2	9	among	among	ADP
ajlm-2018	2	10	treatment	treatment	NOUN
ajlm-2018	2	11	-	-	PUNCT
ajlm-2018	2	12	naïve	naïve	ADJ
ajlm-2018	2	13	and	and	CCONJ
ajlm-2018	2	14	treatment	treatment	NOUN
ajlm-2018	2	15	-	-	PUNCT
ajlm-2018	2	16	experienced	experience	VERB
ajlm-2018	2	17	persons	person	NOUN
ajlm-2018	2	18	with	with	ADP
ajlm-2018	2	19	hiv	hiv	PROPN
ajlm-2018	2	20	in	in	ADP
ajlm-2018	2	21	nigeria	nigeria	PROPN
ajlm-2018	2	22	.	.	PUNCT
ajlm-2018	3	1	afr	afr	PROPN
ajlm-2018	3	2	j	j	PROPN
ajlm-2018	3	3	lab	lab	PROPN
ajlm-2018	3	4	med	med	PROPN
ajlm-2018	3	5	.	.	PUNCT
ajlm-2018	4	1	2023;12(1	2023;12(1	NUM
ajlm-2018	4	2	)	)	PUNCT
ajlm-2018	4	3	,	,	PUNCT
ajlm-2018	4	4	a2018	a2018	PROPN
ajlm-2018	4	5	.	.	PUNCT
ajlm-2018	5	1	https://doi.org/10.4102/ajlm.v12i1.2018	https://doi.org/10.4102/ajlm.v12i1.2018	VERB
ajlm-2018	5	2	original	original	ADJ
ajlm-2018	5	3	research	research	NOUN
ajlm-2018	5	4	lipids	lipid	NOUN
ajlm-2018	5	5	and	and	CCONJ
ajlm-2018	5	6	apolipoproteins	apolipoprotein	VERB
ajlm-2018	5	7	c	c	PROPN
ajlm-2018	5	8	-	-	PUNCT
ajlm-2018	5	9	iii	iii	NOUN
ajlm-2018	5	10	and	and	CCONJ
ajlm-2018	5	11	e	e	X
ajlm-2018	5	12	among	among	ADP
ajlm-2018	5	13	treatment	treatment	NOUN
ajlm-2018	5	14	-	-	PUNCT
ajlm-2018	5	15	naïve	naïve	ADJ
ajlm-2018	5	16	and	and	CCONJ
ajlm-2018	5	17	treatment	treatment	NOUN
ajlm-2018	5	18	-	-	PUNCT
ajlm-2018	5	19	experienced	experience	VERB
ajlm-2018	5	20	persons	person	NOUN
ajlm-2018	5	21	with	with	ADP
ajlm-2018	5	22	hiv	hiv	PROPN
ajlm-2018	5	23	in	in	ADP
ajlm-2018	5	24	nigeria	nigeria	PROPN
ajlm-2018	5	25	mercy	mercy	NOUN
ajlm-2018	5	26	n.	n.	PROPN
ajlm-2018	5	27	okunorobo	okunorobo	PROPN
ajlm-2018	5	28	,	,	PUNCT
ajlm-2018	5	29	nwakasi	nwakasi	PROPN
ajlm-2018	5	30	k.	k.	PROPN
ajlm-2018	5	31	nnamah	nnamah	PROPN
ajlm-2018	5	32	,	,	PUNCT
ajlm-2018	5	33	ugomma	ugomma	PROPN
ajlm-2018	5	34	a.	a.	NOUN
ajlm-2018	5	35	ude	ude	NOUN
ajlm-2018	5	36	,	,	PUNCT
ajlm-2018	5	37	enyioma	enyioma	ADJ
ajlm-2018	5	38	a.	a.	NOUN
ajlm-2018	5	39	ude	ude	PROPN
ajlm-2018	5	40	received	receive	VERB
ajlm-2018	5	41	:	:	PUNCT
ajlm-2018	5	42	18	18	NUM
ajlm-2018	5	43	july	july	PROPN
ajlm-2018	5	44	2022	2022	NUM
ajlm-2018	5	45	;	;	PUNCT
ajlm-2018	5	46	accepted	accept	VERB
ajlm-2018	5	47	:	:	PUNCT
ajlm-2018	5	48	12	12	NUM
ajlm-2018	5	49	apr	apr	NOUN
ajlm-2018	5	50	.	.	PUNCT
ajlm-2018	5	51	2023	2023	NUM
ajlm-2018	5	52	;	;	PUNCT
ajlm-2018	5	53	published	publish	VERB
ajlm-2018	5	54	:	:	PUNCT
ajlm-2018	5	55	17	17	NUM
ajlm-2018	5	56	july	july	PROPN
ajlm-2018	5	57	2023	2023	NUM
ajlm-2018	5	58	copyright	copyright	NOUN
ajlm-2018	5	59	:	:	PUNCT
ajlm-2018	5	60	©	©	PROPN
ajlm-2018	5	61	2023	2023	NUM
ajlm-2018	5	62	.	.	PUNCT
ajlm-2018	6	1	the	the	DET
ajlm-2018	6	2	author(s	author(s	NOUN
ajlm-2018	6	3	)	)	PUNCT
ajlm-2018	6	4	.	.	PUNCT
ajlm-2018	7	1	licensee	licensee	NOUN
ajlm-2018	7	2	:	:	PUNCT
ajlm-2018	7	3	aosis	aosis	NOUN
ajlm-2018	7	4	.	.	PUNCT
ajlm-2018	8	1	this	this	PRON
ajlm-2018	8	2	is	be	AUX
ajlm-2018	8	3	an	an	DET
ajlm-2018	8	4	open	open	ADJ
ajlm-2018	8	5	access	access	NOUN
ajlm-2018	8	6	article	article	NOUN
ajlm-2018	8	7	distributed	distribute	VERB
ajlm-2018	8	8	under	under	ADP
ajlm-2018	8	9	the	the	DET
ajlm-2018	8	10	terms	term	NOUN
ajlm-2018	8	11	of	of	ADP
ajlm-2018	8	12	the	the	DET
ajlm-2018	8	13	creative	creative	ADJ
ajlm-2018	8	14	commons	common	NOUN
ajlm-2018	8	15	attribution	attribution	NOUN
ajlm-2018	8	16	license	license	NOUN
ajlm-2018	8	17	,	,	PUNCT
ajlm-2018	8	18	which	which	PRON
ajlm-2018	8	19	permits	permit	VERB
ajlm-2018	8	20	unrestricted	unrestricted	ADJ
ajlm-2018	8	21	use	use	NOUN
ajlm-2018	8	22	,	,	PUNCT
ajlm-2018	8	23	distribution	distribution	NOUN
ajlm-2018	8	24	,	,	PUNCT
ajlm-2018	8	25	and	and	CCONJ
ajlm-2018	8	26	reproduction	reproduction	NOUN
ajlm-2018	8	27	in	in	ADP
ajlm-2018	8	28	any	any	DET
ajlm-2018	8	29	medium	medium	NOUN
ajlm-2018	8	30	,	,	PUNCT
ajlm-2018	8	31	provided	provide	VERB
ajlm-2018	8	32	the	the	DET
ajlm-2018	8	33	original	original	ADJ
ajlm-2018	8	34	work	work	NOUN
ajlm-2018	8	35	is	be	AUX
ajlm-2018	8	36	properly	properly	ADV
ajlm-2018	8	37	cited	cite	VERB
ajlm-2018	8	38	.	.	PUNCT
ajlm-2018	9	1	abstract	abstract	ADJ
ajlm-2018	9	2	background	background	NOUN
ajlm-2018	9	3	:	:	PUNCT
ajlm-2018	9	4	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	9	5	is	be	AUX
ajlm-2018	9	6	a	a	DET
ajlm-2018	9	7	known	know	VERB
ajlm-2018	9	8	cause	cause	NOUN
ajlm-2018	9	9	of	of	ADP
ajlm-2018	9	10	cardiovascular	cardiovascular	ADJ
ajlm-2018	9	11	mortality	mortality	NOUN
ajlm-2018	9	12	.	.	PUNCT
ajlm-2018	10	1	persons	person	NOUN
ajlm-2018	10	2	living	live	VERB
ajlm-2018	10	3	with	with	ADP
ajlm-2018	10	4	hiv	hiv	PROPN
ajlm-2018	10	5	are	be	AUX
ajlm-2018	10	6	at	at	ADP
ajlm-2018	10	7	high	high	ADJ
ajlm-2018	10	8	risk	risk	NOUN
ajlm-2018	10	9	of	of	ADP
ajlm-2018	10	10	developing	develop	VERB
ajlm-2018	10	11	cardiovascular	cardiovascular	ADJ
ajlm-2018	10	12	disease	disease	NOUN
ajlm-2018	10	13	due	due	ADP
ajlm-2018	10	14	to	to	ADP
ajlm-2018	10	15	lipid	lipid	ADJ
ajlm-2018	10	16	metabolism	metabolism	NOUN
ajlm-2018	10	17	disorders	disorder	NOUN
ajlm-2018	10	18	associated	associate	VERB
ajlm-2018	10	19	with	with	ADP
ajlm-2018	10	20	hiv	hiv	PROPN
ajlm-2018	10	21	or	or	CCONJ
ajlm-2018	10	22	its	its	PRON
ajlm-2018	10	23	therapy	therapy	NOUN
ajlm-2018	10	24	.	.	PUNCT
ajlm-2018	11	1	objective	objective	NOUN
ajlm-2018	11	2	:	:	PUNCT
ajlm-2018	11	3	this	this	DET
ajlm-2018	11	4	study	study	NOUN
ajlm-2018	11	5	evaluated	evaluate	VERB
ajlm-2018	11	6	concentrations	concentration	NOUN
ajlm-2018	11	7	of	of	ADP
ajlm-2018	11	8	lipoproteins	lipoprotein	NOUN
ajlm-2018	11	9	and	and	CCONJ
ajlm-2018	11	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	11	11	c	c	NOUN
ajlm-2018	11	12	-	-	PUNCT
ajlm-2018	11	13	iii	iii	NOUN
ajlm-2018	11	14	and	and	CCONJ
ajlm-2018	11	15	e	e	NOUN
ajlm-2018	11	16	,	,	PUNCT
ajlm-2018	11	17	as	as	ADP
ajlm-2018	11	18	a	a	DET
ajlm-2018	11	19	way	way	NOUN
ajlm-2018	11	20	of	of	ADP
ajlm-2018	11	21	assessing	assess	VERB
ajlm-2018	11	22	cardiometabolic	cardiometabolic	NOUN
ajlm-2018	11	23	risks	risk	NOUN
ajlm-2018	11	24	among	among	ADP
ajlm-2018	11	25	hiv	hiv	PROPN
ajlm-2018	11	26	patients	patient	NOUN
ajlm-2018	11	27	.	.	PUNCT
ajlm-2018	12	1	methods	method	NOUN
ajlm-2018	12	2	:	:	PUNCT
ajlm-2018	12	3	we	we	PRON
ajlm-2018	12	4	enrolled	enrol	VERB
ajlm-2018	12	5	50	50	NUM
ajlm-2018	12	6	hiv	hiv	NOUN
ajlm-2018	12	7	-	-	PUNCT
ajlm-2018	12	8	negative	negative	ADJ
ajlm-2018	12	9	persons	person	NOUN
ajlm-2018	12	10	and	and	CCONJ
ajlm-2018	12	11	100	100	NUM
ajlm-2018	12	12	hiv	hiv	NOUN
ajlm-2018	12	13	-	-	PUNCT
ajlm-2018	12	14	positive	positive	ADJ
ajlm-2018	12	15	patients	patient	NOUN
ajlm-2018	12	16	,	,	PUNCT
ajlm-2018	12	17	50	50	NUM
ajlm-2018	12	18	on	on	ADP
ajlm-2018	12	19	antiretroviral	antiretroviral	ADJ
ajlm-2018	12	20	therapy	therapy	NOUN
ajlm-2018	12	21	(	(	PUNCT
ajlm-2018	12	22	art	art	NOUN
ajlm-2018	12	23	)	)	PUNCT
ajlm-2018	12	24	and	and	CCONJ
ajlm-2018	12	25	50	50	NUM
ajlm-2018	12	26	treatment	treatment	NOUN
ajlm-2018	12	27	-	-	PUNCT
ajlm-2018	12	28	naïve	naïve	ADJ
ajlm-2018	12	29	persons	person	NOUN
ajlm-2018	12	30	,	,	PUNCT
ajlm-2018	12	31	from	from	ADP
ajlm-2018	12	32	the	the	DET
ajlm-2018	12	33	central	central	ADJ
ajlm-2018	12	34	hospital	hospital	NOUN
ajlm-2018	12	35	and	and	CCONJ
ajlm-2018	12	36	the	the	DET
ajlm-2018	12	37	stella	stella	PROPN
ajlm-2018	12	38	obasanjo	obasanjo	PROPN
ajlm-2018	12	39	hospital	hospital	PROPN
ajlm-2018	12	40	,	,	PUNCT
ajlm-2018	12	41	benin	benin	PROPN
ajlm-2018	12	42	city	city	PROPN
ajlm-2018	12	43	,	,	PUNCT
ajlm-2018	12	44	edo	edo	PROPN
ajlm-2018	12	45	state	state	PROPN
ajlm-2018	12	46	,	,	PUNCT
ajlm-2018	12	47	nigeria	nigeria	PROPN
ajlm-2018	12	48	,	,	PUNCT
ajlm-2018	12	49	between	between	ADP
ajlm-2018	12	50	may	may	PROPN
ajlm-2018	12	51	2015	2015	NUM
ajlm-2018	12	52	and	and	CCONJ
ajlm-2018	12	53	november	november	PROPN
ajlm-2018	12	54	2015	2015	NUM
ajlm-2018	12	55	.	.	PUNCT
ajlm-2018	13	1	participants	participant	NOUN
ajlm-2018	13	2	with	with	ADP
ajlm-2018	13	3	a	a	DET
ajlm-2018	13	4	history	history	NOUN
ajlm-2018	13	5	of	of	ADP
ajlm-2018	13	6	metabolic	metabolic	NOUN
ajlm-2018	13	7	abnormalities	abnormality	NOUN
ajlm-2018	13	8	were	be	AUX
ajlm-2018	13	9	excluded	exclude	VERB
ajlm-2018	13	10	.	.	PUNCT
ajlm-2018	14	1	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	14	2	were	be	AUX
ajlm-2018	14	3	assessed	assess	VERB
ajlm-2018	14	4	by	by	ADP
ajlm-2018	14	5	enzyme	enzyme	NOUN
ajlm-2018	14	6	-	-	PUNCT
ajlm-2018	14	7	linked	link	VERB
ajlm-2018	14	8	immunosorbent	immunosorbent	NOUN
ajlm-2018	14	9	assay	assay	ADV
ajlm-2018	14	10	,	,	PUNCT
ajlm-2018	14	11	while	while	SCONJ
ajlm-2018	14	12	lipids	lipid	NOUN
ajlm-2018	14	13	were	be	AUX
ajlm-2018	14	14	measured	measure	VERB
ajlm-2018	14	15	by	by	ADP
ajlm-2018	14	16	spectrophotometry	spectrophotometry	NOUN
ajlm-2018	14	17	.	.	PUNCT
ajlm-2018	15	1	results	result	NOUN
ajlm-2018	15	2	:	:	PUNCT
ajlm-2018	15	3	there	there	PRON
ajlm-2018	15	4	were	be	VERB
ajlm-2018	15	5	significant	significant	ADJ
ajlm-2018	15	6	abnormalities	abnormality	NOUN
ajlm-2018	15	7	in	in	ADP
ajlm-2018	15	8	the	the	DET
ajlm-2018	15	9	lipid	lipid	NOUN
ajlm-2018	15	10	profile	profile	NOUN
ajlm-2018	15	11	of	of	ADP
ajlm-2018	15	12	patients	patient	NOUN
ajlm-2018	15	13	with	with	ADP
ajlm-2018	15	14	hiv	hiv	PROPN
ajlm-2018	15	15	.	.	PUNCT
ajlm-2018	16	1	triglycerides	triglyceride	NOUN
ajlm-2018	16	2	levels	level	NOUN
ajlm-2018	16	3	of	of	ADP
ajlm-2018	16	4	hiv	hiv	PROPN
ajlm-2018	16	5	patients	patient	NOUN
ajlm-2018	16	6	(	(	PUNCT
ajlm-2018	16	7	art	art	NOUN
ajlm-2018	16	8	-	-	PUNCT
ajlm-2018	16	9	naïve	naïve	ADJ
ajlm-2018	16	10	:	:	PUNCT
ajlm-2018	16	11	1.44	1.44	NUM
ajlm-2018	16	12	±	±	NUM
ajlm-2018	16	13	0.65	0.65	NUM
ajlm-2018	16	14	mmol	mmol	NOUN
ajlm-2018	16	15	/	/	SYM
ajlm-2018	16	16	l	l	NOUN
ajlm-2018	16	17	;	;	PUNCT
ajlm-2018	16	18	p	p	X
ajlm-2018	16	19	<	<	X
ajlm-2018	16	20	0.001	0.001	NUM
ajlm-2018	16	21	and	and	CCONJ
ajlm-2018	16	22	art	art	NOUN
ajlm-2018	16	23	-	-	PUNCT
ajlm-2018	16	24	experienced	experienced	ADJ
ajlm-2018	16	25	:	:	PUNCT
ajlm-2018	16	26	1.49	1.49	NUM
ajlm-2018	16	27	±	±	NUM
ajlm-2018	16	28	0.70	0.70	NUM
ajlm-2018	16	29	mmol	mmol	NOUN
ajlm-2018	16	30	/	/	SYM
ajlm-2018	16	31	l	l	NOUN
ajlm-2018	16	32	;	;	PUNCT
ajlm-2018	16	33	p	p	X
ajlm-2018	16	34	=	=	NOUN
ajlm-2018	16	35	0.001	0.001	NUM
ajlm-2018	16	36	)	)	PUNCT
ajlm-2018	16	37	were	be	AUX
ajlm-2018	16	38	significantly	significantly	ADV
ajlm-2018	16	39	higher	high	ADJ
ajlm-2018	16	40	than	than	ADP
ajlm-2018	16	41	among	among	ADP
ajlm-2018	16	42	controls	control	NOUN
ajlm-2018	16	43	(	(	PUNCT
ajlm-2018	16	44	0.95	0.95	NUM
ajlm-2018	16	45	±	±	NUM
ajlm-2018	16	46	0.54	0.54	NUM
ajlm-2018	16	47	mmol	mmol	NOUN
ajlm-2018	16	48	/	/	SYM
ajlm-2018	16	49	l	l	NOUN
ajlm-2018	16	50	)	)	PUNCT
ajlm-2018	16	51	.	.	PUNCT
ajlm-2018	17	1	hiv	hiv	PROPN
ajlm-2018	17	2	patients	patient	NOUN
ajlm-2018	17	3	had	have	VERB
ajlm-2018	17	4	higher	high	ADJ
ajlm-2018	17	5	concentrations	concentration	NOUN
ajlm-2018	17	6	of	of	ADP
ajlm-2018	17	7	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	17	8	c	c	PROPN
ajlm-2018	17	9	-	-	PUNCT
ajlm-2018	17	10	iii	iii	NOUN
ajlm-2018	17	11	than	than	ADP
ajlm-2018	17	12	controls	control	NOUN
ajlm-2018	17	13	(	(	PUNCT
ajlm-2018	17	14	p	p	X
ajlm-2018	17	15	<	<	X
ajlm-2018	17	16	0.001	0.001	NUM
ajlm-2018	17	17	)	)	PUNCT
ajlm-2018	17	18	and	and	CCONJ
ajlm-2018	17	19	higher	high	ADJ
ajlm-2018	17	20	low	low	ADJ
ajlm-2018	17	21	-	-	PUNCT
ajlm-2018	17	22	density	density	NOUN
ajlm-2018	17	23	lipoprotein	lipoprotein	ADJ
ajlm-2018	17	24	cholesterol	cholesterol	NOUN
ajlm-2018	17	25	levels	level	NOUN
ajlm-2018	17	26	(	(	PUNCT
ajlm-2018	17	27	treatment	treatment	NOUN
ajlm-2018	17	28	-	-	PUNCT
ajlm-2018	17	29	naïve	naïve	ADJ
ajlm-2018	17	30	:	:	PUNCT
ajlm-2018	17	31	2.83	2.83	NUM
ajlm-2018	17	32	mmol	mmol	NOUN
ajlm-2018	17	33	/	/	SYM
ajlm-2018	17	34	l	l	NOUN
ajlm-2018	17	35	and	and	CCONJ
ajlm-2018	17	36	art	art	NOUN
ajlm-2018	17	37	-	-	PUNCT
ajlm-2018	17	38	experienced	experience	VERB
ajlm-2018	17	39	patients	patient	NOUN
ajlm-2018	17	40	:	:	PUNCT
ajlm-2018	17	41	3.59	3.59	NUM
ajlm-2018	17	42	mmol	mmol	NOUN
ajlm-2018	17	43	/	/	SYM
ajlm-2018	17	44	l	l	NOUN
ajlm-2018	17	45	)	)	PUNCT
ajlm-2018	17	46	than	than	ADP
ajlm-2018	17	47	controls	control	NOUN
ajlm-2018	17	48	(	(	PUNCT
ajlm-2018	17	49	2.50	2.50	NUM
ajlm-2018	17	50	mmol	mmol	NOUN
ajlm-2018	17	51	/	/	SYM
ajlm-2018	17	52	l	l	NOUN
ajlm-2018	17	53	;	;	PUNCT
ajlm-2018	17	54	p	p	X
ajlm-2018	17	55	=	=	NOUN
ajlm-2018	17	56	0.003	0.003	NUM
ajlm-2018	17	57	)	)	PUNCT
ajlm-2018	17	58	.	.	PUNCT
ajlm-2018	18	1	conversely	conversely	ADV
ajlm-2018	18	2	,	,	PUNCT
ajlm-2018	18	3	hiv	hiv	PROPN
ajlm-2018	18	4	patients	patient	NOUN
ajlm-2018	18	5	had	have	AUX
ajlm-2018	18	6	significantly	significantly	ADV
ajlm-2018	18	7	lowered	lower	VERB
ajlm-2018	18	8	high	high	ADJ
ajlm-2018	18	9	-	-	PUNCT
ajlm-2018	18	10	density	density	NOUN
ajlm-2018	18	11	lipoprotein	lipoprotein	ADJ
ajlm-2018	18	12	cholesterol	cholesterol	NOUN
ajlm-2018	18	13	levels	level	NOUN
ajlm-2018	18	14	compared	compare	VERB
ajlm-2018	18	15	to	to	ADP
ajlm-2018	18	16	controls	control	NOUN
ajlm-2018	18	17	(	(	PUNCT
ajlm-2018	18	18	p	p	X
ajlm-2018	18	19	<	<	X
ajlm-2018	18	20	0.001	0.001	NUM
ajlm-2018	18	21	)	)	PUNCT
ajlm-2018	18	22	.	.	PUNCT
ajlm-2018	19	1	conclusion	conclusion	NOUN
ajlm-2018	19	2	:	:	PUNCT
ajlm-2018	19	3	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	19	4	was	be	AUX
ajlm-2018	19	5	observed	observe	VERB
ajlm-2018	19	6	among	among	ADP
ajlm-2018	19	7	hiv	hiv	PROPN
ajlm-2018	19	8	participants	participant	NOUN
ajlm-2018	19	9	,	,	PUNCT
ajlm-2018	19	10	irrespective	irrespective	ADV
ajlm-2018	19	11	of	of	ADP
ajlm-2018	19	12	their	their	PRON
ajlm-2018	19	13	art	art	NOUN
ajlm-2018	19	14	experience	experience	NOUN
ajlm-2018	19	15	.	.	PUNCT
ajlm-2018	20	1	therefore	therefore	ADV
ajlm-2018	20	2	,	,	PUNCT
ajlm-2018	20	3	it	it	PRON
ajlm-2018	20	4	is	be	AUX
ajlm-2018	20	5	crucial	crucial	ADJ
ajlm-2018	20	6	that	that	SCONJ
ajlm-2018	20	7	the	the	DET
ajlm-2018	20	8	lipids	lipid	NOUN
ajlm-2018	20	9	of	of	ADP
ajlm-2018	20	10	hiv	hiv	PROPN
ajlm-2018	20	11	patients	patient	NOUN
ajlm-2018	20	12	be	be	AUX
ajlm-2018	20	13	closely	closely	ADV
ajlm-2018	20	14	monitored	monitor	VERB
ajlm-2018	20	15	to	to	PART
ajlm-2018	20	16	enable	enable	VERB
ajlm-2018	20	17	early	early	ADJ
ajlm-2018	20	18	intervention	intervention	NOUN
ajlm-2018	20	19	and	and	CCONJ
ajlm-2018	20	20	decrease	decrease	VERB
ajlm-2018	20	21	cardiovascular	cardiovascular	ADJ
ajlm-2018	20	22	death	death	NOUN
ajlm-2018	20	23	.	.	PUNCT
ajlm-2018	21	1	what	what	PRON
ajlm-2018	21	2	this	this	DET
ajlm-2018	21	3	study	study	NOUN
ajlm-2018	21	4	adds	add	VERB
ajlm-2018	21	5	:	:	PUNCT
ajlm-2018	21	6	this	this	DET
ajlm-2018	21	7	study	study	NOUN
ajlm-2018	21	8	affirms	affirm	VERB
ajlm-2018	21	9	that	that	SCONJ
ajlm-2018	21	10	dyslipidemia	dyslipidemia	NOUN
ajlm-2018	21	11	is	be	AUX
ajlm-2018	21	12	a	a	DET
ajlm-2018	21	13	complication	complication	NOUN
ajlm-2018	21	14	of	of	ADP
ajlm-2018	21	15	hiv	hiv	PROPN
ajlm-2018	21	16	or	or	CCONJ
ajlm-2018	21	17	the	the	DET
ajlm-2018	21	18	prolonged	prolonged	ADJ
ajlm-2018	21	19	use	use	NOUN
ajlm-2018	21	20	of	of	ADP
ajlm-2018	21	21	art	art	NOUN
ajlm-2018	21	22	.	.	PUNCT
ajlm-2018	22	1	keywords	keyword	NOUN
ajlm-2018	22	2	:	:	PUNCT
ajlm-2018	22	3	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	22	4	;	;	PUNCT
ajlm-2018	22	5	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	22	6	c	c	PROPN
ajlm-2018	22	7	-	-	PUNCT
ajlm-2018	22	8	iii	iii	NOUN
ajlm-2018	22	9	;	;	PUNCT
ajlm-2018	22	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	22	11	e	e	PROPN
ajlm-2018	22	12	;	;	PUNCT
ajlm-2018	22	13	hiv	hiv	PROPN
ajlm-2018	22	14	;	;	PUNCT
ajlm-2018	22	15	antiretroviral	antiretroviral	ADJ
ajlm-2018	22	16	therapy	therapy	NOUN
ajlm-2018	22	17	;	;	PUNCT
ajlm-2018	22	18	cardiometabolic	cardiometabolic	NOUN
ajlm-2018	22	19	disorders	disorder	NOUN
ajlm-2018	22	20	;	;	PUNCT
ajlm-2018	22	21	lipid	lipid	NOUN
ajlm-2018	22	22	profile	profile	NOUN
ajlm-2018	22	23	.	.	PUNCT
ajlm-2018	23	1	introduction	introduction	NOUN
ajlm-2018	23	2	hiv	hiv	PROPN
ajlm-2018	23	3	is	be	AUX
ajlm-2018	23	4	a	a	DET
ajlm-2018	23	5	global	global	ADJ
ajlm-2018	23	6	pandemic	pandemic	NOUN
ajlm-2018	23	7	associated	associate	VERB
ajlm-2018	23	8	with	with	ADP
ajlm-2018	23	9	aberrations	aberration	NOUN
ajlm-2018	23	10	in	in	ADP
ajlm-2018	23	11	the	the	DET
ajlm-2018	23	12	immune	immune	ADJ
ajlm-2018	23	13	system	system	NOUN
ajlm-2018	23	14	and	and	CCONJ
ajlm-2018	23	15	biochemical	biochemical	ADJ
ajlm-2018	23	16	parameters	parameter	NOUN
ajlm-2018	23	17	,	,	PUNCT
ajlm-2018	23	18	which	which	PRON
ajlm-2018	23	19	increases	increase	VERB
ajlm-2018	23	20	the	the	DET
ajlm-2018	23	21	vulnerability	vulnerability	NOUN
ajlm-2018	23	22	of	of	ADP
ajlm-2018	23	23	the	the	DET
ajlm-2018	23	24	infected	infected	ADJ
ajlm-2018	23	25	individual	individual	NOUN
ajlm-2018	23	26	to	to	ADP
ajlm-2018	23	27	diseases.1,2	diseases.1,2	ADJ
ajlm-2018	23	28	according	accord	VERB
ajlm-2018	23	29	to	to	ADP
ajlm-2018	23	30	the	the	DET
ajlm-2018	23	31	nigeria	nigeria	PROPN
ajlm-2018	23	32	hiv	hiv	PROPN
ajlm-2018	23	33	/	/	SYM
ajlm-2018	23	34	aids	aids	PROPN
ajlm-2018	23	35	indicator	indicator	NOUN
ajlm-2018	23	36	and	and	CCONJ
ajlm-2018	23	37	impact	impact	NOUN
ajlm-2018	23	38	survey	survey	NOUN
ajlm-2018	23	39	,	,	PUNCT
ajlm-2018	23	40	hiv	hiv	PROPN
ajlm-2018	23	41	is	be	AUX
ajlm-2018	23	42	highly	highly	ADV
ajlm-2018	23	43	prevalent	prevalent	ADJ
ajlm-2018	23	44	among	among	ADP
ajlm-2018	23	45	adults	adult	NOUN
ajlm-2018	23	46	in	in	ADP
ajlm-2018	23	47	the	the	DET
ajlm-2018	23	48	south	south	ADJ
ajlm-2018	23	49	-	-	PUNCT
ajlm-2018	23	50	south	south	NOUN
ajlm-2018	23	51	region	region	NOUN
ajlm-2018	23	52	of	of	ADP
ajlm-2018	23	53	nigeria.3	nigeria.3	NOUN
ajlm-2018	23	54	the	the	DET
ajlm-2018	23	55	use	use	NOUN
ajlm-2018	23	56	of	of	ADP
ajlm-2018	23	57	antiretroviral	antiretroviral	ADJ
ajlm-2018	23	58	therapy	therapy	NOUN
ajlm-2018	23	59	(	(	PUNCT
ajlm-2018	23	60	art	art	NOUN
ajlm-2018	23	61	)	)	PUNCT
ajlm-2018	23	62	in	in	ADP
ajlm-2018	23	63	the	the	DET
ajlm-2018	23	64	management	management	NOUN
ajlm-2018	23	65	of	of	ADP
ajlm-2018	23	66	hiv	hiv	PROPN
ajlm-2018	23	67	has	have	AUX
ajlm-2018	23	68	improved	improve	VERB
ajlm-2018	23	69	the	the	DET
ajlm-2018	23	70	life	life	NOUN
ajlm-2018	23	71	expectancy	expectancy	NOUN
ajlm-2018	23	72	of	of	ADP
ajlm-2018	23	73	persons	person	NOUN
ajlm-2018	23	74	living	live	VERB
ajlm-2018	23	75	with	with	ADP
ajlm-2018	23	76	hiv4	hiv4	NOUN
ajlm-2018	23	77	but	but	CCONJ
ajlm-2018	23	78	has	have	AUX
ajlm-2018	23	79	also	also	ADV
ajlm-2018	23	80	been	be	AUX
ajlm-2018	23	81	associated	associate	VERB
ajlm-2018	23	82	with	with	ADP
ajlm-2018	23	83	an	an	DET
ajlm-2018	23	84	increased	increase	VERB
ajlm-2018	23	85	risk	risk	NOUN
ajlm-2018	23	86	of	of	ADP
ajlm-2018	23	87	metabolic	metabolic	NOUN
ajlm-2018	23	88	abnormalities	abnormality	NOUN
ajlm-2018	23	89	,	,	PUNCT
ajlm-2018	23	90	including	include	VERB
ajlm-2018	23	91	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	23	92	and	and	CCONJ
ajlm-2018	23	93	cardiovascular	cardiovascular	ADJ
ajlm-2018	23	94	death.5,6,7	death.5,6,7	VERB
ajlm-2018	23	95	a	a	DET
ajlm-2018	23	96	higher	high	ADJ
ajlm-2018	23	97	burden	burden	NOUN
ajlm-2018	23	98	of	of	ADP
ajlm-2018	23	99	cardiovascular	cardiovascular	ADJ
ajlm-2018	23	100	disease	disease	NOUN
ajlm-2018	23	101	has	have	AUX
ajlm-2018	23	102	been	be	AUX
ajlm-2018	23	103	reported	report	VERB
ajlm-2018	23	104	among	among	ADP
ajlm-2018	23	105	hiv	hiv	PROPN
ajlm-2018	23	106	patients	patient	NOUN
ajlm-2018	23	107	on	on	ADP
ajlm-2018	23	108	highly	highly	ADV
ajlm-2018	23	109	active	active	ADJ
ajlm-2018	23	110	antiretroviral	antiretroviral	ADJ
ajlm-2018	23	111	therapy	therapy	NOUN
ajlm-2018	23	112	treatment	treatment	NOUN
ajlm-2018	23	113	compared	compare	VERB
ajlm-2018	23	114	to	to	ADP
ajlm-2018	23	115	highly	highly	ADV
ajlm-2018	23	116	active	active	ADJ
ajlm-2018	23	117	antiretroviral	antiretroviral	ADJ
ajlm-2018	23	118	therapy	therapy	NOUN
ajlm-2018	23	119	-	-	PUNCT
ajlm-2018	23	120	naïve	naïve	ADJ
ajlm-2018	23	121	patients.8	patients.8	PROPN
ajlm-2018	23	122	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	23	123	refers	refer	VERB
ajlm-2018	23	124	to	to	ADP
ajlm-2018	23	125	abnormal	abnormal	ADJ
ajlm-2018	23	126	plasma	plasma	NOUN
ajlm-2018	23	127	lipid	lipid	NOUN
ajlm-2018	23	128	concentrations	concentration	NOUN
ajlm-2018	23	129	,	,	PUNCT
ajlm-2018	23	130	including	include	VERB
ajlm-2018	23	131	elevated	elevated	ADJ
ajlm-2018	23	132	plasma	plasma	NOUN
ajlm-2018	23	133	total	total	NOUN
ajlm-2018	23	134	cholesterol	cholesterol	NOUN
ajlm-2018	23	135	,	,	PUNCT
ajlm-2018	23	136	low	low	ADJ
ajlm-2018	23	137	-	-	PUNCT
ajlm-2018	23	138	density	density	NOUN
ajlm-2018	23	139	lipoprotein	lipoprotein	ADJ
ajlm-2018	23	140	cholesterol	cholesterol	NOUN
ajlm-2018	23	141	(	(	PUNCT
ajlm-2018	23	142	ldl	ldl	NOUN
ajlm-2018	23	143	-	-	PUNCT
ajlm-2018	23	144	c	c	NOUN
ajlm-2018	23	145	)	)	PUNCT
ajlm-2018	23	146	,	,	PUNCT
ajlm-2018	23	147	triglycerides	triglyceride	NOUN
ajlm-2018	23	148	,	,	PUNCT
ajlm-2018	23	149	and	and	CCONJ
ajlm-2018	23	150	reduced	reduce	VERB
ajlm-2018	23	151	high	high	ADJ
ajlm-2018	23	152	-	-	PUNCT
ajlm-2018	23	153	density	density	NOUN
ajlm-2018	23	154	lipoprotein	lipoprotein	ADJ
ajlm-2018	23	155	cholesterol	cholesterol	NOUN
ajlm-2018	23	156	(	(	PUNCT
ajlm-2018	23	157	hdl	hdl	NOUN
ajlm-2018	23	158	-	-	PUNCT
ajlm-2018	23	159	c	c	NOUN
ajlm-2018	23	160	)	)	PUNCT
ajlm-2018	23	161	.	.	PUNCT
ajlm-2018	24	1	these	these	PRON
ajlm-2018	24	2	could	could	AUX
ajlm-2018	24	3	occur	occur	VERB
ajlm-2018	24	4	as	as	SCONJ
ajlm-2018	24	5	single	single	ADJ
ajlm-2018	24	6	entities	entity	NOUN
ajlm-2018	24	7	or	or	CCONJ
ajlm-2018	24	8	in	in	ADP
ajlm-2018	24	9	combination.9,10	combination.9,10	NOUN
ajlm-2018	24	10	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	24	11	is	be	AUX
ajlm-2018	24	12	a	a	DET
ajlm-2018	24	13	known	known	ADJ
ajlm-2018	24	14	predictor	predictor	NOUN
ajlm-2018	24	15	of	of	ADP
ajlm-2018	24	16	endothelial	endothelial	ADJ
ajlm-2018	24	17	dysfunction	dysfunction	NOUN
ajlm-2018	24	18	,	,	PUNCT
ajlm-2018	24	19	cardiovascular	cardiovascular	ADJ
ajlm-2018	24	20	disease	disease	NOUN
ajlm-2018	24	21	,	,	PUNCT
ajlm-2018	24	22	and	and	CCONJ
ajlm-2018	24	23	atherosclerosis	atherosclerosis	NOUN
ajlm-2018	24	24	.	.	PUNCT
ajlm-2018	25	1	it	it	PRON
ajlm-2018	25	2	is	be	AUX
ajlm-2018	25	3	a	a	DET
ajlm-2018	25	4	common	common	ADJ
ajlm-2018	25	5	non	non	ADJ
ajlm-2018	25	6	-	-	ADJ
ajlm-2018	25	7	communicable	communicable	ADJ
ajlm-2018	25	8	disease	disease	NOUN
ajlm-2018	25	9	among	among	ADP
ajlm-2018	25	10	persons	person	NOUN
ajlm-2018	25	11	living	live	VERB
ajlm-2018	25	12	with	with	ADP
ajlm-2018	25	13	hiv	hiv	PROPN
ajlm-2018	25	14	.	.	PUNCT
ajlm-2018	26	1	thirty	thirty	NUM
ajlm-2018	26	2	percent	percent	NOUN
ajlm-2018	26	3	of	of	ADP
ajlm-2018	26	4	persons	person	NOUN
ajlm-2018	26	5	living	live	VERB
ajlm-2018	26	6	with	with	ADP
ajlm-2018	26	7	hiv	hiv	PROPN
ajlm-2018	26	8	have	have	AUX
ajlm-2018	26	9	been	be	AUX
ajlm-2018	26	10	reported	report	VERB
ajlm-2018	26	11	to	to	PART
ajlm-2018	26	12	have	have	VERB
ajlm-2018	26	13	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	26	14	.	.	PUNCT
ajlm-2018	27	1	the	the	DET
ajlm-2018	27	2	use	use	NOUN
ajlm-2018	27	3	of	of	ADP
ajlm-2018	27	4	art	art	NOUN
ajlm-2018	27	5	may	may	AUX
ajlm-2018	27	6	contribute	contribute	VERB
ajlm-2018	27	7	to	to	ADP
ajlm-2018	27	8	the	the	DET
ajlm-2018	27	9	development	development	NOUN
ajlm-2018	27	10	of	of	ADP
ajlm-2018	27	11	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	27	12	in	in	ADP
ajlm-2018	27	13	persons	person	NOUN
ajlm-2018	27	14	living	live	VERB
ajlm-2018	27	15	with	with	ADP
ajlm-2018	27	16	hiv.8	hiv.8	PROPN
ajlm-2018	27	17	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	27	18	has	have	AUX
ajlm-2018	27	19	been	be	AUX
ajlm-2018	27	20	reported	report	VERB
ajlm-2018	27	21	among	among	ADP
ajlm-2018	27	22	both	both	DET
ajlm-2018	27	23	treatment	treatment	NOUN
ajlm-2018	27	24	-	-	PUNCT
ajlm-2018	27	25	naïve	naïve	ADJ
ajlm-2018	27	26	and	and	CCONJ
ajlm-2018	27	27	art	art	NOUN
ajlm-2018	27	28	-	-	PUNCT
ajlm-2018	27	29	experienced	experience	VERB
ajlm-2018	27	30	hiv	hiv	PROPN
ajlm-2018	27	31	-	-	PUNCT
ajlm-2018	27	32	positive	positive	ADJ
ajlm-2018	27	33	patients,10	patients,10	NOUN
ajlm-2018	27	34	suggesting	suggest	VERB
ajlm-2018	27	35	that	that	SCONJ
ajlm-2018	27	36	lipid	lipid	ADJ
ajlm-2018	27	37	abnormalities	abnormality	NOUN
ajlm-2018	27	38	among	among	ADP
ajlm-2018	27	39	hiv	hiv	PROPN
ajlm-2018	27	40	patients	patient	NOUN
ajlm-2018	27	41	may	may	AUX
ajlm-2018	27	42	be	be	AUX
ajlm-2018	27	43	caused	cause	VERB
ajlm-2018	27	44	by	by	ADP
ajlm-2018	27	45	hiv	hiv	PROPN
ajlm-2018	27	46	itself	itself	PRON
ajlm-2018	27	47	and	and	CCONJ
ajlm-2018	27	48	may	may	AUX
ajlm-2018	27	49	be	be	AUX
ajlm-2018	27	50	worsened	worsen	VERB
ajlm-2018	27	51	by	by	ADP
ajlm-2018	27	52	art.11	art.11	NOUN
ajlm-2018	27	53	changes	change	NOUN
ajlm-2018	27	54	in	in	ADP
ajlm-2018	27	55	lipid	lipid	ADJ
ajlm-2018	27	56	synthesis	synthesis	NOUN
ajlm-2018	27	57	or	or	CCONJ
ajlm-2018	27	58	transportation	transportation	NOUN
ajlm-2018	27	59	can	can	AUX
ajlm-2018	27	60	cause	cause	VERB
ajlm-2018	27	61	dyslipidaemia.12	dyslipidaemia.12	NOUN
ajlm-2018	27	62	consequently	consequently	ADV
ajlm-2018	27	63	,	,	PUNCT
ajlm-2018	27	64	changes	change	NOUN
ajlm-2018	27	65	in	in	ADP
ajlm-2018	27	66	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	27	67	,	,	PUNCT
ajlm-2018	27	68	protein	protein	NOUN
ajlm-2018	27	69	components	component	NOUN
ajlm-2018	27	70	of	of	ADP
ajlm-2018	27	71	lipoproteins	lipoprotein	NOUN
ajlm-2018	27	72	that	that	PRON
ajlm-2018	27	73	bind	bind	VERB
ajlm-2018	27	74	and	and	CCONJ
ajlm-2018	27	75	transport	transport	NOUN
ajlm-2018	27	76	lipids	lipid	NOUN
ajlm-2018	27	77	for	for	ADP
ajlm-2018	27	78	metabolism	metabolism	NOUN
ajlm-2018	27	79	or	or	CCONJ
ajlm-2018	27	80	utilisation	utilisation	NOUN
ajlm-2018	27	81	,	,	PUNCT
ajlm-2018	27	82	could	could	AUX
ajlm-2018	27	83	modulate	modulate	VERB
ajlm-2018	27	84	serum	serum	NOUN
ajlm-2018	27	85	lipid	lipid	NOUN
ajlm-2018	27	86	concentrations	concentration	NOUN
ajlm-2018	27	87	causing	cause	VERB
ajlm-2018	27	88	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	27	89	.	.	PUNCT
ajlm-2018	28	1	apolipoprotein	apolipoprotein	PROPN
ajlm-2018	28	2	e	e	PROPN
ajlm-2018	28	3	(	(	PUNCT
ajlm-2018	28	4	ae	ae	PROPN
ajlm-2018	28	5	)	)	PUNCT
ajlm-2018	28	6	is	be	AUX
ajlm-2018	28	7	essential	essential	ADJ
ajlm-2018	28	8	for	for	ADP
ajlm-2018	28	9	the	the	DET
ajlm-2018	28	10	catabolism	catabolism	NOUN
ajlm-2018	28	11	of	of	ADP
ajlm-2018	28	12	remnant	remnant	NOUN
ajlm-2018	28	13	(	(	PUNCT
ajlm-2018	28	14	triglyceride	triglyceride	NOUN
ajlm-2018	28	15	-	-	PUNCT
ajlm-2018	28	16	rich	rich	ADJ
ajlm-2018	28	17	)	)	PUNCT
ajlm-2018	28	18	lipoproteins	lipoprotein	NOUN
ajlm-2018	28	19	as	as	SCONJ
ajlm-2018	28	20	it	it	PRON
ajlm-2018	28	21	is	be	AUX
ajlm-2018	28	22	a	a	DET
ajlm-2018	28	23	major	major	ADJ
ajlm-2018	28	24	transporter	transporter	NOUN
ajlm-2018	28	25	of	of	ADP
ajlm-2018	28	26	cholesterol	cholesterol	NOUN
ajlm-2018	28	27	and	and	CCONJ
ajlm-2018	28	28	triglyceride	triglyceride	ADJ
ajlm-2018	28	29	-	-	PUNCT
ajlm-2018	28	30	rich	rich	ADJ
ajlm-2018	28	31	lipoproteins.13	lipoproteins.13	NOUN
ajlm-2018	28	32	apolipoprotein	apolipoprotein	VERB
ajlm-2018	28	33	c	c	X
ajlm-2018	28	34	-	-	PUNCT
ajlm-2018	28	35	iii	iii	X
ajlm-2018	28	36	(	(	PUNCT
ajlm-2018	28	37	aciii	aciii	PROPN
ajlm-2018	28	38	)	)	PUNCT
ajlm-2018	28	39	plays	play	VERB
ajlm-2018	28	40	a	a	DET
ajlm-2018	28	41	crucial	crucial	ADJ
ajlm-2018	28	42	role	role	NOUN
ajlm-2018	28	43	in	in	ADP
ajlm-2018	28	44	the	the	DET
ajlm-2018	28	45	synthesis	synthesis	NOUN
ajlm-2018	28	46	and	and	CCONJ
ajlm-2018	28	47	catabolism	catabolism	NOUN
ajlm-2018	28	48	of	of	ADP
ajlm-2018	28	49	very	very	ADV
ajlm-2018	28	50	low	low	ADJ
ajlm-2018	28	51	-	-	PUNCT
ajlm-2018	28	52	density	density	NOUN
ajlm-2018	28	53	lipoproteins.13	lipoproteins.13	NOUN
ajlm-2018	28	54	these	these	DET
ajlm-2018	28	55	proteins	protein	NOUN
ajlm-2018	28	56	have	have	AUX
ajlm-2018	28	57	been	be	AUX
ajlm-2018	28	58	associated	associate	VERB
ajlm-2018	28	59	with	with	ADP
ajlm-2018	28	60	hypertriglyceridaemia,14,15	hypertriglyceridaemia,14,15	PROPN
ajlm-2018	28	61	a	a	DET
ajlm-2018	28	62	known	know	VERB
ajlm-2018	28	63	predictor	predictor	NOUN
ajlm-2018	28	64	of	of	ADP
ajlm-2018	28	65	cardiovascular	cardiovascular	ADJ
ajlm-2018	28	66	disease.16	disease.16	VERB
ajlm-2018	28	67	aside	aside	ADV
ajlm-2018	28	68	from	from	ADP
ajlm-2018	28	69	its	its	PRON
ajlm-2018	28	70	role	role	NOUN
ajlm-2018	28	71	in	in	ADP
ajlm-2018	28	72	lipid	lipid	NOUN
ajlm-2018	28	73	and	and	CCONJ
ajlm-2018	28	74	lipoprotein	lipoprotein	ADJ
ajlm-2018	28	75	metabolism	metabolism	NOUN
ajlm-2018	28	76	,	,	PUNCT
ajlm-2018	28	77	ae	ae	PROPN
ajlm-2018	28	78	is	be	AUX
ajlm-2018	28	79	also	also	ADV
ajlm-2018	28	80	involved	involve	VERB
ajlm-2018	28	81	in	in	ADP
ajlm-2018	28	82	the	the	DET
ajlm-2018	28	83	immune	immune	ADJ
ajlm-2018	28	84	response	response	NOUN
ajlm-2018	28	85	by	by	ADP
ajlm-2018	28	86	stimulating	stimulate	VERB
ajlm-2018	28	87	or	or	CCONJ
ajlm-2018	28	88	inhibiting	inhibit	VERB
ajlm-2018	28	89	antigen	antigen	NOUN
ajlm-2018	28	90	-	-	PUNCT
ajlm-2018	28	91	t	t	NOUN
ajlm-2018	28	92	-	-	PUNCT
ajlm-2018	28	93	lymphocyte	lymphocyte	NOUN
ajlm-2018	28	94	proliferation.17	proliferation.17	NOUN
ajlm-2018	28	95	studies	study	NOUN
ajlm-2018	28	96	assessing	assess	VERB
ajlm-2018	28	97	serum	serum	NOUN
ajlm-2018	28	98	lipid	lipid	NOUN
ajlm-2018	28	99	levels	level	NOUN
ajlm-2018	28	100	of	of	ADP
ajlm-2018	28	101	hiv	hiv	PROPN
ajlm-2018	28	102	-	-	PUNCT
ajlm-2018	28	103	positive	positive	ADJ
ajlm-2018	28	104	subjects	subject	NOUN
ajlm-2018	28	105	abound	abound	VERB
ajlm-2018	28	106	.	.	PUNCT
ajlm-2018	29	1	however	however	ADV
ajlm-2018	29	2	,	,	PUNCT
ajlm-2018	29	3	there	there	PRON
ajlm-2018	29	4	is	be	VERB
ajlm-2018	29	5	a	a	DET
ajlm-2018	29	6	paucity	paucity	NOUN
ajlm-2018	29	7	of	of	ADP
ajlm-2018	29	8	research	research	NOUN
ajlm-2018	29	9	evaluating	evaluating	NOUN
ajlm-2018	29	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	29	11	concentrations	concentration	NOUN
ajlm-2018	29	12	,	,	PUNCT
ajlm-2018	29	13	despite	despite	SCONJ
ajlm-2018	29	14	their	their	PRON
ajlm-2018	29	15	importance	importance	NOUN
ajlm-2018	29	16	in	in	ADP
ajlm-2018	29	17	lipid	lipid	ADJ
ajlm-2018	29	18	concentrations	concentration	NOUN
ajlm-2018	29	19	and	and	CCONJ
ajlm-2018	29	20	metabolism	metabolism	NOUN
ajlm-2018	29	21	.	.	PUNCT
ajlm-2018	30	1	little	little	ADJ
ajlm-2018	30	2	is	be	AUX
ajlm-2018	30	3	known	know	VERB
ajlm-2018	30	4	about	about	ADP
ajlm-2018	30	5	the	the	DET
ajlm-2018	30	6	concentration	concentration	NOUN
ajlm-2018	30	7	of	of	ADP
ajlm-2018	30	8	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	30	9	and	and	CCONJ
ajlm-2018	30	10	their	their	PRON
ajlm-2018	30	11	role	role	NOUN
ajlm-2018	30	12	in	in	ADP
ajlm-2018	30	13	the	the	DET
ajlm-2018	30	14	course	course	NOUN
ajlm-2018	30	15	of	of	ADP
ajlm-2018	30	16	hiv	hiv	PROPN
ajlm-2018	30	17	infection	infection	NOUN
ajlm-2018	30	18	.	.	PUNCT
ajlm-2018	31	1	the	the	DET
ajlm-2018	31	2	study	study	NOUN
ajlm-2018	31	3	aimed	aim	VERB
ajlm-2018	31	4	to	to	PART
ajlm-2018	31	5	assess	assess	VERB
ajlm-2018	31	6	the	the	DET
ajlm-2018	31	7	risk	risk	NOUN
ajlm-2018	31	8	of	of	ADP
ajlm-2018	31	9	cardiometabolic	cardiometabolic	ADJ
ajlm-2018	31	10	disorder	disorder	NOUN
ajlm-2018	31	11	and	and	CCONJ
ajlm-2018	31	12	determine	determine	VERB
ajlm-2018	31	13	the	the	DET
ajlm-2018	31	14	correlation	correlation	NOUN
ajlm-2018	31	15	between	between	ADP
ajlm-2018	31	16	lipids	lipid	NOUN
ajlm-2018	31	17	and	and	CCONJ
ajlm-2018	31	18	the	the	DET
ajlm-2018	31	19	studied	study	VERB
ajlm-2018	31	20	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	31	21	of	of	ADP
ajlm-2018	31	22	hiv	hiv	PROPN
ajlm-2018	31	23	-	-	PUNCT
ajlm-2018	31	24	positive	positive	ADJ
ajlm-2018	31	25	patients	patient	NOUN
ajlm-2018	31	26	.	.	PUNCT
ajlm-2018	32	1	methods	method	NOUN
ajlm-2018	32	2	ethical	ethical	ADJ
ajlm-2018	32	3	considerations	consideration	NOUN
ajlm-2018	32	4	ethical	ethical	ADJ
ajlm-2018	32	5	study	study	NOUN
ajlm-2018	32	6	approval	approval	NOUN
ajlm-2018	32	7	was	be	AUX
ajlm-2018	32	8	sought	seek	VERB
ajlm-2018	32	9	and	and	CCONJ
ajlm-2018	32	10	obtained	obtain	VERB
ajlm-2018	32	11	from	from	ADP
ajlm-2018	32	12	the	the	DET
ajlm-2018	32	13	hospital	hospital	NOUN
ajlm-2018	32	14	management	management	PROPN
ajlm-2018	32	15	board	board	NOUN
ajlm-2018	32	16	of	of	ADP
ajlm-2018	32	17	edo	edo	PROPN
ajlm-2018	32	18	state	state	PROPN
ajlm-2018	32	19	,	,	PUNCT
ajlm-2018	32	20	nigeria	nigeria	PROPN
ajlm-2018	32	21	(	(	PUNCT
ajlm-2018	32	22	study	study	VERB
ajlm-2018	32	23	approval	approval	NOUN
ajlm-2018	32	24	number	number	NOUN
ajlm-2018	32	25	:	:	PUNCT
ajlm-2018	32	26	ch	ch	NOUN
ajlm-2018	32	27	/	/	SYM
ajlm-2018	32	28	a406	a406	PROPN
ajlm-2018	32	29	voliii/177a	voliii/177a	PROPN
ajlm-2018	32	30	)	)	PUNCT
ajlm-2018	32	31	.	.	PUNCT
ajlm-2018	33	1	the	the	DET
ajlm-2018	33	2	study	study	NOUN
ajlm-2018	33	3	participants	participant	NOUN
ajlm-2018	33	4	were	be	AUX
ajlm-2018	33	5	educated	educate	VERB
ajlm-2018	33	6	on	on	ADP
ajlm-2018	33	7	the	the	DET
ajlm-2018	33	8	study	study	NOUN
ajlm-2018	33	9	’s	’s	PART
ajlm-2018	33	10	details	detail	NOUN
ajlm-2018	33	11	and	and	CCONJ
ajlm-2018	33	12	assured	assure	VERB
ajlm-2018	33	13	of	of	ADP
ajlm-2018	33	14	the	the	DET
ajlm-2018	33	15	confidentiality	confidentiality	NOUN
ajlm-2018	33	16	and	and	CCONJ
ajlm-2018	33	17	anonymity	anonymity	NOUN
ajlm-2018	33	18	of	of	ADP
ajlm-2018	33	19	the	the	DET
ajlm-2018	33	20	information	information	NOUN
ajlm-2018	33	21	and	and	CCONJ
ajlm-2018	33	22	data	datum	NOUN
ajlm-2018	33	23	obtained	obtain	VERB
ajlm-2018	33	24	during	during	ADP
ajlm-2018	33	25	the	the	DET
ajlm-2018	33	26	study	study	NOUN
ajlm-2018	33	27	.	.	PUNCT
ajlm-2018	34	1	we	we	PRON
ajlm-2018	34	2	enrolled	enrol	VERB
ajlm-2018	34	3	only	only	ADV
ajlm-2018	34	4	participants	participant	NOUN
ajlm-2018	34	5	who	who	PRON
ajlm-2018	34	6	consented	consent	VERB
ajlm-2018	34	7	in	in	ADP
ajlm-2018	34	8	writing	writing	NOUN
ajlm-2018	34	9	.	.	PUNCT
ajlm-2018	35	1	data	datum	NOUN
ajlm-2018	35	2	that	that	PRON
ajlm-2018	35	3	could	could	AUX
ajlm-2018	35	4	be	be	AUX
ajlm-2018	35	5	traced	trace	VERB
ajlm-2018	35	6	back	back	ADV
ajlm-2018	35	7	to	to	ADP
ajlm-2018	35	8	the	the	DET
ajlm-2018	35	9	participants	participant	NOUN
ajlm-2018	35	10	were	be	AUX
ajlm-2018	35	11	not	not	PART
ajlm-2018	35	12	collected	collect	VERB
ajlm-2018	35	13	.	.	PUNCT
ajlm-2018	36	1	all	all	DET
ajlm-2018	36	2	information	information	NOUN
ajlm-2018	36	3	obtained	obtain	VERB
ajlm-2018	36	4	from	from	ADP
ajlm-2018	36	5	the	the	DET
ajlm-2018	36	6	participants	participant	NOUN
ajlm-2018	36	7	was	be	AUX
ajlm-2018	36	8	treated	treat	VERB
ajlm-2018	36	9	with	with	ADP
ajlm-2018	36	10	the	the	DET
ajlm-2018	36	11	utmost	utmost	ADJ
ajlm-2018	36	12	confidentiality	confidentiality	NOUN
ajlm-2018	36	13	and	and	CCONJ
ajlm-2018	36	14	used	use	VERB
ajlm-2018	36	15	strictly	strictly	ADV
ajlm-2018	36	16	for	for	ADP
ajlm-2018	36	17	research	research	NOUN
ajlm-2018	36	18	.	.	PUNCT
ajlm-2018	37	1	study	study	NOUN
ajlm-2018	37	2	location	location	NOUN
ajlm-2018	37	3	the	the	DET
ajlm-2018	37	4	study	study	NOUN
ajlm-2018	37	5	was	be	AUX
ajlm-2018	37	6	carried	carry	VERB
ajlm-2018	37	7	out	out	ADP
ajlm-2018	37	8	at	at	ADP
ajlm-2018	37	9	the	the	DET
ajlm-2018	37	10	heart	heart	NOUN
ajlm-2018	37	11	to	to	ADP
ajlm-2018	37	12	heart	heart	NOUN
ajlm-2018	37	13	clinic	clinic	NOUN
ajlm-2018	37	14	of	of	ADP
ajlm-2018	37	15	central	central	ADJ
ajlm-2018	37	16	hospital	hospital	NOUN
ajlm-2018	37	17	and	and	CCONJ
ajlm-2018	37	18	stella	stella	PROPN
ajlm-2018	37	19	obasanjo	obasanjo	PROPN
ajlm-2018	37	20	hospital	hospital	PROPN
ajlm-2018	37	21	,	,	PUNCT
ajlm-2018	37	22	both	both	PRON
ajlm-2018	37	23	in	in	ADP
ajlm-2018	37	24	benin	benin	PROPN
ajlm-2018	37	25	city	city	NOUN
ajlm-2018	37	26	,	,	PUNCT
ajlm-2018	37	27	edo	edo	PROPN
ajlm-2018	37	28	state	state	NOUN
ajlm-2018	37	29	of	of	ADP
ajlm-2018	37	30	nigeria	nigeria	PROPN
ajlm-2018	37	31	,	,	PUNCT
ajlm-2018	37	32	between	between	ADP
ajlm-2018	37	33	may	may	PROPN
ajlm-2018	37	34	2015	2015	NUM
ajlm-2018	37	35	and	and	CCONJ
ajlm-2018	37	36	november	november	PROPN
ajlm-2018	37	37	2015	2015	NUM
ajlm-2018	37	38	.	.	PUNCT
ajlm-2018	38	1	both	both	DET
ajlm-2018	38	2	hospitals	hospital	NOUN
ajlm-2018	38	3	have	have	VERB
ajlm-2018	38	4	major	major	ADJ
ajlm-2018	38	5	hiv	hiv	PROPN
ajlm-2018	38	6	and	and	CCONJ
ajlm-2018	38	7	aids	aids	PROPN
ajlm-2018	38	8	centres	centre	NOUN
ajlm-2018	38	9	serving	serve	VERB
ajlm-2018	38	10	patients	patient	NOUN
ajlm-2018	38	11	from	from	ADP
ajlm-2018	38	12	all	all	ADV
ajlm-2018	38	13	over	over	ADP
ajlm-2018	38	14	the	the	DET
ajlm-2018	38	15	state	state	NOUN
ajlm-2018	38	16	.	.	PUNCT
ajlm-2018	39	1	study	study	NOUN
ajlm-2018	39	2	design	design	NOUN
ajlm-2018	39	3	this	this	DET
ajlm-2018	39	4	cross	cross	ADJ
ajlm-2018	39	5	-	-	ADJ
ajlm-2018	39	6	sectional	sectional	ADJ
ajlm-2018	39	7	study	study	NOUN
ajlm-2018	39	8	compared	compare	VERB
ajlm-2018	39	9	the	the	DET
ajlm-2018	39	10	lipid	lipid	NOUN
ajlm-2018	39	11	profile	profile	NOUN
ajlm-2018	39	12	and	and	CCONJ
ajlm-2018	39	13	aciii	aciii	PROPN
ajlm-2018	39	14	and	and	CCONJ
ajlm-2018	39	15	ae	ae	PROPN
ajlm-2018	39	16	levels	level	NOUN
ajlm-2018	39	17	of	of	ADP
ajlm-2018	39	18	hiv	hiv	PROPN
ajlm-2018	39	19	-	-	PUNCT
ajlm-2018	39	20	positive	positive	ADJ
ajlm-2018	39	21	and	and	CCONJ
ajlm-2018	39	22	hiv	hiv	NOUN
ajlm-2018	39	23	-	-	PUNCT
ajlm-2018	39	24	negative	negative	ADJ
ajlm-2018	39	25	participants	participant	NOUN
ajlm-2018	39	26	.	.	PUNCT
ajlm-2018	40	1	for	for	ADP
ajlm-2018	40	2	the	the	DET
ajlm-2018	40	3	case	case	NOUN
ajlm-2018	40	4	group	group	NOUN
ajlm-2018	40	5	,	,	PUNCT
ajlm-2018	40	6	100	100	NUM
ajlm-2018	40	7	participants	participant	NOUN
ajlm-2018	40	8	were	be	AUX
ajlm-2018	40	9	hiv	hiv	NOUN
ajlm-2018	40	10	-	-	PUNCT
ajlm-2018	40	11	positive	positive	ADJ
ajlm-2018	40	12	and	and	CCONJ
ajlm-2018	40	13	grouped	group	VERB
ajlm-2018	40	14	based	base	VERB
ajlm-2018	40	15	on	on	ADP
ajlm-2018	40	16	their	their	PRON
ajlm-2018	40	17	treatment	treatment	NOUN
ajlm-2018	40	18	experience	experience	NOUN
ajlm-2018	40	19	.	.	PUNCT
ajlm-2018	41	1	group	group	NOUN
ajlm-2018	41	2	one	one	NUM
ajlm-2018	41	3	included	include	VERB
ajlm-2018	41	4	50	50	NUM
ajlm-2018	41	5	hiv	hiv	NOUN
ajlm-2018	41	6	-	-	PUNCT
ajlm-2018	41	7	positive	positive	ADJ
ajlm-2018	41	8	art	art	NOUN
ajlm-2018	41	9	-	-	PUNCT
ajlm-2018	41	10	naïve	naïve	ADJ
ajlm-2018	41	11	individuals	individual	NOUN
ajlm-2018	41	12	.	.	PUNCT
ajlm-2018	42	1	in	in	ADP
ajlm-2018	42	2	contrast	contrast	NOUN
ajlm-2018	42	3	,	,	PUNCT
ajlm-2018	42	4	group	group	NOUN
ajlm-2018	42	5	two	two	NUM
ajlm-2018	42	6	included	include	VERB
ajlm-2018	42	7	50	50	NUM
ajlm-2018	42	8	hiv	hiv	NOUN
ajlm-2018	42	9	-	-	PUNCT
ajlm-2018	42	10	positive	positive	ADJ
ajlm-2018	42	11	individuals	individual	NOUN
ajlm-2018	42	12	receiving	receive	VERB
ajlm-2018	42	13	first	first	ADJ
ajlm-2018	42	14	-	-	PUNCT
ajlm-2018	42	15	line	line	NOUN
ajlm-2018	42	16	art	art	NOUN
ajlm-2018	42	17	made	make	VERB
ajlm-2018	42	18	up	up	ADP
ajlm-2018	42	19	of	of	ADP
ajlm-2018	42	20	a	a	DET
ajlm-2018	42	21	combination	combination	NOUN
ajlm-2018	42	22	of	of	ADP
ajlm-2018	42	23	two	two	NUM
ajlm-2018	42	24	nucleotide	nucleotide	NOUN
ajlm-2018	42	25	reverse	reverse	NOUN
ajlm-2018	42	26	transcriptase	transcriptase	NOUN
ajlm-2018	42	27	inhibitors	inhibitor	NOUN
ajlm-2018	42	28	(	(	PUNCT
ajlm-2018	42	29	zidovudine	zidovudine	NOUN
ajlm-2018	42	30	or	or	CCONJ
ajlm-2018	42	31	tenofovir	tenofovir	NOUN
ajlm-2018	42	32	and	and	CCONJ
ajlm-2018	42	33	lamivudine	lamivudine	NOUN
ajlm-2018	42	34	)	)	PUNCT
ajlm-2018	42	35	with	with	ADP
ajlm-2018	42	36	one	one	NUM
ajlm-2018	42	37	non	non	ADJ
ajlm-2018	42	38	-	-	ADJ
ajlm-2018	42	39	nucleotide	nucleotide	ADJ
ajlm-2018	42	40	reverse	reverse	NOUN
ajlm-2018	42	41	transcriptase	transcriptase	NOUN
ajlm-2018	42	42	inhibitor	inhibitor	NOUN
ajlm-2018	42	43	(	(	PUNCT
ajlm-2018	42	44	efavirenz	efavirenz	PROPN
ajlm-2018	42	45	)	)	PUNCT
ajlm-2018	42	46	.	.	PUNCT
ajlm-2018	43	1	all	all	DET
ajlm-2018	43	2	case	case	NOUN
ajlm-2018	43	3	participants	participant	NOUN
ajlm-2018	43	4	were	be	AUX
ajlm-2018	43	5	adults	adult	NOUN
ajlm-2018	43	6	and	and	CCONJ
ajlm-2018	43	7	enrolled	enrol	VERB
ajlm-2018	43	8	for	for	ADP
ajlm-2018	43	9	care	care	NOUN
ajlm-2018	43	10	in	in	ADP
ajlm-2018	43	11	the	the	DET
ajlm-2018	43	12	study	study	NOUN
ajlm-2018	43	13	’s	’s	PART
ajlm-2018	43	14	hospitals	hospital	NOUN
ajlm-2018	43	15	.	.	PUNCT
ajlm-2018	44	1	for	for	ADP
ajlm-2018	44	2	the	the	DET
ajlm-2018	44	3	control	control	NOUN
ajlm-2018	44	4	group	group	NOUN
ajlm-2018	44	5	,	,	PUNCT
ajlm-2018	44	6	50	50	NUM
ajlm-2018	44	7	hiv	hiv	NOUN
ajlm-2018	44	8	-	-	PUNCT
ajlm-2018	44	9	negative	negative	ADJ
ajlm-2018	44	10	adults	adult	NOUN
ajlm-2018	44	11	with	with	ADP
ajlm-2018	44	12	no	no	DET
ajlm-2018	44	13	history	history	NOUN
ajlm-2018	44	14	of	of	ADP
ajlm-2018	44	15	organ	organ	NOUN
ajlm-2018	44	16	or	or	CCONJ
ajlm-2018	44	17	metabolic	metabolic	NOUN
ajlm-2018	44	18	disease	disease	NOUN
ajlm-2018	44	19	were	be	AUX
ajlm-2018	44	20	recruited	recruit	VERB
ajlm-2018	44	21	from	from	ADP
ajlm-2018	44	22	among	among	ADP
ajlm-2018	44	23	staff	staff	NOUN
ajlm-2018	44	24	and	and	CCONJ
ajlm-2018	44	25	patient	patient	ADJ
ajlm-2018	44	26	relatives	relative	NOUN
ajlm-2018	44	27	in	in	ADP
ajlm-2018	44	28	the	the	DET
ajlm-2018	44	29	hospitals	hospital	NOUN
ajlm-2018	44	30	.	.	PUNCT
ajlm-2018	45	1	any	any	DET
ajlm-2018	45	2	individual	individual	NOUN
ajlm-2018	45	3	with	with	ADP
ajlm-2018	45	4	a	a	DET
ajlm-2018	45	5	known	know	VERB
ajlm-2018	45	6	history	history	NOUN
ajlm-2018	45	7	of	of	ADP
ajlm-2018	45	8	diabetes	diabetes	NOUN
ajlm-2018	45	9	mellitus	mellitus	NOUN
ajlm-2018	45	10	or	or	CCONJ
ajlm-2018	45	11	on	on	ADP
ajlm-2018	45	12	treatment	treatment	NOUN
ajlm-2018	45	13	for	for	ADP
ajlm-2018	45	14	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	45	15	was	be	AUX
ajlm-2018	45	16	excluded	exclude	VERB
ajlm-2018	45	17	from	from	ADP
ajlm-2018	45	18	the	the	DET
ajlm-2018	45	19	study	study	NOUN
ajlm-2018	45	20	.	.	PUNCT
ajlm-2018	46	1	also	also	ADV
ajlm-2018	46	2	excluded	exclude	VERB
ajlm-2018	46	3	were	be	AUX
ajlm-2018	46	4	current	current	ADJ
ajlm-2018	46	5	smokers	smoker	NOUN
ajlm-2018	46	6	and	and	CCONJ
ajlm-2018	46	7	excessive	excessive	ADJ
ajlm-2018	46	8	alcohol	alcohol	NOUN
ajlm-2018	46	9	drinkers	drinker	NOUN
ajlm-2018	46	10	.	.	PUNCT
ajlm-2018	47	1	excessive	excessive	ADJ
ajlm-2018	47	2	alcohol	alcohol	NOUN
ajlm-2018	47	3	drinking	drinking	NOUN
ajlm-2018	47	4	was	be	AUX
ajlm-2018	47	5	defined	define	VERB
ajlm-2018	47	6	as	as	ADP
ajlm-2018	47	7	a	a	DET
ajlm-2018	47	8	pattern	pattern	NOUN
ajlm-2018	47	9	of	of	ADP
ajlm-2018	47	10	alcohol	alcohol	NOUN
ajlm-2018	47	11	use	use	NOUN
ajlm-2018	47	12	,	,	PUNCT
ajlm-2018	47	13	including	include	VERB
ajlm-2018	47	14	binge	binge	ADJ
ajlm-2018	47	15	consumption	consumption	NOUN
ajlm-2018	47	16	(	(	PUNCT
ajlm-2018	47	17	four	four	NUM
ajlm-2018	47	18	drinks	drink	NOUN
ajlm-2018	47	19	or	or	CCONJ
ajlm-2018	47	20	70	70	NUM
ajlm-2018	47	21	g	g	NOUN
ajlm-2018	47	22	[	[	X
ajlm-2018	47	23	for	for	ADP
ajlm-2018	47	24	men	man	NOUN
ajlm-2018	47	25	]	]	PUNCT
ajlm-2018	47	26	and	and	CCONJ
ajlm-2018	47	27	56	56	NUM
ajlm-2018	47	28	g	g	NOUN
ajlm-2018	47	29	[	[	X
ajlm-2018	47	30	for	for	ADP
ajlm-2018	47	31	women	woman	NOUN
ajlm-2018	47	32	]	]	PUNCT
ajlm-2018	47	33	in	in	ADP
ajlm-2018	47	34	two	two	NUM
ajlm-2018	47	35	hours	hour	NOUN
ajlm-2018	47	36	)	)	PUNCT
ajlm-2018	47	37	,	,	PUNCT
ajlm-2018	47	38	frequent	frequent	ADJ
ajlm-2018	47	39	or	or	CCONJ
ajlm-2018	47	40	heavy	heavy	ADJ
ajlm-2018	47	41	consumption	consumption	NOUN
ajlm-2018	47	42	,	,	PUNCT
ajlm-2018	47	43	hazardous	hazardous	ADJ
ajlm-2018	47	44	use	use	NOUN
ajlm-2018	47	45	and	and	CCONJ
ajlm-2018	47	46	dependency18	dependency18	NOUN
ajlm-2018	47	47	.	.	PUNCT
ajlm-2018	48	1	sample	sample	NOUN
ajlm-2018	48	2	processing	processing	NOUN
ajlm-2018	48	3	and	and	CCONJ
ajlm-2018	48	4	analytical	analytical	ADJ
ajlm-2018	48	5	methods	method	NOUN
ajlm-2018	48	6	five	five	NUM
ajlm-2018	48	7	millilitres	millilitre	NOUN
ajlm-2018	48	8	of	of	ADP
ajlm-2018	48	9	blood	blood	NOUN
ajlm-2018	48	10	was	be	AUX
ajlm-2018	48	11	obtained	obtain	VERB
ajlm-2018	48	12	after	after	ADP
ajlm-2018	48	13	an	an	DET
ajlm-2018	48	14	overnight	overnight	ADJ
ajlm-2018	48	15	fast	fast	ADV
ajlm-2018	48	16	from	from	ADP
ajlm-2018	48	17	each	each	PRON
ajlm-2018	48	18	of	of	ADP
ajlm-2018	48	19	the	the	DET
ajlm-2018	48	20	participants	participant	NOUN
ajlm-2018	48	21	.	.	PUNCT
ajlm-2018	49	1	the	the	DET
ajlm-2018	49	2	blood	blood	NOUN
ajlm-2018	49	3	sample	sample	NOUN
ajlm-2018	49	4	was	be	AUX
ajlm-2018	49	5	withdrawn	withdraw	VERB
ajlm-2018	49	6	from	from	ADP
ajlm-2018	49	7	the	the	DET
ajlm-2018	49	8	antecubital	antecubital	ADJ
ajlm-2018	49	9	vein	vein	NOUN
ajlm-2018	49	10	using	use	VERB
ajlm-2018	49	11	sterile	sterile	ADJ
ajlm-2018	49	12	hypodermic	hypodermic	ADJ
ajlm-2018	49	13	syringes	syrinx	NOUN
ajlm-2018	49	14	into	into	ADP
ajlm-2018	49	15	plain	plain	ADJ
ajlm-2018	49	16	containers	container	NOUN
ajlm-2018	49	17	.	.	PUNCT
ajlm-2018	50	1	all	all	DET
ajlm-2018	50	2	samples	sample	NOUN
ajlm-2018	50	3	were	be	AUX
ajlm-2018	50	4	transported	transport	VERB
ajlm-2018	50	5	from	from	ADP
ajlm-2018	50	6	the	the	DET
ajlm-2018	50	7	collection	collection	NOUN
ajlm-2018	50	8	site	site	NOUN
ajlm-2018	50	9	in	in	ADP
ajlm-2018	50	10	the	the	DET
ajlm-2018	50	11	cold	cold	ADJ
ajlm-2018	50	12	chain	chain	NOUN
ajlm-2018	50	13	to	to	ADP
ajlm-2018	50	14	the	the	DET
ajlm-2018	50	15	chemical	chemical	NOUN
ajlm-2018	50	16	pathology	pathology	NOUN
ajlm-2018	50	17	laboratory	laboratory	NOUN
ajlm-2018	50	18	of	of	ADP
ajlm-2018	50	19	a	a	DET
ajlm-2018	50	20	teaching	teaching	NOUN
ajlm-2018	50	21	hospital	hospital	NOUN
ajlm-2018	50	22	in	in	ADP
ajlm-2018	50	23	south	south	PROPN
ajlm-2018	50	24	east	east	PROPN
ajlm-2018	50	25	nigeria	nigeria	PROPN
ajlm-2018	50	26	,	,	PUNCT
ajlm-2018	50	27	where	where	SCONJ
ajlm-2018	50	28	the	the	DET
ajlm-2018	50	29	analysis	analysis	NOUN
ajlm-2018	50	30	was	be	AUX
ajlm-2018	50	31	done	do	VERB
ajlm-2018	50	32	.	.	PUNCT
ajlm-2018	51	1	the	the	DET
ajlm-2018	51	2	blood	blood	NOUN
ajlm-2018	51	3	was	be	AUX
ajlm-2018	51	4	allowed	allow	VERB
ajlm-2018	51	5	to	to	PART
ajlm-2018	51	6	clot	clot	VERB
ajlm-2018	51	7	,	,	PUNCT
ajlm-2018	51	8	and	and	CCONJ
ajlm-2018	51	9	the	the	DET
ajlm-2018	51	10	serum	serum	NOUN
ajlm-2018	51	11	separated	separate	VERB
ajlm-2018	51	12	from	from	ADP
ajlm-2018	51	13	the	the	DET
ajlm-2018	51	14	cells	cell	NOUN
ajlm-2018	51	15	by	by	ADP
ajlm-2018	51	16	centrifuging	centrifuge	VERB
ajlm-2018	51	17	at	at	ADP
ajlm-2018	51	18	1500	1500	NUM
ajlm-2018	51	19	revolutions	revolution	NOUN
ajlm-2018	51	20	per	per	ADP
ajlm-2018	51	21	minute	minute	NOUN
ajlm-2018	51	22	for	for	ADP
ajlm-2018	51	23	5	5	NUM
ajlm-2018	51	24	min	min	NOUN
ajlm-2018	51	25	.	.	PUNCT
ajlm-2018	52	1	the	the	DET
ajlm-2018	52	2	serum	serum	NOUN
ajlm-2018	52	3	was	be	AUX
ajlm-2018	52	4	stored	store	VERB
ajlm-2018	52	5	at	at	ADP
ajlm-2018	52	6	−20	−20	PROPN
ajlm-2018	52	7	°	°	PUNCT
ajlm-2018	53	1	c	c	NOUN
ajlm-2018	53	2	for	for	ADP
ajlm-2018	53	3	one	one	NUM
ajlm-2018	53	4	week	week	NOUN
ajlm-2018	53	5	before	before	SCONJ
ajlm-2018	53	6	the	the	DET
ajlm-2018	53	7	samples	sample	NOUN
ajlm-2018	53	8	were	be	AUX
ajlm-2018	53	9	analysed	analyse	VERB
ajlm-2018	53	10	.	.	PUNCT
ajlm-2018	54	1	hiv	hiv	PROPN
ajlm-2018	54	2	screening	screen	VERB
ajlm-2018	54	3	all	all	DET
ajlm-2018	54	4	enrolled	enrol	VERB
ajlm-2018	54	5	participants	participant	NOUN
ajlm-2018	54	6	were	be	AUX
ajlm-2018	54	7	tested	test	VERB
ajlm-2018	54	8	to	to	PART
ajlm-2018	54	9	confirm	confirm	VERB
ajlm-2018	54	10	their	their	PRON
ajlm-2018	54	11	hiv	hiv	PROPN
ajlm-2018	54	12	status	status	NOUN
ajlm-2018	54	13	per	per	ADP
ajlm-2018	54	14	the	the	DET
ajlm-2018	54	15	national	national	PROPN
ajlm-2018	54	16	hiv	hiv	PROPN
ajlm-2018	54	17	testing	testing	NOUN
ajlm-2018	54	18	algorithm19	algorithm19	NOUN
ajlm-2018	54	19	using	use	VERB
ajlm-2018	54	20	hiv	hiv	PROPN
ajlm-2018	54	21	determine	determine	VERB
ajlm-2018	54	22	™	™	PROPN
ajlm-2018	54	23	(	(	PUNCT
ajlm-2018	54	24	alere	alere	PROPN
ajlm-2018	54	25	medical	medical	PROPN
ajlm-2018	54	26	co.	co.	PROPN
ajlm-2018	54	27	limited	limit	VERB
ajlm-2018	54	28	,	,	PUNCT
ajlm-2018	54	29	tokyo	tokyo	PROPN
ajlm-2018	54	30	,	,	PUNCT
ajlm-2018	54	31	japan	japan	PROPN
ajlm-2018	54	32	)	)	PUNCT
ajlm-2018	54	33	,	,	PUNCT
ajlm-2018	54	34	uni	uni	ADJ
ajlm-2018	54	35	-	-	ADJ
ajlm-2018	54	36	gold	gold	ADJ
ajlm-2018	54	37	recombigen	recombigen	NOUN
ajlm-2018	54	38	hiv	hiv	PROPN
ajlm-2018	54	39	1/2	1/2	NUM
ajlm-2018	54	40	test	test	NOUN
ajlm-2018	54	41	(	(	PUNCT
ajlm-2018	54	42	trinity	trinity	NOUN
ajlm-2018	54	43	biotech	biotech	NOUN
ajlm-2018	54	44	,	,	PUNCT
ajlm-2018	54	45	bray	bray	PROPN
ajlm-2018	54	46	,	,	PUNCT
ajlm-2018	54	47	ireland	ireland	PROPN
ajlm-2018	54	48	)	)	PUNCT
ajlm-2018	54	49	,	,	PUNCT
ajlm-2018	54	50	and	and	CCONJ
ajlm-2018	54	51	hiv	hiv	PROPN
ajlm-2018	54	52	1/2	1/2	NUM
ajlm-2018	54	53	stat	stat	NOUN
ajlm-2018	54	54	-	-	PUNCT
ajlm-2018	54	55	pak	pak	NOUN
ajlm-2018	54	56	(	(	PUNCT
ajlm-2018	54	57	chembio	chembio	NOUN
ajlm-2018	54	58	diagnostic	diagnostic	ADJ
ajlm-2018	54	59	systems	system	NOUN
ajlm-2018	54	60	,	,	PUNCT
ajlm-2018	54	61	medford	medford	PROPN
ajlm-2018	54	62	,	,	PUNCT
ajlm-2018	54	63	new	new	PROPN
ajlm-2018	54	64	york	york	PROPN
ajlm-2018	54	65	,	,	PUNCT
ajlm-2018	54	66	united	united	PROPN
ajlm-2018	54	67	states	states	PROPN
ajlm-2018	54	68	)	)	PUNCT
ajlm-2018	54	69	.	.	PUNCT
ajlm-2018	55	1	anthropometric	anthropometric	ADJ
ajlm-2018	55	2	variables	variable	NOUN
ajlm-2018	55	3	anthropometric	anthropometric	ADJ
ajlm-2018	55	4	data	datum	NOUN
ajlm-2018	55	5	of	of	ADP
ajlm-2018	55	6	the	the	DET
ajlm-2018	55	7	participants	participant	NOUN
ajlm-2018	55	8	,	,	PUNCT
ajlm-2018	55	9	including	include	VERB
ajlm-2018	55	10	height	height	NOUN
ajlm-2018	55	11	and	and	CCONJ
ajlm-2018	55	12	weight	weight	NOUN
ajlm-2018	55	13	,	,	PUNCT
ajlm-2018	55	14	waist	waist	NOUN
ajlm-2018	55	15	circumference	circumference	NOUN
ajlm-2018	55	16	,	,	PUNCT
ajlm-2018	55	17	and	and	CCONJ
ajlm-2018	55	18	systolic	systolic	ADJ
ajlm-2018	55	19	and	and	CCONJ
ajlm-2018	55	20	diastolic	diastolic	ADJ
ajlm-2018	55	21	blood	blood	NOUN
ajlm-2018	55	22	pressure	pressure	NOUN
ajlm-2018	55	23	,	,	PUNCT
ajlm-2018	55	24	were	be	AUX
ajlm-2018	55	25	measured	measure	VERB
ajlm-2018	55	26	,	,	PUNCT
ajlm-2018	55	27	and	and	CCONJ
ajlm-2018	55	28	body	body	NOUN
ajlm-2018	55	29	mass	mass	NOUN
ajlm-2018	55	30	index	index	NOUN
ajlm-2018	55	31	was	be	AUX
ajlm-2018	55	32	computed	compute	VERB
ajlm-2018	55	33	using	use	VERB
ajlm-2018	55	34	the	the	DET
ajlm-2018	55	35	ratio	ratio	NOUN
ajlm-2018	55	36	of	of	ADP
ajlm-2018	55	37	weight	weight	NOUN
ajlm-2018	55	38	(	(	PUNCT
ajlm-2018	55	39	kg	kg	NOUN
ajlm-2018	55	40	)	)	PUNCT
ajlm-2018	55	41	to	to	ADP
ajlm-2018	55	42	height	height	NOUN
ajlm-2018	55	43	(	(	PUNCT
ajlm-2018	55	44	m2	m2	PROPN
ajlm-2018	55	45	)	)	PUNCT
ajlm-2018	55	46	.	.	PUNCT
ajlm-2018	56	1	lipid	lipid	NOUN
ajlm-2018	56	2	and	and	CCONJ
ajlm-2018	56	3	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	56	4	measurement	measurement	NOUN
ajlm-2018	56	5	lipid	lipid	NOUN
ajlm-2018	56	6	profile	profile	NOUN
ajlm-2018	56	7	parameters	parameter	NOUN
ajlm-2018	56	8	were	be	AUX
ajlm-2018	56	9	estimated	estimate	VERB
ajlm-2018	56	10	using	use	VERB
ajlm-2018	56	11	commercially	commercially	ADV
ajlm-2018	56	12	available	available	ADJ
ajlm-2018	56	13	reagents	reagent	NOUN
ajlm-2018	56	14	(	(	PUNCT
ajlm-2018	56	15	randox	randox	NOUN
ajlm-2018	56	16	cholesterol	cholesterol	NOUN
ajlm-2018	56	17	,	,	PUNCT
ajlm-2018	56	18	triglycerides	triglyceride	NOUN
ajlm-2018	56	19	,	,	PUNCT
ajlm-2018	56	20	hdl	hdl	NOUN
ajlm-2018	56	21	-	-	PUNCT
ajlm-2018	56	22	cholesterol	cholesterol	NOUN
ajlm-2018	56	23	)	)	PUNCT
ajlm-2018	56	24	from	from	ADP
ajlm-2018	56	25	randox	randox	ADJ
ajlm-2018	56	26	laboratories	laboratory	NOUN
ajlm-2018	56	27	,	,	PUNCT
ajlm-2018	56	28	crumlin	crumlin	PROPN
ajlm-2018	56	29	,	,	PUNCT
ajlm-2018	56	30	ireland	ireland	PROPN
ajlm-2018	56	31	.	.	PUNCT
ajlm-2018	57	1	to	to	PART
ajlm-2018	57	2	estimate	estimate	VERB
ajlm-2018	57	3	of	of	ADP
ajlm-2018	57	4	total	total	ADJ
ajlm-2018	57	5	cholesterol	cholesterol	NOUN
ajlm-2018	57	6	and	and	CCONJ
ajlm-2018	57	7	hdl	hdl	PROPN
ajlm-2018	57	8	-	-	PUNCT
ajlm-2018	57	9	c	c	PROPN
ajlm-2018	57	10	,	,	PUNCT
ajlm-2018	57	11	the	the	DET
ajlm-2018	57	12	method	method	NOUN
ajlm-2018	57	13	of	of	ADP
ajlm-2018	57	14	allan	allan	PROPN
ajlm-2018	57	15	et	et	PROPN
ajlm-2018	57	16	al.20	al.20	PROPN
ajlm-2018	57	17	was	be	AUX
ajlm-2018	57	18	employed	employ	VERB
ajlm-2018	57	19	,	,	PUNCT
ajlm-2018	57	20	while	while	SCONJ
ajlm-2018	57	21	the	the	DET
ajlm-2018	57	22	method	method	NOUN
ajlm-2018	57	23	of	of	ADP
ajlm-2018	57	24	bucolo	bucolo	NOUN
ajlm-2018	57	25	and	and	CCONJ
ajlm-2018	57	26	david21	david21	NOUN
ajlm-2018	57	27	was	be	AUX
ajlm-2018	57	28	used	use	VERB
ajlm-2018	57	29	to	to	PART
ajlm-2018	57	30	estimate	estimate	VERB
ajlm-2018	57	31	triglyceride	triglyceride	ADJ
ajlm-2018	57	32	.	.	PUNCT
ajlm-2018	58	1	low	low	ADJ
ajlm-2018	58	2	-	-	PUNCT
ajlm-2018	58	3	density	density	NOUN
ajlm-2018	58	4	lipoprotein	lipoprotein	ADJ
ajlm-2018	58	5	cholesterol	cholesterol	NOUN
ajlm-2018	58	6	was	be	AUX
ajlm-2018	58	7	calculated	calculate	VERB
ajlm-2018	58	8	using	use	VERB
ajlm-2018	58	9	the	the	DET
ajlm-2018	58	10	friedewald	friedewald	ADJ
ajlm-2018	58	11	equation:22	equation:22	NOUN
ajlm-2018	58	12	in	in	ADP
ajlm-2018	58	13	equation	equation	NOUN
ajlm-2018	58	14	1	1	NUM
ajlm-2018	58	15	,	,	PUNCT
ajlm-2018	58	16	ldl	ldl	NOUN
ajlm-2018	58	17	-	-	PUNCT
ajlm-2018	58	18	c	c	PROPN
ajlm-2018	58	19	is	be	AUX
ajlm-2018	58	20	low	low	ADJ
ajlm-2018	58	21	-	-	PUNCT
ajlm-2018	58	22	density	density	NOUN
ajlm-2018	58	23	lipoprotein	lipoprotein	NOUN
ajlm-2018	58	24	,	,	PUNCT
ajlm-2018	58	25	tchol	tchol	NOUN
ajlm-2018	58	26	is	be	AUX
ajlm-2018	58	27	total	total	ADJ
ajlm-2018	58	28	cholesterol	cholesterol	NOUN
ajlm-2018	58	29	,	,	PUNCT
ajlm-2018	58	30	tg	tg	PROPN
ajlm-2018	58	31	is	be	AUX
ajlm-2018	58	32	triglyceride	triglyceride	ADJ
ajlm-2018	58	33	and	and	CCONJ
ajlm-2018	58	34	hdl	hdl	PROPN
ajlm-2018	58	35	-	-	PUNCT
ajlm-2018	58	36	c	c	PROPN
ajlm-2018	58	37	is	be	AUX
ajlm-2018	58	38	high	high	ADJ
ajlm-2018	58	39	-	-	PUNCT
ajlm-2018	58	40	density	density	NOUN
ajlm-2018	58	41	lipoprotein	lipoprotein	NOUN
ajlm-2018	58	42	.	.	PUNCT
ajlm-2018	59	1	apolipoprotein	apolipoprotein	VERB
ajlm-2018	59	2	c	c	X
ajlm-2018	59	3	-	-	PUNCT
ajlm-2018	59	4	iii	iii	NOUN
ajlm-2018	59	5	and	and	CCONJ
ajlm-2018	59	6	ae	ae	PROPN
ajlm-2018	59	7	were	be	AUX
ajlm-2018	59	8	measured	measure	VERB
ajlm-2018	59	9	by	by	ADP
ajlm-2018	59	10	the	the	DET
ajlm-2018	59	11	enzyme	enzyme	NOUN
ajlm-2018	59	12	-	-	PUNCT
ajlm-2018	59	13	linked	link	VERB
ajlm-2018	59	14	immunosorbent	immunosorbent	NOUN
ajlm-2018	59	15	assay	assay	NOUN
ajlm-2018	59	16	method	method	NOUN
ajlm-2018	59	17	using	use	VERB
ajlm-2018	59	18	commercially	commercially	ADV
ajlm-2018	59	19	available	available	ADJ
ajlm-2018	59	20	reagents	reagent	NOUN
ajlm-2018	59	21	from	from	ADP
ajlm-2018	59	22	abcam	abcam	PROPN
ajlm-2018	59	23	(	(	PUNCT
ajlm-2018	59	24	cambridge	cambridge	PROPN
ajlm-2018	59	25	biomedical	biomedical	PROPN
ajlm-2018	59	26	campus	campus	PROPN
ajlm-2018	59	27	,	,	PUNCT
ajlm-2018	59	28	cambridge	cambridge	PROPN
ajlm-2018	59	29	,	,	PUNCT
ajlm-2018	59	30	united	united	ADJ
ajlm-2018	59	31	kingdom	kingdom	PROPN
ajlm-2018	59	32	)	)	PUNCT
ajlm-2018	59	33	.	.	PUNCT
ajlm-2018	60	1	commercially	commercially	ADV
ajlm-2018	60	2	sourced	source	VERB
ajlm-2018	60	3	control	control	NOUN
ajlm-2018	60	4	sera	sera	NOUN
ajlm-2018	60	5	(	(	PUNCT
ajlm-2018	60	6	randox	randox	NOUN
ajlm-2018	60	7	laboratories	laboratory	NOUN
ajlm-2018	60	8	,	,	PUNCT
ajlm-2018	60	9	crumlin	crumlin	PROPN
ajlm-2018	60	10	,	,	PUNCT
ajlm-2018	60	11	ireland	ireland	PROPN
ajlm-2018	60	12	)	)	PUNCT
ajlm-2018	60	13	were	be	AUX
ajlm-2018	60	14	included	include	VERB
ajlm-2018	60	15	in	in	ADP
ajlm-2018	60	16	every	every	DET
ajlm-2018	60	17	test	test	NOUN
ajlm-2018	60	18	,	,	PUNCT
ajlm-2018	60	19	and	and	CCONJ
ajlm-2018	60	20	the	the	DET
ajlm-2018	60	21	routine	routine	ADJ
ajlm-2018	60	22	quality	quality	NOUN
ajlm-2018	60	23	control	control	NOUN
ajlm-2018	60	24	procedures	procedure	NOUN
ajlm-2018	60	25	were	be	AUX
ajlm-2018	60	26	maintained	maintain	VERB
ajlm-2018	60	27	.	.	PUNCT
ajlm-2018	61	1	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	61	2	was	be	AUX
ajlm-2018	61	3	defined	define	VERB
ajlm-2018	61	4	as	as	ADP
ajlm-2018	61	5	elevated	elevated	ADJ
ajlm-2018	61	6	total	total	ADJ
ajlm-2018	61	7	cholesterol	cholesterol	NOUN
ajlm-2018	61	8	(	(	PUNCT
ajlm-2018	61	9	≥	≥	NOUN
ajlm-2018	61	10	5.0	5.0	NUM
ajlm-2018	61	11	mmol	mmol	NOUN
ajlm-2018	61	12	/	/	SYM
ajlm-2018	61	13	l	l	NOUN
ajlm-2018	61	14	)	)	PUNCT
ajlm-2018	61	15	,	,	PUNCT
ajlm-2018	61	16	elevated	elevated	ADJ
ajlm-2018	61	17	ldl	ldl	NOUN
ajlm-2018	61	18	-	-	PUNCT
ajlm-2018	61	19	c	c	PROPN
ajlm-2018	61	20	(	(	PUNCT
ajlm-2018	61	21	≥	≥	NOUN
ajlm-2018	61	22	3.4	3.4	NUM
ajlm-2018	61	23	mmol	mmol	NOUN
ajlm-2018	61	24	/	/	SYM
ajlm-2018	61	25	l	l	NOUN
ajlm-2018	61	26	)	)	PUNCT
ajlm-2018	61	27	,	,	PUNCT
ajlm-2018	61	28	elevated	elevate	VERB
ajlm-2018	61	29	triglyceride	triglyceride	ADV
ajlm-2018	61	30	(	(	PUNCT
ajlm-2018	61	31	≥	≥	NUM
ajlm-2018	61	32	1.6	1.6	NUM
ajlm-2018	61	33	mmol	mmol	NOUN
ajlm-2018	61	34	/	/	SYM
ajlm-2018	61	35	l	l	NOUN
ajlm-2018	61	36	)	)	PUNCT
ajlm-2018	61	37	or	or	CCONJ
ajlm-2018	61	38	as	as	ADP
ajlm-2018	61	39	low	low	ADJ
ajlm-2018	61	40	hdl	hdl	PROPN
ajlm-2018	61	41	-	-	PUNCT
ajlm-2018	61	42	c	c	PROPN
ajlm-2018	61	43	(	(	PUNCT
ajlm-2018	61	44	≤	≤	ADV
ajlm-2018	61	45	1.04	1.04	NUM
ajlm-2018	61	46	mmol/	mmol/	NUM
ajlm-2018	61	47	l	l	NOUN
ajlm-2018	61	48	)	)	PUNCT
ajlm-2018	61	49	.	.	PUNCT
ajlm-2018	62	1	hyperglycaemia	hyperglycaemia	PROPN
ajlm-2018	62	2	was	be	AUX
ajlm-2018	62	3	defined	define	VERB
ajlm-2018	62	4	as	as	ADP
ajlm-2018	62	5	fasting	fast	VERB
ajlm-2018	62	6	blood	blood	NOUN
ajlm-2018	62	7	glucose	glucose	NOUN
ajlm-2018	62	8	≥	≥	NUM
ajlm-2018	62	9	6.2	6.2	NUM
ajlm-2018	62	10	mmol	mmol	NOUN
ajlm-2018	62	11	/	/	SYM
ajlm-2018	62	12	l.	l.	PROPN
ajlm-2018	62	13	elevated	elevated	ADJ
ajlm-2018	62	14	blood	blood	NOUN
ajlm-2018	62	15	pressure	pressure	NOUN
ajlm-2018	62	16	was	be	AUX
ajlm-2018	62	17	defined	define	VERB
ajlm-2018	62	18	as	as	ADP
ajlm-2018	62	19	systolic	systolic	ADJ
ajlm-2018	62	20	and	and	CCONJ
ajlm-2018	62	21	diastolic	diastolic	ADJ
ajlm-2018	62	22	pressure	pressure	NOUN
ajlm-2018	62	23	greater	great	ADJ
ajlm-2018	62	24	than	than	ADP
ajlm-2018	62	25	130/85	130/85	NUM
ajlm-2018	62	26	millimetre	millimetre	NOUN
ajlm-2018	62	27	of	of	ADP
ajlm-2018	62	28	mercury	mercury	NOUN
ajlm-2018	62	29	.	.	PUNCT
ajlm-2018	63	1	statistical	statistical	ADJ
ajlm-2018	63	2	analysis	analysis	NOUN
ajlm-2018	63	3	data	datum	NOUN
ajlm-2018	63	4	analysis	analysis	NOUN
ajlm-2018	63	5	was	be	AUX
ajlm-2018	63	6	conducted	conduct	VERB
ajlm-2018	63	7	using	use	VERB
ajlm-2018	63	8	statistical	statistical	ADJ
ajlm-2018	63	9	package	package	NOUN
ajlm-2018	63	10	for	for	ADP
ajlm-2018	63	11	social	social	ADJ
ajlm-2018	63	12	sciences	science	NOUN
ajlm-2018	63	13	statistical	statistical	ADJ
ajlm-2018	63	14	software	software	NOUN
ajlm-2018	63	15	version	version	NOUN
ajlm-2018	63	16	20	20	NUM
ajlm-2018	63	17	for	for	ADP
ajlm-2018	63	18	windows	window	NOUN
ajlm-2018	63	19	7	7	NUM
ajlm-2018	63	20	(	(	PUNCT
ajlm-2018	63	21	ibm	ibm	PROPN
ajlm-2018	63	22	corp	corp	PROPN
ajlm-2018	63	23	.	.	PROPN
ajlm-2018	63	24	,	,	PUNCT
ajlm-2018	63	25	chicago	chicago	PROPN
ajlm-2018	63	26	,	,	PUNCT
ajlm-2018	63	27	illinois	illinois	PROPN
ajlm-2018	63	28	,	,	PUNCT
ajlm-2018	63	29	united	united	PROPN
ajlm-2018	63	30	states	states	PROPN
ajlm-2018	63	31	)	)	PUNCT
ajlm-2018	63	32	.	.	PUNCT
ajlm-2018	64	1	the	the	DET
ajlm-2018	64	2	results	result	NOUN
ajlm-2018	64	3	were	be	AUX
ajlm-2018	64	4	expressed	express	VERB
ajlm-2018	64	5	as	as	ADP
ajlm-2018	64	6	mean	mean	NOUN
ajlm-2018	64	7	±	±	NUM
ajlm-2018	64	8	standard	standard	ADJ
ajlm-2018	64	9	deviation	deviation	NOUN
ajlm-2018	64	10	(	(	PUNCT
ajlm-2018	64	11	s.d	s.d	PROPN
ajlm-2018	64	12	.	.	PROPN
ajlm-2018	64	13	)	)	PUNCT
ajlm-2018	64	14	.	.	PUNCT
ajlm-2018	65	1	data	datum	NOUN
ajlm-2018	65	2	obtained	obtain	VERB
ajlm-2018	65	3	from	from	ADP
ajlm-2018	65	4	this	this	DET
ajlm-2018	65	5	study	study	NOUN
ajlm-2018	65	6	were	be	AUX
ajlm-2018	65	7	analysed	analyse	VERB
ajlm-2018	65	8	using	use	VERB
ajlm-2018	65	9	one	one	NUM
ajlm-2018	65	10	-	-	PUNCT
ajlm-2018	65	11	way	way	NOUN
ajlm-2018	65	12	analysis	analysis	NOUN
ajlm-2018	65	13	of	of	ADP
ajlm-2018	65	14	variance	variance	NOUN
ajlm-2018	65	15	,	,	PUNCT
ajlm-2018	65	16	and	and	CCONJ
ajlm-2018	65	17	post	post	VERB
ajlm-2018	65	18	hoc	hoc	X
ajlm-2018	65	19	tests	test	NOUN
ajlm-2018	65	20	were	be	AUX
ajlm-2018	65	21	used	use	VERB
ajlm-2018	65	22	to	to	PART
ajlm-2018	65	23	compare	compare	VERB
ajlm-2018	65	24	means	mean	NOUN
ajlm-2018	65	25	.	.	PUNCT
ajlm-2018	66	1	pearson	pearson	PROPN
ajlm-2018	66	2	bivariate	bivariate	ADJ
ajlm-2018	66	3	correlation	correlation	NOUN
ajlm-2018	66	4	was	be	AUX
ajlm-2018	66	5	used	use	VERB
ajlm-2018	66	6	to	to	PART
ajlm-2018	66	7	assess	assess	VERB
ajlm-2018	66	8	associations	association	NOUN
ajlm-2018	66	9	between	between	ADP
ajlm-2018	66	10	protein	protein	NOUN
ajlm-2018	66	11	levels	level	NOUN
ajlm-2018	66	12	and	and	CCONJ
ajlm-2018	66	13	lipid	lipid	NOUN
ajlm-2018	66	14	profiles	profile	NOUN
ajlm-2018	66	15	.	.	PUNCT
ajlm-2018	67	1	a	a	DET
ajlm-2018	67	2	p	p	NOUN
ajlm-2018	67	3	-	-	PUNCT
ajlm-2018	67	4	value	value	NOUN
ajlm-2018	67	5	was	be	AUX
ajlm-2018	67	6	considered	consider	VERB
ajlm-2018	67	7	significant	significant	ADJ
ajlm-2018	67	8	at	at	ADP
ajlm-2018	67	9	≤	≤	NUM
ajlm-2018	67	10	0.05	0.05	NUM
ajlm-2018	67	11	.	.	PUNCT
ajlm-2018	68	1	results	result	VERB
ajlm-2018	68	2	characteristics	characteristic	NOUN
ajlm-2018	68	3	of	of	ADP
ajlm-2018	68	4	study	study	NOUN
ajlm-2018	68	5	population	population	NOUN
ajlm-2018	68	6	the	the	DET
ajlm-2018	68	7	mean	mean	ADJ
ajlm-2018	68	8	ages	age	NOUN
ajlm-2018	68	9	were	be	AUX
ajlm-2018	68	10	39.36	39.36	NUM
ajlm-2018	68	11	±	±	NUM
ajlm-2018	68	12	7.02	7.02	NUM
ajlm-2018	68	13	years	year	NOUN
ajlm-2018	68	14	for	for	ADP
ajlm-2018	68	15	art	art	NOUN
ajlm-2018	68	16	-	-	PUNCT
ajlm-2018	68	17	naive	naive	ADJ
ajlm-2018	68	18	,	,	PUNCT
ajlm-2018	68	19	38.46	38.46	NUM
ajlm-2018	68	20	±	±	NUM
ajlm-2018	68	21	7.70	7.70	NUM
ajlm-2018	68	22	years	year	NOUN
ajlm-2018	68	23	for	for	ADP
ajlm-2018	68	24	art	art	NOUN
ajlm-2018	68	25	-	-	PUNCT
ajlm-2018	68	26	experienced	experience	VERB
ajlm-2018	68	27	and	and	CCONJ
ajlm-2018	68	28	31.20	31.20	NUM
ajlm-2018	68	29	±	±	NUM
ajlm-2018	68	30	7.26	7.26	NUM
ajlm-2018	68	31	years	year	NOUN
ajlm-2018	68	32	for	for	ADP
ajlm-2018	68	33	hiv	hiv	PROPN
ajlm-2018	68	34	-	-	PUNCT
ajlm-2018	68	35	negative	negative	ADJ
ajlm-2018	68	36	participants	participant	NOUN
ajlm-2018	68	37	(	(	PUNCT
ajlm-2018	68	38	table	table	NOUN
ajlm-2018	68	39	1	1	NUM
ajlm-2018	68	40	)	)	PUNCT
ajlm-2018	68	41	.	.	PUNCT
ajlm-2018	69	1	the	the	DET
ajlm-2018	69	2	mean	mean	ADJ
ajlm-2018	69	3	sbp	sbp	NOUN
ajlm-2018	69	4	of	of	ADP
ajlm-2018	69	5	the	the	DET
ajlm-2018	69	6	art	art	NOUN
ajlm-2018	69	7	-	-	PUNCT
ajlm-2018	69	8	naive	naive	ADJ
ajlm-2018	69	9	participants	participant	NOUN
ajlm-2018	69	10	was	be	AUX
ajlm-2018	69	11	135.52	135.52	NUM
ajlm-2018	69	12	±	±	NUM
ajlm-2018	69	13	24.79	24.79	NUM
ajlm-2018	69	14	millimetres	millimetre	NOUN
ajlm-2018	69	15	of	of	ADP
ajlm-2018	69	16	mercury	mercury	NOUN
ajlm-2018	69	17	,	,	PUNCT
ajlm-2018	69	18	143.26	143.26	NUM
ajlm-2018	69	19	±	±	NUM
ajlm-2018	69	20	27.98	27.98	NUM
ajlm-2018	69	21	millimetres	millimetre	NOUN
ajlm-2018	69	22	of	of	ADP
ajlm-2018	69	23	mercury	mercury	NOUN
ajlm-2018	69	24	for	for	ADP
ajlm-2018	69	25	art	art	NOUN
ajlm-2018	69	26	-	-	PUNCT
ajlm-2018	69	27	experienced	experience	VERB
ajlm-2018	69	28	participants	participant	NOUN
ajlm-2018	69	29	and	and	CCONJ
ajlm-2018	69	30	130.72	130.72	NUM
ajlm-2018	69	31	±	±	NUM
ajlm-2018	69	32	14.56	14.56	NUM
ajlm-2018	69	33	millimetres	millimetre	NOUN
ajlm-2018	69	34	of	of	ADP
ajlm-2018	69	35	mercury	mercury	NOUN
ajlm-2018	69	36	for	for	ADP
ajlm-2018	69	37	the	the	DET
ajlm-2018	69	38	hiv	hiv	PROPN
ajlm-2018	69	39	-	-	PUNCT
ajlm-2018	69	40	negative	negative	ADJ
ajlm-2018	69	41	participants	participant	NOUN
ajlm-2018	69	42	.	.	PUNCT
ajlm-2018	70	1	patients	patient	NOUN
ajlm-2018	70	2	on	on	ADP
ajlm-2018	70	3	art	art	NOUN
ajlm-2018	70	4	had	have	VERB
ajlm-2018	70	5	significantly	significantly	ADV
ajlm-2018	70	6	higher	high	ADJ
ajlm-2018	70	7	sbp	sbp	NOUN
ajlm-2018	70	8	compared	compare	VERB
ajlm-2018	70	9	to	to	ADP
ajlm-2018	70	10	the	the	DET
ajlm-2018	70	11	control	control	NOUN
ajlm-2018	70	12	group	group	NOUN
ajlm-2018	70	13	(	(	PUNCT
ajlm-2018	70	14	p	p	X
ajlm-2018	70	15	=	=	NOUN
ajlm-2018	70	16	0.023	0.023	NUM
ajlm-2018	70	17	)	)	PUNCT
ajlm-2018	70	18	.	.	PUNCT
ajlm-2018	71	1	no	no	DET
ajlm-2018	71	2	significant	significant	ADJ
ajlm-2018	71	3	difference	difference	NOUN
ajlm-2018	71	4	was	be	AUX
ajlm-2018	71	5	observed	observe	VERB
ajlm-2018	71	6	when	when	SCONJ
ajlm-2018	71	7	the	the	DET
ajlm-2018	71	8	sbp	sbp	NOUN
ajlm-2018	71	9	of	of	ADP
ajlm-2018	71	10	the	the	DET
ajlm-2018	71	11	art	art	NOUN
ajlm-2018	71	12	-	-	PUNCT
ajlm-2018	71	13	naïve	naïve	ADJ
ajlm-2018	71	14	participants	participant	NOUN
ajlm-2018	71	15	was	be	AUX
ajlm-2018	71	16	compared	compare	VERB
ajlm-2018	71	17	with	with	ADP
ajlm-2018	71	18	that	that	PRON
ajlm-2018	71	19	of	of	ADP
ajlm-2018	71	20	controls	control	NOUN
ajlm-2018	71	21	(	(	PUNCT
ajlm-2018	71	22	p	p	X
ajlm-2018	71	23	=	=	NOUN
ajlm-2018	71	24	0.905	0.905	NUM
ajlm-2018	71	25	)	)	PUNCT
ajlm-2018	71	26	or	or	CCONJ
ajlm-2018	71	27	with	with	ADP
ajlm-2018	71	28	the	the	DET
ajlm-2018	71	29	art	art	NOUN
ajlm-2018	71	30	-	-	PUNCT
ajlm-2018	71	31	experienced	experience	VERB
ajlm-2018	71	32	participants	participant	NOUN
ajlm-2018	71	33	(	(	PUNCT
ajlm-2018	71	34	p	p	X
ajlm-2018	71	35	=	=	NOUN
ajlm-2018	71	36	0.291	0.291	NUM
ajlm-2018	71	37	)	)	PUNCT
ajlm-2018	71	38	.	.	PUNCT
ajlm-2018	72	1	table	table	NOUN
ajlm-2018	72	2	1	1	NUM
ajlm-2018	72	3	:	:	PUNCT
ajlm-2018	72	4	 	 	SPACE
ajlm-2018	72	5	socio	socio	NOUN
ajlm-2018	72	6	-	-	PUNCT
ajlm-2018	72	7	clinical	clinical	ADJ
ajlm-2018	72	8	characteristics	characteristic	NOUN
ajlm-2018	72	9	and	and	CCONJ
ajlm-2018	72	10	lipid	lipid	NOUN
ajlm-2018	72	11	profile	profile	NOUN
ajlm-2018	72	12	of	of	ADP
ajlm-2018	72	13	controls	control	NOUN
ajlm-2018	72	14	,	,	PUNCT
ajlm-2018	72	15	antiretroviral	antiretroviral	ADJ
ajlm-2018	72	16	therapy	therapy	NOUN
ajlm-2018	72	17	-	-	PUNCT
ajlm-2018	72	18	naïve	naïve	ADJ
ajlm-2018	72	19	and	and	CCONJ
ajlm-2018	72	20	treatment	treatment	NOUN
ajlm-2018	72	21	-	-	PUNCT
ajlm-2018	72	22	experienced	experience	VERB
ajlm-2018	72	23	hiv	hiv	NOUN
ajlm-2018	72	24	-	-	PUNCT
ajlm-2018	72	25	positive	positive	ADJ
ajlm-2018	72	26	patients	patient	NOUN
ajlm-2018	72	27	,	,	PUNCT
ajlm-2018	72	28	benin	benin	PROPN
ajlm-2018	72	29	city	city	PROPN
ajlm-2018	72	30	,	,	PUNCT
ajlm-2018	72	31	nigeria	nigeria	PROPN
ajlm-2018	72	32	between	between	ADP
ajlm-2018	72	33	may	may	PROPN
ajlm-2018	72	34	2015	2015	NUM
ajlm-2018	72	35	and	and	CCONJ
ajlm-2018	72	36	november	november	PROPN
ajlm-2018	72	37	2015	2015	NUM
ajlm-2018	72	38	.	.	PUNCT
ajlm-2018	73	1	fasting	fast	VERB
ajlm-2018	73	2	lipid	lipid	NOUN
ajlm-2018	73	3	profile	profile	NOUN
ajlm-2018	73	4	levels	level	NOUN
ajlm-2018	73	5	in	in	ADP
ajlm-2018	73	6	patients	patient	NOUN
ajlm-2018	73	7	and	and	CCONJ
ajlm-2018	73	8	controls	control	VERB
ajlm-2018	73	9	all	all	DET
ajlm-2018	73	10	hiv	hiv	PROPN
ajlm-2018	73	11	-	-	PUNCT
ajlm-2018	73	12	positive	positive	ADJ
ajlm-2018	73	13	patients	patient	NOUN
ajlm-2018	73	14	irrespective	irrespective	ADV
ajlm-2018	73	15	of	of	ADP
ajlm-2018	73	16	art	art	NOUN
ajlm-2018	73	17	experience	experience	NOUN
ajlm-2018	73	18	had	have	VERB
ajlm-2018	73	19	significantly	significantly	ADV
ajlm-2018	73	20	higher	high	ADJ
ajlm-2018	73	21	mean	mean	ADJ
ajlm-2018	73	22	values	value	NOUN
ajlm-2018	73	23	for	for	ADP
ajlm-2018	73	24	total	total	ADJ
ajlm-2018	73	25	cholesterol	cholesterol	NOUN
ajlm-2018	73	26	(	(	PUNCT
ajlm-2018	73	27	p	p	X
ajlm-2018	73	28	=	=	NOUN
ajlm-2018	73	29	0.003	0.003	NUM
ajlm-2018	73	30	)	)	PUNCT
ajlm-2018	73	31	,	,	PUNCT
ajlm-2018	73	32	triglycerides	triglyceride	NOUN
ajlm-2018	73	33	(	(	PUNCT
ajlm-2018	73	34	p	p	X
ajlm-2018	73	35	<	<	X
ajlm-2018	73	36	0.001	0.001	NUM
ajlm-2018	73	37	)	)	PUNCT
ajlm-2018	73	38	,	,	PUNCT
ajlm-2018	73	39	ldl	ldl	NOUN
ajlm-2018	73	40	-	-	PUNCT
ajlm-2018	73	41	c	c	NOUN
ajlm-2018	73	42	(	(	PUNCT
ajlm-2018	73	43	p	p	X
ajlm-2018	73	44	=	=	NOUN
ajlm-2018	73	45	0.003	0.003	NUM
ajlm-2018	73	46	)	)	PUNCT
ajlm-2018	73	47	,	,	PUNCT
ajlm-2018	73	48	aciii	aciii	PRON
ajlm-2018	73	49	(	(	PUNCT
ajlm-2018	73	50	p	p	X
ajlm-2018	73	51	<	<	X
ajlm-2018	73	52	0.001	0.001	NUM
ajlm-2018	73	53	)	)	PUNCT
ajlm-2018	73	54	,	,	PUNCT
ajlm-2018	73	55	and	and	CCONJ
ajlm-2018	73	56	ae	ae	PROPN
ajlm-2018	73	57	(	(	PUNCT
ajlm-2018	73	58	p	p	X
ajlm-2018	73	59	<	<	X
ajlm-2018	73	60	0.001	0.001	NUM
ajlm-2018	73	61	)	)	PUNCT
ajlm-2018	73	62	levels	level	NOUN
ajlm-2018	73	63	compared	compare	VERB
ajlm-2018	73	64	to	to	ADP
ajlm-2018	73	65	the	the	DET
ajlm-2018	73	66	hiv	hiv	PROPN
ajlm-2018	73	67	-	-	PUNCT
ajlm-2018	73	68	negative	negative	ADJ
ajlm-2018	73	69	participants	participant	NOUN
ajlm-2018	73	70	(	(	PUNCT
ajlm-2018	73	71	table	table	NOUN
ajlm-2018	73	72	1	1	NUM
ajlm-2018	73	73	)	)	PUNCT
ajlm-2018	73	74	.	.	PUNCT
ajlm-2018	74	1	conversely	conversely	ADV
ajlm-2018	74	2	,	,	PUNCT
ajlm-2018	74	3	the	the	DET
ajlm-2018	74	4	hdl	hdl	PROPN
ajlm-2018	74	5	-	-	PUNCT
ajlm-2018	74	6	c	c	NOUN
ajlm-2018	74	7	concentrations	concentration	NOUN
ajlm-2018	74	8	was	be	AUX
ajlm-2018	74	9	significantly	significantly	ADV
ajlm-2018	74	10	lower	low	ADJ
ajlm-2018	74	11	(	(	PUNCT
ajlm-2018	74	12	p	p	X
ajlm-2018	74	13	<	<	X
ajlm-2018	74	14	0.001	0.001	NUM
ajlm-2018	74	15	)	)	PUNCT
ajlm-2018	74	16	among	among	ADP
ajlm-2018	74	17	the	the	DET
ajlm-2018	74	18	hiv	hiv	PROPN
ajlm-2018	74	19	-	-	PUNCT
ajlm-2018	74	20	negative	negative	ADJ
ajlm-2018	74	21	patients	patient	NOUN
ajlm-2018	74	22	compared	compare	VERB
ajlm-2018	74	23	to	to	ADP
ajlm-2018	74	24	the	the	DET
ajlm-2018	74	25	hiv	hiv	NOUN
ajlm-2018	74	26	-	-	PUNCT
ajlm-2018	74	27	positive	positive	ADJ
ajlm-2018	74	28	patients	patient	NOUN
ajlm-2018	74	29	.	.	PUNCT
ajlm-2018	75	1	when	when	SCONJ
ajlm-2018	75	2	the	the	DET
ajlm-2018	75	3	art	art	NOUN
ajlm-2018	75	4	experience	experience	NOUN
ajlm-2018	75	5	was	be	AUX
ajlm-2018	75	6	considered	consider	VERB
ajlm-2018	75	7	,	,	PUNCT
ajlm-2018	75	8	hiv	hiv	NOUN
ajlm-2018	75	9	-	-	PUNCT
ajlm-2018	75	10	positive	positive	ADJ
ajlm-2018	75	11	art	art	NOUN
ajlm-2018	75	12	-	-	PUNCT
ajlm-2018	75	13	experienced	experience	VERB
ajlm-2018	75	14	patients	patient	NOUN
ajlm-2018	75	15	had	have	VERB
ajlm-2018	75	16	significantly	significantly	ADV
ajlm-2018	75	17	higher	high	ADJ
ajlm-2018	75	18	total	total	ADJ
ajlm-2018	75	19	cholesterol	cholesterol	NOUN
ajlm-2018	75	20	(	(	PUNCT
ajlm-2018	75	21	p	p	NOUN
ajlm-2018	75	22	=	=	NOUN
ajlm-2018	75	23	0.054	0.054	NUM
ajlm-2018	75	24	)	)	PUNCT
ajlm-2018	75	25	,	,	PUNCT
ajlm-2018	75	26	ldl	ldl	NOUN
ajlm-2018	75	27	-	-	PUNCT
ajlm-2018	75	28	c	c	NOUN
ajlm-2018	75	29	(	(	PUNCT
ajlm-2018	75	30	p	p	X
ajlm-2018	75	31	=	=	NOUN
ajlm-2018	75	32	0.054	0.054	NUM
ajlm-2018	75	33	)	)	PUNCT
ajlm-2018	75	34	and	and	CCONJ
ajlm-2018	75	35	ae	ae	PROPN
ajlm-2018	75	36	(	(	PUNCT
ajlm-2018	75	37	p	p	NOUN
ajlm-2018	75	38	=	=	NOUN
ajlm-2018	75	39	0.049	0.049	NUM
ajlm-2018	75	40	)	)	PUNCT
ajlm-2018	75	41	compared	compare	VERB
ajlm-2018	75	42	to	to	ADP
ajlm-2018	75	43	the	the	DET
ajlm-2018	75	44	art	art	NOUN
ajlm-2018	75	45	-	-	PUNCT
ajlm-2018	75	46	naïve	naïve	ADJ
ajlm-2018	75	47	hiv	hiv	NOUN
ajlm-2018	75	48	-	-	PUNCT
ajlm-2018	75	49	positive	positive	ADJ
ajlm-2018	75	50	patients	patient	NOUN
ajlm-2018	75	51	.	.	PUNCT
ajlm-2018	76	1	no	no	DET
ajlm-2018	76	2	significant	significant	ADJ
ajlm-2018	76	3	difference	difference	NOUN
ajlm-2018	76	4	was	be	AUX
ajlm-2018	76	5	noted	note	VERB
ajlm-2018	76	6	when	when	SCONJ
ajlm-2018	76	7	the	the	DET
ajlm-2018	76	8	triglycerides	triglyceride	NOUN
ajlm-2018	76	9	,	,	PUNCT
ajlm-2018	76	10	hdl	hdl	NOUN
ajlm-2018	76	11	-	-	PUNCT
ajlm-2018	76	12	c	c	PROPN
ajlm-2018	76	13	and	and	CCONJ
ajlm-2018	76	14	aciii	aciii	DET
ajlm-2018	76	15	values	value	NOUN
ajlm-2018	76	16	were	be	AUX
ajlm-2018	76	17	compared	compare	VERB
ajlm-2018	76	18	among	among	ADP
ajlm-2018	76	19	the	the	DET
ajlm-2018	76	20	art	art	NOUN
ajlm-2018	76	21	-	-	PUNCT
ajlm-2018	76	22	naïve	naïve	ADJ
ajlm-2018	76	23	and	and	CCONJ
ajlm-2018	76	24	art	art	NOUN
ajlm-2018	76	25	-	-	PUNCT
ajlm-2018	76	26	experienced	experience	VERB
ajlm-2018	76	27	hiv	hiv	NOUN
ajlm-2018	76	28	-	-	PUNCT
ajlm-2018	76	29	positive	positive	ADJ
ajlm-2018	76	30	patients	patient	NOUN
ajlm-2018	76	31	.	.	PUNCT
ajlm-2018	77	1	table	table	NOUN
ajlm-2018	77	2	2	2	NUM
ajlm-2018	77	3	:	:	PUNCT
ajlm-2018	77	4	 	 	SPACE
ajlm-2018	77	5	therapy	therapy	NOUN
ajlm-2018	77	6	consideration	consideration	NOUN
ajlm-2018	77	7	of	of	ADP
ajlm-2018	77	8	the	the	DET
ajlm-2018	77	9	socio	socio	NOUN
ajlm-2018	77	10	-	-	PUNCT
ajlm-2018	77	11	clinical	clinical	ADJ
ajlm-2018	77	12	characteristics	characteristic	NOUN
ajlm-2018	77	13	of	of	ADP
ajlm-2018	77	14	the	the	DET
ajlm-2018	77	15	controls	control	NOUN
ajlm-2018	77	16	,	,	PUNCT
ajlm-2018	77	17	antiretroviral	antiretroviral	ADJ
ajlm-2018	77	18	therapy	therapy	NOUN
ajlm-2018	77	19	-	-	PUNCT
ajlm-2018	77	20	naïve	naïve	ADJ
ajlm-2018	77	21	and	and	CCONJ
ajlm-2018	77	22	treatment	treatment	NOUN
ajlm-2018	77	23	-	-	PUNCT
ajlm-2018	77	24	experienced	experience	VERB
ajlm-2018	77	25	hiv	hiv	NOUN
ajlm-2018	77	26	-	-	PUNCT
ajlm-2018	77	27	positive	positive	ADJ
ajlm-2018	77	28	patients	patient	NOUN
ajlm-2018	77	29	,	,	PUNCT
ajlm-2018	77	30	benin	benin	PROPN
ajlm-2018	77	31	city	city	PROPN
ajlm-2018	77	32	,	,	PUNCT
ajlm-2018	77	33	nigeria	nigeria	PROPN
ajlm-2018	77	34	,	,	PUNCT
ajlm-2018	77	35	between	between	ADP
ajlm-2018	77	36	may	may	PROPN
ajlm-2018	77	37	2015	2015	NUM
ajlm-2018	77	38	and	and	CCONJ
ajlm-2018	77	39	november	november	PROPN
ajlm-2018	77	40	2015	2015	NUM
ajlm-2018	77	41	.	.	PUNCT
ajlm-2018	78	1	therapy	therapy	NOUN
ajlm-2018	78	2	duration	duration	NOUN
ajlm-2018	78	3	characteristics	characteristic	NOUN
ajlm-2018	78	4	there	there	PRON
ajlm-2018	78	5	was	be	VERB
ajlm-2018	78	6	no	no	DET
ajlm-2018	78	7	significant	significant	ADJ
ajlm-2018	78	8	difference	difference	NOUN
ajlm-2018	78	9	in	in	ADP
ajlm-2018	78	10	the	the	DET
ajlm-2018	78	11	age	age	NOUN
ajlm-2018	78	12	,	,	PUNCT
ajlm-2018	78	13	sbp	sbp	NOUN
ajlm-2018	78	14	,	,	PUNCT
ajlm-2018	78	15	diastolic	diastolic	ADJ
ajlm-2018	78	16	blood	blood	NOUN
ajlm-2018	78	17	pressure	pressure	NOUN
ajlm-2018	78	18	,	,	PUNCT
ajlm-2018	78	19	weight	weight	NOUN
ajlm-2018	78	20	,	,	PUNCT
ajlm-2018	78	21	height	height	NOUN
ajlm-2018	78	22	,	,	PUNCT
ajlm-2018	78	23	and	and	CCONJ
ajlm-2018	78	24	body	body	NOUN
ajlm-2018	78	25	mass	mass	NOUN
ajlm-2018	78	26	index	index	NOUN
ajlm-2018	78	27	was	be	AUX
ajlm-2018	78	28	of	of	ADP
ajlm-2018	78	29	the	the	DET
ajlm-2018	78	30	various	various	ADJ
ajlm-2018	78	31	art	art	NOUN
ajlm-2018	78	32	-	-	PUNCT
ajlm-2018	78	33	duration	duration	NOUN
ajlm-2018	78	34	groups	group	NOUN
ajlm-2018	78	35	(	(	PUNCT
ajlm-2018	78	36	table	table	NOUN
ajlm-2018	78	37	2	2	NUM
ajlm-2018	78	38	)	)	PUNCT
ajlm-2018	78	39	.	.	PUNCT
ajlm-2018	79	1	lipids	lipid	NOUN
ajlm-2018	79	2	and	and	CCONJ
ajlm-2018	79	3	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	79	4	levels	level	NOUN
ajlm-2018	79	5	based	base	VERB
ajlm-2018	79	6	on	on	ADP
ajlm-2018	79	7	therapy	therapy	NOUN
ajlm-2018	79	8	duration	duration	NOUN
ajlm-2018	79	9	there	there	PRON
ajlm-2018	79	10	was	be	VERB
ajlm-2018	79	11	a	a	DET
ajlm-2018	79	12	statistically	statistically	ADV
ajlm-2018	79	13	significant	significant	ADJ
ajlm-2018	79	14	difference	difference	NOUN
ajlm-2018	79	15	when	when	SCONJ
ajlm-2018	79	16	total	total	ADJ
ajlm-2018	79	17	cholesterol	cholesterol	NOUN
ajlm-2018	79	18	and	and	CCONJ
ajlm-2018	79	19	ldl	ldl	NOUN
ajlm-2018	79	20	-	-	PUNCT
ajlm-2018	79	21	c	c	PROPN
ajlm-2018	79	22	were	be	AUX
ajlm-2018	79	23	compared	compare	VERB
ajlm-2018	79	24	among	among	ADP
ajlm-2018	79	25	the	the	DET
ajlm-2018	79	26	various	various	ADJ
ajlm-2018	79	27	groups	group	NOUN
ajlm-2018	79	28	(	(	PUNCT
ajlm-2018	79	29	table	table	NOUN
ajlm-2018	79	30	3	3	NUM
ajlm-2018	79	31	)	)	PUNCT
ajlm-2018	79	32	.	.	PUNCT
ajlm-2018	80	1	when	when	SCONJ
ajlm-2018	80	2	the	the	DET
ajlm-2018	80	3	values	value	NOUN
ajlm-2018	80	4	of	of	ADP
ajlm-2018	80	5	triglycerides	triglyceride	NOUN
ajlm-2018	80	6	,	,	PUNCT
ajlm-2018	80	7	hdl	hdl	NOUN
ajlm-2018	80	8	-	-	PUNCT
ajlm-2018	80	9	c	c	PROPN
ajlm-2018	80	10	,	,	PUNCT
ajlm-2018	80	11	aciii	aciii	PRON
ajlm-2018	80	12	,	,	PUNCT
ajlm-2018	80	13	and	and	CCONJ
ajlm-2018	80	14	ae	ae	PROPN
ajlm-2018	80	15	were	be	AUX
ajlm-2018	80	16	compared	compare	VERB
ajlm-2018	80	17	for	for	ADP
ajlm-2018	80	18	hiv	hiv	PROPN
ajlm-2018	80	19	-	-	PUNCT
ajlm-2018	80	20	positive	positive	ADJ
ajlm-2018	80	21	patients	patient	NOUN
ajlm-2018	80	22	based	base	VERB
ajlm-2018	80	23	on	on	ADP
ajlm-2018	80	24	the	the	DET
ajlm-2018	80	25	duration	duration	NOUN
ajlm-2018	80	26	of	of	ADP
ajlm-2018	80	27	therapy	therapy	NOUN
ajlm-2018	80	28	,	,	PUNCT
ajlm-2018	80	29	there	there	PRON
ajlm-2018	80	30	were	be	VERB
ajlm-2018	80	31	no	no	DET
ajlm-2018	80	32	statistically	statistically	ADV
ajlm-2018	80	33	significant	significant	ADJ
ajlm-2018	80	34	variations	variation	NOUN
ajlm-2018	80	35	(	(	PUNCT
ajlm-2018	80	36	table	table	NOUN
ajlm-2018	80	37	3	3	NUM
ajlm-2018	80	38	)	)	PUNCT
ajlm-2018	80	39	.	.	PUNCT
ajlm-2018	81	1	table	table	NOUN
ajlm-2018	81	2	3	3	NUM
ajlm-2018	81	3	:	:	PUNCT
ajlm-2018	81	4	 	 	SPACE
ajlm-2018	81	5	therapy	therapy	NOUN
ajlm-2018	81	6	consideration	consideration	NOUN
ajlm-2018	81	7	of	of	ADP
ajlm-2018	81	8	lipids	lipid	NOUN
ajlm-2018	81	9	and	and	CCONJ
ajlm-2018	81	10	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	81	11	for	for	ADP
ajlm-2018	81	12	therapy	therapy	NOUN
ajlm-2018	81	13	duration	duration	NOUN
ajlm-2018	81	14	of	of	ADP
ajlm-2018	81	15	the	the	DET
ajlm-2018	81	16	controls	control	NOUN
ajlm-2018	81	17	,	,	PUNCT
ajlm-2018	81	18	antiretroviral	antiretroviral	ADJ
ajlm-2018	81	19	treatment	treatment	NOUN
ajlm-2018	81	20	-	-	PUNCT
ajlm-2018	81	21	naïve	naïve	ADJ
ajlm-2018	81	22	and	and	CCONJ
ajlm-2018	81	23	treatment	treatment	NOUN
ajlm-2018	81	24	-	-	PUNCT
ajlm-2018	81	25	experienced	experience	VERB
ajlm-2018	81	26	hiv	hiv	NOUN
ajlm-2018	81	27	-	-	PUNCT
ajlm-2018	81	28	positive	positive	ADJ
ajlm-2018	81	29	patients	patient	NOUN
ajlm-2018	81	30	,	,	PUNCT
ajlm-2018	81	31	benin	benin	PROPN
ajlm-2018	81	32	city	city	PROPN
ajlm-2018	81	33	,	,	PUNCT
ajlm-2018	81	34	nigeria	nigeria	PROPN
ajlm-2018	81	35	,	,	PUNCT
ajlm-2018	81	36	between	between	ADP
ajlm-2018	81	37	may	may	PROPN
ajlm-2018	81	38	2015	2015	NUM
ajlm-2018	81	39	and	and	CCONJ
ajlm-2018	81	40	november	november	PROPN
ajlm-2018	81	41	2015	2015	NUM
ajlm-2018	81	42	.	.	PUNCT
ajlm-2018	82	1	lipids	lipid	NOUN
ajlm-2018	82	2	and	and	CCONJ
ajlm-2018	82	3	body	body	NOUN
ajlm-2018	82	4	mass	mass	NOUN
ajlm-2018	82	5	index	index	NOUN
ajlm-2018	82	6	for	for	ADP
ajlm-2018	82	7	patient	patient	ADJ
ajlm-2018	82	8	staging	staging	NOUN
ajlm-2018	82	9	we	we	PRON
ajlm-2018	82	10	observed	observe	VERB
ajlm-2018	82	11	no	no	DET
ajlm-2018	82	12	significant	significant	ADJ
ajlm-2018	82	13	difference	difference	NOUN
ajlm-2018	82	14	in	in	ADP
ajlm-2018	82	15	the	the	DET
ajlm-2018	82	16	body	body	NOUN
ajlm-2018	82	17	mass	mass	PROPN
ajlm-2018	82	18	index	index	NOUN
ajlm-2018	82	19	,	,	PUNCT
ajlm-2018	82	20	total	total	ADJ
ajlm-2018	82	21	cholesterol	cholesterol	NOUN
ajlm-2018	82	22	,	,	PUNCT
ajlm-2018	82	23	hdl	hdl	PROPN
ajlm-2018	82	24	-	-	PUNCT
ajlm-2018	82	25	c	c	PROPN
ajlm-2018	82	26	,	,	PUNCT
ajlm-2018	82	27	ldl	ldl	NOUN
ajlm-2018	82	28	-	-	PUNCT
ajlm-2018	82	29	c	c	PROPN
ajlm-2018	82	30	,	,	PUNCT
ajlm-2018	82	31	aciii	aciii	PRON
ajlm-2018	82	32	,	,	PUNCT
ajlm-2018	82	33	and	and	CCONJ
ajlm-2018	82	34	ae	ae	PROPN
ajlm-2018	82	35	among	among	ADP
ajlm-2018	82	36	both	both	DET
ajlm-2018	82	37	art	art	NOUN
ajlm-2018	82	38	-	-	PUNCT
ajlm-2018	82	39	experienced	experienced	ADJ
ajlm-2018	82	40	and	and	CCONJ
ajlm-2018	82	41	art	art	NOUN
ajlm-2018	82	42	-	-	PUNCT
ajlm-2018	82	43	naïve	naïve	ADJ
ajlm-2018	82	44	hiv	hiv	NOUN
ajlm-2018	82	45	-	-	PUNCT
ajlm-2018	82	46	positive	positive	ADJ
ajlm-2018	82	47	patients	patient	NOUN
ajlm-2018	82	48	in	in	ADP
ajlm-2018	82	49	different	different	ADJ
ajlm-2018	82	50	stages	stage	NOUN
ajlm-2018	82	51	of	of	ADP
ajlm-2018	82	52	the	the	DET
ajlm-2018	82	53	disease	disease	NOUN
ajlm-2018	82	54	.	.	PUNCT
ajlm-2018	83	1	stage	stage	NOUN
ajlm-2018	83	2	3	3	NUM
ajlm-2018	83	3	patients	patient	NOUN
ajlm-2018	83	4	had	have	VERB
ajlm-2018	83	5	significantly	significantly	ADV
ajlm-2018	83	6	lower	low	ADJ
ajlm-2018	83	7	triglycerides	triglyceride	NOUN
ajlm-2018	83	8	levels	level	NOUN
ajlm-2018	83	9	(	(	PUNCT
ajlm-2018	83	10	0.92	0.92	NUM
ajlm-2018	83	11	±	±	NUM
ajlm-2018	83	12	0.27	0.27	NUM
ajlm-2018	83	13	mmol	mmol	NOUN
ajlm-2018	83	14	/	/	SYM
ajlm-2018	83	15	l	l	NOUN
ajlm-2018	83	16	)	)	PUNCT
ajlm-2018	83	17	compared	compare	VERB
ajlm-2018	83	18	with	with	ADP
ajlm-2018	83	19	stage	stage	NOUN
ajlm-2018	83	20	4	4	NUM
ajlm-2018	83	21	patients	patient	NOUN
ajlm-2018	83	22	(	(	PUNCT
ajlm-2018	83	23	1.82	1.82	NUM
ajlm-2018	83	24	±	±	NUM
ajlm-2018	83	25	0.78	0.78	NUM
ajlm-2018	83	26	mmol	mmol	NOUN
ajlm-2018	83	27	/	/	SYM
ajlm-2018	83	28	l	l	NOUN
ajlm-2018	83	29	)	)	PUNCT
ajlm-2018	83	30	but	but	CCONJ
ajlm-2018	83	31	not	not	PART
ajlm-2018	83	32	significantly	significantly	ADV
ajlm-2018	83	33	different	different	ADJ
ajlm-2018	83	34	compared	compare	VERB
ajlm-2018	83	35	to	to	ADP
ajlm-2018	83	36	stages	stage	NOUN
ajlm-2018	83	37	1	1	NUM
ajlm-2018	83	38	and	and	CCONJ
ajlm-2018	83	39	2	2	NUM
ajlm-2018	83	40	patients	patient	NOUN
ajlm-2018	83	41	(	(	PUNCT
ajlm-2018	83	42	table	table	NOUN
ajlm-2018	83	43	4	4	NUM
ajlm-2018	83	44	)	)	PUNCT
ajlm-2018	83	45	.	.	PUNCT
ajlm-2018	84	1	table	table	NOUN
ajlm-2018	84	2	4	4	NUM
ajlm-2018	84	3	:	:	PUNCT
ajlm-2018	84	4	 	 	SPACE
ajlm-2018	84	5	lipid	lipid	NOUN
ajlm-2018	84	6	and	and	CCONJ
ajlm-2018	84	7	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	84	8	levels	level	NOUN
ajlm-2018	84	9	among	among	ADP
ajlm-2018	84	10	antiretroviral	antiretroviral	ADJ
ajlm-2018	84	11	treatment	treatment	NOUN
ajlm-2018	84	12	-	-	PUNCT
ajlm-2018	84	13	naïve	naïve	ADJ
ajlm-2018	84	14	and	and	CCONJ
ajlm-2018	84	15	treatment	treatment	NOUN
ajlm-2018	84	16	-	-	PUNCT
ajlm-2018	84	17	experienced	experience	VERB
ajlm-2018	84	18	hiv	hiv	NOUN
ajlm-2018	84	19	-	-	PUNCT
ajlm-2018	84	20	positive	positive	ADJ
ajlm-2018	84	21	participants	participant	NOUN
ajlm-2018	84	22	per	per	ADP
ajlm-2018	84	23	disease	disease	NOUN
ajlm-2018	84	24	staging	staging	NOUN
ajlm-2018	84	25	(	(	PUNCT
ajlm-2018	84	26	who	who	PRON
ajlm-2018	84	27	,	,	PUNCT
ajlm-2018	84	28	2005	2005	NUM
ajlm-2018	84	29	)	)	PUNCT
ajlm-2018	84	30	,	,	PUNCT
ajlm-2018	84	31	benin	benin	PROPN
ajlm-2018	84	32	city	city	PROPN
ajlm-2018	84	33	,	,	PUNCT
ajlm-2018	84	34	nigeria	nigeria	PROPN
ajlm-2018	84	35	,	,	PUNCT
ajlm-2018	84	36	between	between	ADP
ajlm-2018	84	37	may	may	PROPN
ajlm-2018	84	38	2015	2015	NUM
ajlm-2018	84	39	and	and	CCONJ
ajlm-2018	84	40	november	november	PROPN
ajlm-2018	84	41	2015	2015	NUM
ajlm-2018	84	42	.	.	PUNCT
ajlm-2018	85	1	associations	association	NOUN
ajlm-2018	85	2	between	between	ADP
ajlm-2018	85	3	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	85	4	c	c	PROPN
ajlm-2018	85	5	-	-	PUNCT
ajlm-2018	85	6	iii	iii	NOUN
ajlm-2018	85	7	and	and	CCONJ
ajlm-2018	85	8	e	e	NOUN
ajlm-2018	85	9	and	and	CCONJ
ajlm-2018	85	10	lipid	lipid	NOUN
ajlm-2018	85	11	profiles	profile	NOUN
ajlm-2018	85	12	the	the	DET
ajlm-2018	85	13	triglycerides	triglyceride	NOUN
ajlm-2018	85	14	of	of	ADP
ajlm-2018	85	15	the	the	DET
ajlm-2018	85	16	healthy	healthy	ADJ
ajlm-2018	85	17	controls	control	NOUN
ajlm-2018	85	18	and	and	CCONJ
ajlm-2018	85	19	art	art	NOUN
ajlm-2018	85	20	-	-	PUNCT
ajlm-2018	85	21	naïve	naïve	ADJ
ajlm-2018	85	22	groups	group	NOUN
ajlm-2018	85	23	correlated	correlate	VERB
ajlm-2018	85	24	positively	positively	ADV
ajlm-2018	85	25	with	with	ADP
ajlm-2018	85	26	ae	ae	PROPN
ajlm-2018	85	27	and	and	CCONJ
ajlm-2018	85	28	aciii	aciii	PRON
ajlm-2018	85	29	.	.	PUNCT
ajlm-2018	86	1	among	among	ADP
ajlm-2018	86	2	the	the	DET
ajlm-2018	86	3	art	art	NOUN
ajlm-2018	86	4	-	-	PUNCT
ajlm-2018	86	5	experienced	experience	VERB
ajlm-2018	86	6	group	group	NOUN
ajlm-2018	86	7	,	,	PUNCT
ajlm-2018	86	8	triglycerides	triglyceride	NOUN
ajlm-2018	86	9	correlated	correlate	VERB
ajlm-2018	86	10	positively	positively	ADV
ajlm-2018	86	11	with	with	ADP
ajlm-2018	86	12	aciii	aciii	PRON
ajlm-2018	86	13	and	and	CCONJ
ajlm-2018	86	14	negatively	negatively	ADV
ajlm-2018	86	15	with	with	ADP
ajlm-2018	86	16	ae	ae	PROPN
ajlm-2018	86	17	(	(	PUNCT
ajlm-2018	86	18	table	table	NOUN
ajlm-2018	86	19	5	5	NUM
ajlm-2018	86	20	)	)	PUNCT
ajlm-2018	86	21	.	.	PUNCT
ajlm-2018	87	1	there	there	PRON
ajlm-2018	87	2	was	be	VERB
ajlm-2018	87	3	a	a	DET
ajlm-2018	87	4	negative	negative	ADJ
ajlm-2018	87	5	correlation	correlation	NOUN
ajlm-2018	87	6	between	between	ADP
ajlm-2018	87	7	the	the	DET
ajlm-2018	87	8	total	total	ADJ
ajlm-2018	87	9	cholesterol	cholesterol	NOUN
ajlm-2018	87	10	and	and	CCONJ
ajlm-2018	87	11	ae	ae	PROPN
ajlm-2018	87	12	in	in	ADP
ajlm-2018	87	13	the	the	DET
ajlm-2018	87	14	healthy	healthy	ADJ
ajlm-2018	87	15	controls	control	NOUN
ajlm-2018	87	16	and	and	CCONJ
ajlm-2018	87	17	the	the	DET
ajlm-2018	87	18	treatment	treatment	NOUN
ajlm-2018	87	19	-	-	PUNCT
ajlm-2018	87	20	naïve	naïve	ADJ
ajlm-2018	87	21	patients	patient	NOUN
ajlm-2018	87	22	,	,	PUNCT
ajlm-2018	87	23	while	while	SCONJ
ajlm-2018	87	24	a	a	DET
ajlm-2018	87	25	positive	positive	ADJ
ajlm-2018	87	26	correlation	correlation	NOUN
ajlm-2018	87	27	was	be	AUX
ajlm-2018	87	28	observed	observe	VERB
ajlm-2018	87	29	with	with	ADP
ajlm-2018	87	30	the	the	DET
ajlm-2018	87	31	art	art	NOUN
ajlm-2018	87	32	-	-	PUNCT
ajlm-2018	87	33	experienced	experience	VERB
ajlm-2018	87	34	group	group	NOUN
ajlm-2018	87	35	.	.	PUNCT
ajlm-2018	88	1	with	with	ADP
ajlm-2018	88	2	aciii	aciii	PRON
ajlm-2018	88	3	,	,	PUNCT
ajlm-2018	88	4	total	total	ADJ
ajlm-2018	88	5	cholesterol	cholesterol	NOUN
ajlm-2018	88	6	correlated	correlate	VERB
ajlm-2018	88	7	positively	positively	ADV
ajlm-2018	88	8	among	among	ADP
ajlm-2018	88	9	the	the	DET
ajlm-2018	88	10	healthy	healthy	ADJ
ajlm-2018	88	11	control	control	NOUN
ajlm-2018	88	12	and	and	CCONJ
ajlm-2018	88	13	treatment	treatment	NOUN
ajlm-2018	88	14	-	-	PUNCT
ajlm-2018	88	15	experienced	experience	VERB
ajlm-2018	88	16	group	group	NOUN
ajlm-2018	88	17	and	and	CCONJ
ajlm-2018	88	18	negatively	negatively	ADV
ajlm-2018	88	19	with	with	ADP
ajlm-2018	88	20	the	the	DET
ajlm-2018	88	21	treatment	treatment	NOUN
ajlm-2018	88	22	-	-	PUNCT
ajlm-2018	88	23	naïve	naïve	ADJ
ajlm-2018	88	24	group	group	NOUN
ajlm-2018	88	25	.	.	PUNCT
ajlm-2018	89	1	among	among	ADP
ajlm-2018	89	2	the	the	DET
ajlm-2018	89	3	healthy	healthy	ADJ
ajlm-2018	89	4	controls	control	NOUN
ajlm-2018	89	5	,	,	PUNCT
ajlm-2018	89	6	a	a	DET
ajlm-2018	89	7	positive	positive	ADJ
ajlm-2018	89	8	correlation	correlation	NOUN
ajlm-2018	89	9	was	be	AUX
ajlm-2018	89	10	observed	observe	VERB
ajlm-2018	89	11	between	between	ADP
ajlm-2018	89	12	hdl	hdl	PROPN
ajlm-2018	89	13	-	-	PUNCT
ajlm-2018	89	14	c	c	PROPN
ajlm-2018	89	15	and	and	CCONJ
ajlm-2018	89	16	the	the	DET
ajlm-2018	89	17	studied	studied	ADJ
ajlm-2018	89	18	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	89	19	.	.	PUNCT
ajlm-2018	90	1	in	in	ADP
ajlm-2018	90	2	the	the	DET
ajlm-2018	90	3	hiv	hiv	NOUN
ajlm-2018	90	4	-	-	PUNCT
ajlm-2018	90	5	positive	positive	ADJ
ajlm-2018	90	6	groups	group	NOUN
ajlm-2018	90	7	,	,	PUNCT
ajlm-2018	90	8	hdl	hdl	PROPN
ajlm-2018	90	9	-	-	PUNCT
ajlm-2018	90	10	c	c	PROPN
ajlm-2018	90	11	correlated	correlate	VERB
ajlm-2018	90	12	negatively	negatively	ADV
ajlm-2018	90	13	with	with	ADP
ajlm-2018	90	14	the	the	DET
ajlm-2018	90	15	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	90	16	.	.	PUNCT
ajlm-2018	91	1	the	the	DET
ajlm-2018	91	2	ldl	ldl	NOUN
ajlm-2018	91	3	-	-	PUNCT
ajlm-2018	91	4	c	c	PROPN
ajlm-2018	91	5	correlated	correlate	VERB
ajlm-2018	91	6	negatively	negatively	ADV
ajlm-2018	91	7	with	with	ADP
ajlm-2018	91	8	ae	ae	PROPN
ajlm-2018	91	9	among	among	ADP
ajlm-2018	91	10	healthy	healthy	ADJ
ajlm-2018	91	11	controls	control	NOUN
ajlm-2018	91	12	and	and	CCONJ
ajlm-2018	91	13	treatment	treatment	NOUN
ajlm-2018	91	14	-	-	PUNCT
ajlm-2018	91	15	naïve	naïve	ADJ
ajlm-2018	91	16	group	group	NOUN
ajlm-2018	91	17	and	and	CCONJ
ajlm-2018	91	18	positively	positively	ADV
ajlm-2018	91	19	in	in	ADP
ajlm-2018	91	20	treatment	treatment	NOUN
ajlm-2018	91	21	-	-	PUNCT
ajlm-2018	91	22	experienced	experience	VERB
ajlm-2018	91	23	groups	group	NOUN
ajlm-2018	91	24	.	.	PUNCT
ajlm-2018	92	1	low	low	ADJ
ajlm-2018	92	2	-	-	PUNCT
ajlm-2018	92	3	density	density	NOUN
ajlm-2018	92	4	lipoprotein	lipoprotein	ADJ
ajlm-2018	92	5	cholesterol	cholesterol	NOUN
ajlm-2018	92	6	correlated	correlate	VERB
ajlm-2018	92	7	positively	positively	ADV
ajlm-2018	92	8	with	with	ADP
ajlm-2018	92	9	aciii	aciii	NUM
ajlm-2018	92	10	in	in	ADP
ajlm-2018	92	11	all	all	DET
ajlm-2018	92	12	studied	study	VERB
ajlm-2018	92	13	groups	group	NOUN
ajlm-2018	92	14	.	.	PUNCT
ajlm-2018	93	1	in	in	ADP
ajlm-2018	93	2	all	all	DET
ajlm-2018	93	3	the	the	DET
ajlm-2018	93	4	parameters	parameter	NOUN
ajlm-2018	93	5	in	in	ADP
ajlm-2018	93	6	the	the	DET
ajlm-2018	93	7	various	various	ADJ
ajlm-2018	93	8	groups	group	NOUN
ajlm-2018	93	9	,	,	PUNCT
ajlm-2018	93	10	the	the	DET
ajlm-2018	93	11	associations	association	NOUN
ajlm-2018	93	12	between	between	ADP
ajlm-2018	93	13	the	the	DET
ajlm-2018	93	14	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	93	15	and	and	CCONJ
ajlm-2018	93	16	lipids	lipid	NOUN
ajlm-2018	93	17	were	be	AUX
ajlm-2018	93	18	not	not	PART
ajlm-2018	93	19	statistically	statistically	ADV
ajlm-2018	93	20	significantly	significantly	ADV
ajlm-2018	93	21	(	(	PUNCT
ajlm-2018	93	22	p	p	NOUN
ajlm-2018	93	23	-	-	PUNCT
ajlm-2018	93	24	value	value	NOUN
ajlm-2018	93	25	>	>	NOUN
ajlm-2018	93	26	0.05	0.05	NUM
ajlm-2018	93	27	)	)	PUNCT
ajlm-2018	93	28	.	.	PUNCT
ajlm-2018	94	1	table	table	NOUN
ajlm-2018	94	2	5	5	NUM
ajlm-2018	94	3	:	:	PUNCT
ajlm-2018	94	4	 	 	SPACE
ajlm-2018	94	5	pearson	pearson	PROPN
ajlm-2018	94	6	bivariate	bivariate	ADJ
ajlm-2018	94	7	correlation	correlation	NOUN
ajlm-2018	94	8	between	between	ADP
ajlm-2018	94	9	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	94	10	c	c	PROPN
ajlm-2018	94	11	-	-	PUNCT
ajlm-2018	94	12	iii	iii	NOUN
ajlm-2018	94	13	and	and	CCONJ
ajlm-2018	94	14	e	e	PROPN
ajlm-2018	94	15	and	and	CCONJ
ajlm-2018	94	16	the	the	DET
ajlm-2018	94	17	lipid	lipid	NOUN
ajlm-2018	94	18	profile	profile	NOUN
ajlm-2018	94	19	of	of	ADP
ajlm-2018	94	20	the	the	DET
ajlm-2018	94	21	controls	control	NOUN
ajlm-2018	94	22	,	,	PUNCT
ajlm-2018	94	23	antiretroviral	antiretroviral	ADJ
ajlm-2018	94	24	therapy	therapy	NOUN
ajlm-2018	94	25	-	-	PUNCT
ajlm-2018	94	26	naïve	naïve	ADJ
ajlm-2018	94	27	and	and	CCONJ
ajlm-2018	94	28	treatment	treatment	NOUN
ajlm-2018	94	29	-	-	PUNCT
ajlm-2018	94	30	experienced	experience	VERB
ajlm-2018	94	31	hiv	hiv	NOUN
ajlm-2018	94	32	-	-	PUNCT
ajlm-2018	94	33	positive	positive	ADJ
ajlm-2018	94	34	patients	patient	NOUN
ajlm-2018	94	35	,	,	PUNCT
ajlm-2018	94	36	benin	benin	PROPN
ajlm-2018	94	37	city	city	PROPN
ajlm-2018	94	38	,	,	PUNCT
ajlm-2018	94	39	nigeria	nigeria	PROPN
ajlm-2018	94	40	,	,	PUNCT
ajlm-2018	94	41	between	between	ADP
ajlm-2018	94	42	may	may	PROPN
ajlm-2018	94	43	and	and	CCONJ
ajlm-2018	94	44	november	november	PROPN
ajlm-2018	94	45	2015	2015	NUM
ajlm-2018	94	46	.	.	PUNCT
ajlm-2018	95	1	discussion	discussion	NOUN
ajlm-2018	95	2	the	the	DET
ajlm-2018	95	3	present	present	ADJ
ajlm-2018	95	4	study	study	NOUN
ajlm-2018	95	5	assessed	assess	VERB
ajlm-2018	95	6	and	and	CCONJ
ajlm-2018	95	7	compared	compare	VERB
ajlm-2018	95	8	the	the	DET
ajlm-2018	95	9	lipid	lipid	NOUN
ajlm-2018	95	10	profile	profile	NOUN
ajlm-2018	95	11	,	,	PUNCT
ajlm-2018	95	12	aciii	aciii	INTJ
ajlm-2018	95	13	,	,	PUNCT
ajlm-2018	95	14	and	and	CCONJ
ajlm-2018	95	15	ae	ae	PROPN
ajlm-2018	95	16	among	among	ADP
ajlm-2018	95	17	hiv	hiv	PROPN
ajlm-2018	95	18	-	-	PUNCT
ajlm-2018	95	19	positive	positive	ADJ
ajlm-2018	95	20	art	art	NOUN
ajlm-2018	95	21	-	-	PUNCT
ajlm-2018	95	22	naïve	naïve	ADJ
ajlm-2018	95	23	patients	patient	NOUN
ajlm-2018	95	24	and	and	CCONJ
ajlm-2018	95	25	those	those	PRON
ajlm-2018	95	26	on	on	ADP
ajlm-2018	95	27	art	art	NOUN
ajlm-2018	95	28	.	.	PUNCT
ajlm-2018	96	1	we	we	PRON
ajlm-2018	96	2	found	find	VERB
ajlm-2018	96	3	that	that	SCONJ
ajlm-2018	96	4	the	the	DET
ajlm-2018	96	5	studied	study	VERB
ajlm-2018	96	6	apolipoproteins	apolipoprotein	NOUN
ajlm-2018	96	7	and	and	CCONJ
ajlm-2018	96	8	lipid	lipid	NOUN
ajlm-2018	96	9	profiles	profile	NOUN
ajlm-2018	96	10	of	of	ADP
ajlm-2018	96	11	hiv	hiv	PROPN
ajlm-2018	96	12	-	-	PUNCT
ajlm-2018	96	13	negative	negative	ADJ
ajlm-2018	96	14	participants	participant	NOUN
ajlm-2018	96	15	were	be	AUX
ajlm-2018	96	16	often	often	ADV
ajlm-2018	96	17	lower	low	ADJ
ajlm-2018	96	18	than	than	ADP
ajlm-2018	96	19	those	those	PRON
ajlm-2018	96	20	of	of	ADP
ajlm-2018	96	21	hiv	hiv	PROPN
ajlm-2018	96	22	-	-	PUNCT
ajlm-2018	96	23	positive	positive	ADJ
ajlm-2018	96	24	participants	participant	NOUN
ajlm-2018	96	25	irrespective	irrespective	ADV
ajlm-2018	96	26	of	of	ADP
ajlm-2018	96	27	the	the	DET
ajlm-2018	96	28	treatment	treatment	NOUN
ajlm-2018	96	29	experience	experience	NOUN
ajlm-2018	96	30	.	.	PUNCT
ajlm-2018	97	1	this	this	PRON
ajlm-2018	97	2	suggests	suggest	VERB
ajlm-2018	97	3	that	that	SCONJ
ajlm-2018	97	4	hiv	hiv	PROPN
ajlm-2018	97	5	itself	itself	PRON
ajlm-2018	97	6	disrupts	disrupt	VERB
ajlm-2018	97	7	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	97	8	concentrations	concentration	NOUN
ajlm-2018	97	9	,	,	PUNCT
ajlm-2018	97	10	consequently	consequently	ADV
ajlm-2018	97	11	disrupting	disrupt	VERB
ajlm-2018	97	12	lipid	lipid	ADJ
ajlm-2018	97	13	metabolism	metabolism	NOUN
ajlm-2018	97	14	.	.	PUNCT
ajlm-2018	98	1	we	we	PRON
ajlm-2018	98	2	observed	observe	VERB
ajlm-2018	98	3	a	a	DET
ajlm-2018	98	4	significantly	significantly	ADV
ajlm-2018	98	5	high	high	ADJ
ajlm-2018	98	6	sbp	sbp	NOUN
ajlm-2018	98	7	among	among	ADP
ajlm-2018	98	8	the	the	DET
ajlm-2018	98	9	art	art	NOUN
ajlm-2018	98	10	-	-	PUNCT
ajlm-2018	98	11	experienced	experienced	ADJ
ajlm-2018	98	12	compared	compare	VERB
ajlm-2018	98	13	to	to	ADP
ajlm-2018	98	14	the	the	DET
ajlm-2018	98	15	healthy	healthy	ADJ
ajlm-2018	98	16	control	control	NOUN
ajlm-2018	98	17	participants	participant	NOUN
ajlm-2018	98	18	.	.	PUNCT
ajlm-2018	99	1	hypertension	hypertension	NOUN
ajlm-2018	99	2	is	be	AUX
ajlm-2018	99	3	known	know	VERB
ajlm-2018	99	4	to	to	PART
ajlm-2018	99	5	increase	increase	VERB
ajlm-2018	99	6	the	the	DET
ajlm-2018	99	7	risk	risk	NOUN
ajlm-2018	99	8	of	of	ADP
ajlm-2018	99	9	cardiovascular	cardiovascular	ADJ
ajlm-2018	99	10	disease	disease	NOUN
ajlm-2018	99	11	and	and	CCONJ
ajlm-2018	99	12	atherosclerosis	atherosclerosis	NOUN
ajlm-2018	99	13	.	.	PUNCT
ajlm-2018	100	1	previous	previous	ADJ
ajlm-2018	100	2	studies	study	NOUN
ajlm-2018	100	3	conducted	conduct	VERB
ajlm-2018	100	4	in	in	ADP
ajlm-2018	100	5	ethopia	ethopia	PROPN
ajlm-2018	100	6	in	in	ADP
ajlm-2018	100	7	2018	2018	NUM
ajlm-2018	100	8	and	and	CCONJ
ajlm-2018	100	9	uganda	uganda	PROPN
ajlm-2018	100	10	between	between	ADP
ajlm-2018	100	11	2011	2011	NUM
ajlm-2018	100	12	to	to	ADP
ajlm-2018	100	13	2014	2014	NUM
ajlm-2018	100	14	have	have	AUX
ajlm-2018	100	15	reported	report	VERB
ajlm-2018	100	16	hypertension	hypertension	NOUN
ajlm-2018	100	17	to	to	PART
ajlm-2018	100	18	be	be	AUX
ajlm-2018	100	19	highly	highly	ADV
ajlm-2018	100	20	prevalent	prevalent	ADJ
ajlm-2018	100	21	among	among	ADP
ajlm-2018	100	22	hiv	hiv	PROPN
ajlm-2018	100	23	patients	patient	NOUN
ajlm-2018	100	24	on	on	ADP
ajlm-2018	100	25	art	art	NOUN
ajlm-2018	100	26	treatment.23,24,25,26	treatment.23,24,25,26	PROPN
ajlm-2018	100	27	hiv	hiv	PROPN
ajlm-2018	100	28	patients	patient	NOUN
ajlm-2018	100	29	on	on	ADP
ajlm-2018	100	30	art	art	NOUN
ajlm-2018	100	31	are	be	AUX
ajlm-2018	100	32	highly	highly	ADV
ajlm-2018	100	33	susceptible	susceptible	ADJ
ajlm-2018	100	34	to	to	ADP
ajlm-2018	100	35	developing	develop	VERB
ajlm-2018	100	36	hypertension	hypertension	NOUN
ajlm-2018	100	37	compared	compare	VERB
ajlm-2018	100	38	to	to	ADP
ajlm-2018	100	39	hiv	hiv	PROPN
ajlm-2018	100	40	-	-	PUNCT
ajlm-2018	100	41	negative	negative	ADJ
ajlm-2018	100	42	persons	person	NOUN
ajlm-2018	100	43	.	.	PUNCT
ajlm-2018	101	1	the	the	DET
ajlm-2018	101	2	pathophysiology	pathophysiology	NOUN
ajlm-2018	101	3	of	of	ADP
ajlm-2018	101	4	hypertension	hypertension	NOUN
ajlm-2018	101	5	among	among	ADP
ajlm-2018	101	6	hiv	hiv	PROPN
ajlm-2018	101	7	patients	patient	NOUN
ajlm-2018	101	8	may	may	AUX
ajlm-2018	101	9	be	be	AUX
ajlm-2018	101	10	directly	directly	ADV
ajlm-2018	101	11	or	or	CCONJ
ajlm-2018	101	12	indirectly	indirectly	ADV
ajlm-2018	101	13	influenced	influence	VERB
ajlm-2018	101	14	by	by	ADP
ajlm-2018	101	15	the	the	DET
ajlm-2018	101	16	virus	virus	NOUN
ajlm-2018	101	17	or	or	CCONJ
ajlm-2018	101	18	treatment	treatment	NOUN
ajlm-2018	101	19	-	-	PUNCT
ajlm-2018	101	20	related	relate	VERB
ajlm-2018	101	21	factors	factor	NOUN
ajlm-2018	101	22	.	.	PUNCT
ajlm-2018	102	1	chronic	chronic	ADJ
ajlm-2018	102	2	inflammation	inflammation	NOUN
ajlm-2018	102	3	and	and	CCONJ
ajlm-2018	102	4	lipodystrophy	lipodystrophy	NOUN
ajlm-2018	102	5	associated	associate	VERB
ajlm-2018	102	6	with	with	ADP
ajlm-2018	102	7	hiv	hiv	PROPN
ajlm-2018	102	8	infection	infection	NOUN
ajlm-2018	102	9	have	have	VERB
ajlm-2018	102	10	effects	effect	NOUN
ajlm-2018	102	11	on	on	ADP
ajlm-2018	102	12	the	the	DET
ajlm-2018	102	13	renin	renin	ADJ
ajlm-2018	102	14	-	-	PUNCT
ajlm-2018	102	15	angiotensin	angiotensin	NOUN
ajlm-2018	102	16	-	-	PUNCT
ajlm-2018	102	17	aldosterone	aldosterone	NOUN
ajlm-2018	102	18	pathway	pathway	NOUN
ajlm-2018	102	19	,	,	PUNCT
ajlm-2018	102	20	which	which	PRON
ajlm-2018	102	21	may	may	AUX
ajlm-2018	102	22	lead	lead	VERB
ajlm-2018	102	23	to	to	ADP
ajlm-2018	102	24	kidney	kidney	NOUN
ajlm-2018	102	25	damage	damage	NOUN
ajlm-2018	102	26	,	,	PUNCT
ajlm-2018	102	27	vascular	vascular	ADJ
ajlm-2018	102	28	dysfunction	dysfunction	NOUN
ajlm-2018	102	29	,	,	PUNCT
ajlm-2018	102	30	alterations	alteration	NOUN
ajlm-2018	102	31	in	in	ADP
ajlm-2018	102	32	sympathetic	sympathetic	ADJ
ajlm-2018	102	33	nervous	nervous	ADJ
ajlm-2018	102	34	outflow	outflow	NOUN
ajlm-2018	102	35	,	,	PUNCT
ajlm-2018	102	36	and	and	CCONJ
ajlm-2018	102	37	hence	hence	ADV
ajlm-2018	102	38	hypertension.26	hypertension.26	VERB
ajlm-2018	102	39	the	the	DET
ajlm-2018	102	40	typical	typical	ADJ
ajlm-2018	102	41	risk	risk	NOUN
ajlm-2018	102	42	factors	factor	NOUN
ajlm-2018	102	43	of	of	ADP
ajlm-2018	102	44	hypertension	hypertension	NOUN
ajlm-2018	102	45	include	include	VERB
ajlm-2018	102	46	genetic	genetic	ADJ
ajlm-2018	102	47	predisposition	predisposition	NOUN
ajlm-2018	102	48	and	and	CCONJ
ajlm-2018	102	49	lifestyle.23	lifestyle.23	VERB
ajlm-2018	102	50	the	the	DET
ajlm-2018	102	51	results	result	NOUN
ajlm-2018	102	52	from	from	ADP
ajlm-2018	102	53	this	this	DET
ajlm-2018	102	54	study	study	NOUN
ajlm-2018	102	55	suggest	suggest	VERB
ajlm-2018	102	56	that	that	SCONJ
ajlm-2018	102	57	hiv	hiv	PROPN
ajlm-2018	102	58	increases	increase	VERB
ajlm-2018	102	59	the	the	DET
ajlm-2018	102	60	risk	risk	NOUN
ajlm-2018	102	61	of	of	ADP
ajlm-2018	102	62	isolated	isolated	ADJ
ajlm-2018	102	63	systolic	systolic	ADJ
ajlm-2018	102	64	hypertension	hypertension	NOUN
ajlm-2018	102	65	,	,	PUNCT
ajlm-2018	102	66	which	which	PRON
ajlm-2018	102	67	increases	increase	VERB
ajlm-2018	102	68	a	a	DET
ajlm-2018	102	69	person	person	NOUN
ajlm-2018	102	70	’s	’s	PART
ajlm-2018	102	71	chance	chance	NOUN
ajlm-2018	102	72	of	of	ADP
ajlm-2018	102	73	cardiovascular	cardiovascular	ADV
ajlm-2018	102	74	-	-	PUNCT
ajlm-2018	102	75	related	relate	VERB
ajlm-2018	102	76	mortality.27	mortality.27	PROPN
ajlm-2018	102	77	metabolic	metabolic	NOUN
ajlm-2018	102	78	changes	change	NOUN
ajlm-2018	102	79	may	may	AUX
ajlm-2018	102	80	contribute	contribute	VERB
ajlm-2018	102	81	to	to	ADP
ajlm-2018	102	82	the	the	DET
ajlm-2018	102	83	risk	risk	NOUN
ajlm-2018	102	84	of	of	ADP
ajlm-2018	102	85	developing	develop	VERB
ajlm-2018	102	86	isolated	isolate	VERB
ajlm-2018	102	87	systolic	systolic	ADJ
ajlm-2018	102	88	hypertension.28	hypertension.28	PROPN
ajlm-2018	102	89	the	the	DET
ajlm-2018	102	90	serum	serum	NOUN
ajlm-2018	102	91	concentrations	concentration	NOUN
ajlm-2018	102	92	of	of	ADP
ajlm-2018	102	93	aciii	aciii	PROPN
ajlm-2018	102	94	and	and	CCONJ
ajlm-2018	102	95	ae	ae	PROPN
ajlm-2018	102	96	were	be	AUX
ajlm-2018	102	97	significantly	significantly	ADV
ajlm-2018	102	98	higher	high	ADJ
ajlm-2018	102	99	in	in	ADP
ajlm-2018	102	100	both	both	DET
ajlm-2018	102	101	art	art	NOUN
ajlm-2018	102	102	-	-	PUNCT
ajlm-2018	102	103	experienced	experienced	ADJ
ajlm-2018	102	104	and	and	CCONJ
ajlm-2018	102	105	treatment	treatment	NOUN
ajlm-2018	102	106	-	-	PUNCT
ajlm-2018	102	107	naïve	naïve	ADJ
ajlm-2018	102	108	patients	patient	NOUN
ajlm-2018	102	109	compared	compare	VERB
ajlm-2018	102	110	to	to	ADP
ajlm-2018	102	111	the	the	DET
ajlm-2018	102	112	controls	control	NOUN
ajlm-2018	102	113	,	,	PUNCT
ajlm-2018	102	114	similar	similar	ADJ
ajlm-2018	102	115	to	to	ADP
ajlm-2018	102	116	the	the	DET
ajlm-2018	102	117	findings	finding	NOUN
ajlm-2018	102	118	of	of	ADP
ajlm-2018	102	119	bonnet	bonnet	NOUN
ajlm-2018	102	120	et	et	PROPN
ajlm-2018	102	121	al	al	PROPN
ajlm-2018	102	122	.	.	PROPN
ajlm-2018	102	123	,29	,29	PROPN
ajlm-2018	102	124	who	who	PRON
ajlm-2018	102	125	also	also	ADV
ajlm-2018	102	126	reported	report	VERB
ajlm-2018	102	127	a	a	DET
ajlm-2018	102	128	marked	mark	VERB
ajlm-2018	102	129	increase	increase	NOUN
ajlm-2018	102	130	of	of	ADP
ajlm-2018	102	131	aciii	aciii	PRON
ajlm-2018	102	132	among	among	ADP
ajlm-2018	102	133	patients	patient	NOUN
ajlm-2018	102	134	on	on	ADP
ajlm-2018	102	135	intensive	intensive	ADJ
ajlm-2018	102	136	art	art	NOUN
ajlm-2018	102	137	receiving	receive	VERB
ajlm-2018	102	138	care	care	NOUN
ajlm-2018	102	139	in	in	ADP
ajlm-2018	102	140	france	france	PROPN
ajlm-2018	102	141	in	in	ADP
ajlm-2018	102	142	1999	1999	NUM
ajlm-2018	102	143	.	.	PUNCT
ajlm-2018	103	1	apolipoprotein	apolipoprotein	VERB
ajlm-2018	103	2	c	c	X
ajlm-2018	103	3	-	-	PUNCT
ajlm-2018	103	4	iii	iii	NOUN
ajlm-2018	103	5	plays	play	VERB
ajlm-2018	103	6	a	a	DET
ajlm-2018	103	7	major	major	ADJ
ajlm-2018	103	8	role	role	NOUN
ajlm-2018	103	9	in	in	ADP
ajlm-2018	103	10	the	the	DET
ajlm-2018	103	11	metabolism	metabolism	NOUN
ajlm-2018	103	12	of	of	ADP
ajlm-2018	103	13	triglyceride	triglyceride	ADJ
ajlm-2018	103	14	-	-	PUNCT
ajlm-2018	103	15	rich	rich	ADJ
ajlm-2018	103	16	lipoproteins	lipoprotein	NOUN
ajlm-2018	103	17	,	,	PUNCT
ajlm-2018	103	18	such	such	ADJ
ajlm-2018	103	19	as	as	ADP
ajlm-2018	103	20	chylomicrons	chylomicron	NOUN
ajlm-2018	103	21	and	and	CCONJ
ajlm-2018	103	22	very	very	ADV
ajlm-2018	103	23	low	low	ADJ
ajlm-2018	103	24	-	-	PUNCT
ajlm-2018	103	25	density	density	NOUN
ajlm-2018	103	26	lipoproteins	lipoprotein	NOUN
ajlm-2018	103	27	.	.	PUNCT
ajlm-2018	104	1	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	104	2	c	c	X
ajlm-2018	104	3	-	-	PUNCT
ajlm-2018	104	4	iii	iii	NOUN
ajlm-2018	104	5	impairs	impair	VERB
ajlm-2018	104	6	lipolysis	lipolysis	NOUN
ajlm-2018	104	7	by	by	ADP
ajlm-2018	104	8	inhibiting	inhibit	VERB
ajlm-2018	104	9	lipoprotein	lipoprotein	ADJ
ajlm-2018	104	10	lipase	lipase	NOUN
ajlm-2018	104	11	and	and	CCONJ
ajlm-2018	104	12	also	also	ADV
ajlm-2018	104	13	prevents	prevent	VERB
ajlm-2018	104	14	the	the	DET
ajlm-2018	104	15	binding	binding	NOUN
ajlm-2018	104	16	of	of	ADP
ajlm-2018	104	17	ae	ae	PROPN
ajlm-2018	104	18	and	and	CCONJ
ajlm-2018	104	19	apolipoprotein	apolipoprotein	VERB
ajlm-2018	104	20	b	b	NOUN
ajlm-2018	104	21	to	to	ADP
ajlm-2018	104	22	receptors	receptor	NOUN
ajlm-2018	104	23	on	on	ADP
ajlm-2018	104	24	the	the	DET
ajlm-2018	104	25	liver	liver	NOUN
ajlm-2018	104	26	,	,	PUNCT
ajlm-2018	104	27	thereby	thereby	ADV
ajlm-2018	104	28	impeding	impede	VERB
ajlm-2018	104	29	hepatic	hepatic	ADJ
ajlm-2018	104	30	clearance	clearance	NOUN
ajlm-2018	104	31	of	of	ADP
ajlm-2018	104	32	these	these	DET
ajlm-2018	104	33	triglyceride	triglyceride	ADJ
ajlm-2018	104	34	-	-	PUNCT
ajlm-2018	104	35	rich	rich	ADJ
ajlm-2018	104	36	lipoproteins	lipoprotein	NOUN
ajlm-2018	104	37	.	.	PUNCT
ajlm-2018	105	1	in	in	ADP
ajlm-2018	105	2	addition	addition	NOUN
ajlm-2018	105	3	,	,	PUNCT
ajlm-2018	105	4	aciii	aciii	PRON
ajlm-2018	105	5	also	also	ADV
ajlm-2018	105	6	favours	favour	VERB
ajlm-2018	105	7	hepatic	hepatic	ADJ
ajlm-2018	105	8	assembly	assembly	NOUN
ajlm-2018	105	9	and	and	CCONJ
ajlm-2018	105	10	secretion	secretion	NOUN
ajlm-2018	105	11	of	of	ADP
ajlm-2018	105	12	very	very	ADV
ajlm-2018	105	13	low	low	ADJ
ajlm-2018	105	14	-	-	PUNCT
ajlm-2018	105	15	density	density	NOUN
ajlm-2018	105	16	lipoproteins.30	lipoproteins.30	VERB
ajlm-2018	105	17	hence	hence	ADV
ajlm-2018	105	18	,	,	PUNCT
ajlm-2018	105	19	increased	increase	VERB
ajlm-2018	105	20	serum	serum	NOUN
ajlm-2018	105	21	concentration	concentration	NOUN
ajlm-2018	105	22	of	of	ADP
ajlm-2018	105	23	aciii	aciii	PRON
ajlm-2018	105	24	is	be	AUX
ajlm-2018	105	25	associated	associate	VERB
ajlm-2018	105	26	with	with	ADP
ajlm-2018	105	27	decreased	decrease	VERB
ajlm-2018	105	28	clearance	clearance	NOUN
ajlm-2018	105	29	of	of	ADP
ajlm-2018	105	30	triglyceride	triglyceride	ADJ
ajlm-2018	105	31	-	-	PUNCT
ajlm-2018	105	32	rich	rich	ADJ
ajlm-2018	105	33	lipoproteins	lipoprotein	NOUN
ajlm-2018	105	34	.	.	PUNCT
ajlm-2018	106	1	triglyceride	triglyceride	ADJ
ajlm-2018	106	2	levels	level	NOUN
ajlm-2018	106	3	were	be	AUX
ajlm-2018	106	4	unsurprisingly	unsurprisingly	ADV
ajlm-2018	106	5	higher	high	ADJ
ajlm-2018	106	6	in	in	ADP
ajlm-2018	106	7	both	both	PRON
ajlm-2018	106	8	art	art	NOUN
ajlm-2018	106	9	-	-	PUNCT
ajlm-2018	106	10	experienced	experienced	ADJ
ajlm-2018	106	11	and	and	CCONJ
ajlm-2018	106	12	treatment	treatment	NOUN
ajlm-2018	106	13	-	-	PUNCT
ajlm-2018	106	14	naïve	naïve	ADJ
ajlm-2018	106	15	hiv	hiv	NOUN
ajlm-2018	106	16	-	-	PUNCT
ajlm-2018	106	17	positive	positive	ADJ
ajlm-2018	106	18	participants	participant	NOUN
ajlm-2018	106	19	compared	compare	VERB
ajlm-2018	106	20	to	to	ADP
ajlm-2018	106	21	the	the	DET
ajlm-2018	106	22	control	control	NOUN
ajlm-2018	106	23	group	group	NOUN
ajlm-2018	106	24	due	due	ADP
ajlm-2018	106	25	to	to	ADP
ajlm-2018	106	26	increased	increase	VERB
ajlm-2018	106	27	aciii	aciii	DET
ajlm-2018	106	28	concentration	concentration	NOUN
ajlm-2018	106	29	.	.	PUNCT
ajlm-2018	107	1	serum	serum	NOUN
ajlm-2018	107	2	triglyceride	triglyceride	ADJ
ajlm-2018	107	3	concentration	concentration	NOUN
ajlm-2018	107	4	was	be	AUX
ajlm-2018	107	5	not	not	PART
ajlm-2018	107	6	significantly	significantly	ADV
ajlm-2018	107	7	different	different	ADJ
ajlm-2018	107	8	between	between	ADP
ajlm-2018	107	9	art	art	NOUN
ajlm-2018	107	10	-	-	PUNCT
ajlm-2018	107	11	naïve	naïve	ADJ
ajlm-2018	107	12	and	and	CCONJ
ajlm-2018	107	13	art	art	NOUN
ajlm-2018	107	14	-	-	PUNCT
ajlm-2018	107	15	experienced	experience	VERB
ajlm-2018	107	16	hiv	hiv	NOUN
ajlm-2018	107	17	-	-	PUNCT
ajlm-2018	107	18	positive	positive	ADJ
ajlm-2018	107	19	patients	patient	NOUN
ajlm-2018	107	20	.	.	PUNCT
ajlm-2018	108	1	previous	previous	ADJ
ajlm-2018	108	2	studies	study	NOUN
ajlm-2018	108	3	conducted	conduct	VERB
ajlm-2018	108	4	in	in	ADP
ajlm-2018	108	5	nigeria	nigeria	PROPN
ajlm-2018	108	6	in	in	ADP
ajlm-2018	108	7	2010	2010	NUM
ajlm-2018	108	8	and	and	CCONJ
ajlm-2018	108	9	in	in	ADP
ajlm-2018	108	10	india	india	PROPN
ajlm-2018	108	11	in	in	ADP
ajlm-2018	108	12	2014	2014	NUM
ajlm-2018	108	13	have	have	AUX
ajlm-2018	108	14	reported	report	VERB
ajlm-2018	108	15	hypertriglyceridaemia	hypertriglyceridaemia	NOUN
ajlm-2018	108	16	in	in	ADP
ajlm-2018	108	17	hiv	hiv	PROPN
ajlm-2018	108	18	patients31,32	patients31,32	VERB
ajlm-2018	108	19	and	and	CCONJ
ajlm-2018	108	20	increasing	increase	VERB
ajlm-2018	108	21	serum	serum	NOUN
ajlm-2018	108	22	triglyceride	triglyceride	ADP
ajlm-2018	108	23	concentration	concentration	NOUN
ajlm-2018	108	24	with	with	ADP
ajlm-2018	108	25	art	art	NOUN
ajlm-2018	108	26	-	-	PUNCT
ajlm-2018	108	27	duration.32,33,34	duration.32,33,34	NOUN
ajlm-2018	108	28	thus	thus	ADV
ajlm-2018	108	29	,	,	PUNCT
ajlm-2018	108	30	hypertriglyceridaemia	hypertriglyceridaemia	NOUN
ajlm-2018	108	31	may	may	AUX
ajlm-2018	108	32	be	be	AUX
ajlm-2018	108	33	influenced	influence	VERB
ajlm-2018	108	34	by	by	ADP
ajlm-2018	108	35	hiv	hiv	PROPN
ajlm-2018	108	36	itself	itself	PRON
ajlm-2018	108	37	or	or	CCONJ
ajlm-2018	108	38	art	art	NOUN
ajlm-2018	108	39	use	use	NOUN
ajlm-2018	108	40	.	.	PUNCT
ajlm-2018	109	1	hiv	hiv	PROPN
ajlm-2018	109	2	causes	cause	VERB
ajlm-2018	109	3	inflammation	inflammation	NOUN
ajlm-2018	109	4	with	with	ADP
ajlm-2018	109	5	the	the	DET
ajlm-2018	109	6	subsequent	subsequent	ADJ
ajlm-2018	109	7	release	release	NOUN
ajlm-2018	109	8	of	of	ADP
ajlm-2018	109	9	cytokines	cytokine	NOUN
ajlm-2018	109	10	and	and	CCONJ
ajlm-2018	109	11	decreased	decrease	VERB
ajlm-2018	109	12	hepatic	hepatic	ADJ
ajlm-2018	109	13	clearance	clearance	NOUN
ajlm-2018	109	14	,	,	PUNCT
ajlm-2018	109	15	which	which	PRON
ajlm-2018	109	16	may	may	AUX
ajlm-2018	109	17	result	result	VERB
ajlm-2018	109	18	in	in	ADP
ajlm-2018	109	19	hypertriglyceridaemia.6	hypertriglyceridaemia.6	PROPN
ajlm-2018	109	20	however	however	ADV
ajlm-2018	109	21	,	,	PUNCT
ajlm-2018	109	22	we	we	PRON
ajlm-2018	109	23	did	do	AUX
ajlm-2018	109	24	not	not	PART
ajlm-2018	109	25	observe	observe	VERB
ajlm-2018	109	26	a	a	DET
ajlm-2018	109	27	difference	difference	NOUN
ajlm-2018	109	28	in	in	ADP
ajlm-2018	109	29	the	the	DET
ajlm-2018	109	30	triglyceride	triglyceride	ADJ
ajlm-2018	109	31	concentration	concentration	NOUN
ajlm-2018	109	32	when	when	SCONJ
ajlm-2018	109	33	therapy	therapy	NOUN
ajlm-2018	109	34	duration	duration	NOUN
ajlm-2018	109	35	was	be	AUX
ajlm-2018	109	36	considered	consider	VERB
ajlm-2018	109	37	;	;	PUNCT
ajlm-2018	109	38	this	this	PRON
ajlm-2018	109	39	may	may	AUX
ajlm-2018	109	40	be	be	AUX
ajlm-2018	109	41	attributed	attribute	VERB
ajlm-2018	109	42	to	to	ADP
ajlm-2018	109	43	our	our	PRON
ajlm-2018	109	44	low	low	ADJ
ajlm-2018	109	45	sample	sample	NOUN
ajlm-2018	109	46	size	size	NOUN
ajlm-2018	109	47	,	,	PUNCT
ajlm-2018	109	48	which	which	PRON
ajlm-2018	109	49	limits	limit	VERB
ajlm-2018	109	50	statistical	statistical	ADJ
ajlm-2018	109	51	strength	strength	NOUN
ajlm-2018	109	52	.	.	PUNCT
ajlm-2018	110	1	although	although	SCONJ
ajlm-2018	110	2	an	an	DET
ajlm-2018	110	3	increase	increase	NOUN
ajlm-2018	110	4	in	in	ADP
ajlm-2018	110	5	age	age	NOUN
ajlm-2018	110	6	increases	increase	VERB
ajlm-2018	110	7	the	the	DET
ajlm-2018	110	8	risk	risk	NOUN
ajlm-2018	110	9	of	of	ADP
ajlm-2018	110	10	dyslipidaemia,35,36	dyslipidaemia,35,36	NOUN
ajlm-2018	110	11	prolonged	prolong	VERB
ajlm-2018	110	12	use	use	NOUN
ajlm-2018	110	13	of	of	ADP
ajlm-2018	110	14	art	art	NOUN
ajlm-2018	110	15	may	may	AUX
ajlm-2018	110	16	be	be	AUX
ajlm-2018	110	17	a	a	DET
ajlm-2018	110	18	stronger	strong	ADJ
ajlm-2018	110	19	predictor	predictor	NOUN
ajlm-2018	110	20	of	of	ADP
ajlm-2018	110	21	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	110	22	in	in	ADP
ajlm-2018	110	23	hiv	hiv	PROPN
ajlm-2018	110	24	patients	patient	NOUN
ajlm-2018	110	25	.	.	PUNCT
ajlm-2018	111	1	our	our	PRON
ajlm-2018	111	2	results	result	NOUN
ajlm-2018	111	3	did	do	AUX
ajlm-2018	111	4	not	not	PART
ajlm-2018	111	5	record	record	VERB
ajlm-2018	111	6	any	any	DET
ajlm-2018	111	7	difference	difference	NOUN
ajlm-2018	111	8	in	in	ADP
ajlm-2018	111	9	the	the	DET
ajlm-2018	111	10	lipid	lipid	NOUN
ajlm-2018	111	11	status	status	NOUN
ajlm-2018	111	12	of	of	ADP
ajlm-2018	111	13	patients	patient	NOUN
ajlm-2018	111	14	with	with	ADP
ajlm-2018	111	15	different	different	ADJ
ajlm-2018	111	16	age	age	NOUN
ajlm-2018	111	17	groups	group	NOUN
ajlm-2018	111	18	.	.	PUNCT
ajlm-2018	112	1	a	a	DET
ajlm-2018	112	2	high	high	ADJ
ajlm-2018	112	3	prevalence	prevalence	NOUN
ajlm-2018	112	4	of	of	ADP
ajlm-2018	112	5	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	112	6	has	have	AUX
ajlm-2018	112	7	been	be	AUX
ajlm-2018	112	8	associated	associate	VERB
ajlm-2018	112	9	with	with	ADP
ajlm-2018	112	10	the	the	DET
ajlm-2018	112	11	prolonged	prolonged	ADJ
ajlm-2018	112	12	use	use	NOUN
ajlm-2018	112	13	of	of	ADP
ajlm-2018	112	14	first	first	ADJ
ajlm-2018	112	15	-	-	PUNCT
ajlm-2018	112	16	line	line	NOUN
ajlm-2018	112	17	art.6	art.6	PROPN
ajlm-2018	112	18	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	112	19	observed	observe	VERB
ajlm-2018	112	20	among	among	ADP
ajlm-2018	112	21	patients	patient	NOUN
ajlm-2018	112	22	on	on	ADP
ajlm-2018	112	23	antiretroviral	antiretroviral	ADJ
ajlm-2018	112	24	drugs	drug	NOUN
ajlm-2018	112	25	in	in	ADP
ajlm-2018	112	26	this	this	DET
ajlm-2018	112	27	study	study	NOUN
ajlm-2018	112	28	may	may	AUX
ajlm-2018	112	29	be	be	AUX
ajlm-2018	112	30	attributed	attribute	VERB
ajlm-2018	112	31	to	to	ADP
ajlm-2018	112	32	the	the	DET
ajlm-2018	112	33	effects	effect	NOUN
ajlm-2018	112	34	of	of	ADP
ajlm-2018	112	35	art	art	NOUN
ajlm-2018	112	36	on	on	ADP
ajlm-2018	112	37	lipid	lipid	ADJ
ajlm-2018	112	38	metabolism	metabolism	NOUN
ajlm-2018	112	39	,	,	PUNCT
ajlm-2018	112	40	as	as	SCONJ
ajlm-2018	112	41	there	there	PRON
ajlm-2018	112	42	was	be	VERB
ajlm-2018	112	43	significantly	significantly	ADV
ajlm-2018	112	44	high	high	ADJ
ajlm-2018	112	45	total	total	ADJ
ajlm-2018	112	46	cholesterol	cholesterol	NOUN
ajlm-2018	112	47	(	(	PUNCT
ajlm-2018	112	48	p	p	X
ajlm-2018	112	49	<	<	X
ajlm-2018	112	50	0.033	0.033	NUM
ajlm-2018	112	51	)	)	PUNCT
ajlm-2018	112	52	and	and	CCONJ
ajlm-2018	112	53	ldl	ldl	NOUN
ajlm-2018	112	54	-	-	PUNCT
ajlm-2018	112	55	c	c	NOUN
ajlm-2018	112	56	(	(	PUNCT
ajlm-2018	112	57	p	p	X
ajlm-2018	112	58	<	<	X
ajlm-2018	112	59	0.025	0.025	NUM
ajlm-2018	112	60	)	)	PUNCT
ajlm-2018	112	61	among	among	ADP
ajlm-2018	112	62	patients	patient	NOUN
ajlm-2018	112	63	on	on	ADP
ajlm-2018	112	64	art	art	NOUN
ajlm-2018	112	65	for	for	ADP
ajlm-2018	112	66	more	more	ADJ
ajlm-2018	112	67	than	than	ADP
ajlm-2018	112	68	two	two	NUM
ajlm-2018	112	69	years	year	NOUN
ajlm-2018	112	70	.	.	PUNCT
ajlm-2018	113	1	an	an	DET
ajlm-2018	113	2	increased	increase	VERB
ajlm-2018	113	3	ldl	ldl	NOUN
ajlm-2018	113	4	-	-	PUNCT
ajlm-2018	113	5	c	c	NOUN
ajlm-2018	113	6	strongly	strongly	ADV
ajlm-2018	113	7	predicts	predict	VERB
ajlm-2018	113	8	cardiovascular	cardiovascular	ADJ
ajlm-2018	113	9	risk.30,31	risk.30,31	NOUN
ajlm-2018	113	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	113	11	e	e	PROPN
ajlm-2018	113	12	is	be	AUX
ajlm-2018	113	13	a	a	DET
ajlm-2018	113	14	multifunctional	multifunctional	ADJ
ajlm-2018	113	15	protein	protein	NOUN
ajlm-2018	113	16	secreted	secrete	VERB
ajlm-2018	113	17	primarily	primarily	ADV
ajlm-2018	113	18	in	in	ADP
ajlm-2018	113	19	the	the	DET
ajlm-2018	113	20	liver	liver	NOUN
ajlm-2018	113	21	.	.	PUNCT
ajlm-2018	114	1	it	it	PRON
ajlm-2018	114	2	plays	play	VERB
ajlm-2018	114	3	a	a	DET
ajlm-2018	114	4	significant	significant	ADJ
ajlm-2018	114	5	role	role	NOUN
ajlm-2018	114	6	in	in	ADP
ajlm-2018	114	7	the	the	DET
ajlm-2018	114	8	plasma	plasma	NOUN
ajlm-2018	114	9	clearance	clearance	NOUN
ajlm-2018	114	10	of	of	ADP
ajlm-2018	114	11	lipoproteins.37	lipoproteins.37	ADJ
ajlm-2018	114	12	high	high	ADJ
ajlm-2018	114	13	plasma	plasma	NOUN
ajlm-2018	114	14	concentrations	concentration	NOUN
ajlm-2018	114	15	of	of	ADP
ajlm-2018	114	16	ae	ae	PROPN
ajlm-2018	114	17	are	be	AUX
ajlm-2018	114	18	a	a	DET
ajlm-2018	114	19	reflection	reflection	NOUN
ajlm-2018	114	20	of	of	ADP
ajlm-2018	114	21	high	high	ADJ
ajlm-2018	114	22	circulating	circulate	VERB
ajlm-2018	114	23	ldl	ldl	NOUN
ajlm-2018	114	24	-	-	PUNCT
ajlm-2018	114	25	c	c	NOUN
ajlm-2018	114	26	and	and	CCONJ
ajlm-2018	114	27	triglycerides	triglyceride	NOUN
ajlm-2018	114	28	.	.	PUNCT
ajlm-2018	115	1	it	it	PRON
ajlm-2018	115	2	has	have	AUX
ajlm-2018	115	3	been	be	AUX
ajlm-2018	115	4	described	describe	VERB
ajlm-2018	115	5	as	as	ADP
ajlm-2018	115	6	an	an	DET
ajlm-2018	115	7	early	early	ADJ
ajlm-2018	115	8	and	and	CCONJ
ajlm-2018	115	9	specific	specific	ADJ
ajlm-2018	115	10	indicator	indicator	NOUN
ajlm-2018	115	11	of	of	ADP
ajlm-2018	115	12	cardiovascular	cardiovascular	ADJ
ajlm-2018	115	13	disease.38	disease.38	PROPN
ajlm-2018	115	14	apolipoprotein	apolipoprotein	VERB
ajlm-2018	115	15	e	e	PROPN
ajlm-2018	115	16	serum	serum	NOUN
ajlm-2018	115	17	concentration	concentration	NOUN
ajlm-2018	115	18	between	between	ADP
ajlm-2018	115	19	hiv	hiv	PROPN
ajlm-2018	115	20	-	-	PUNCT
ajlm-2018	115	21	positive	positive	ADJ
ajlm-2018	115	22	treatment	treatment	NOUN
ajlm-2018	115	23	-	-	PUNCT
ajlm-2018	115	24	experienced	experience	VERB
ajlm-2018	115	25	and	and	CCONJ
ajlm-2018	115	26	treatment	treatment	NOUN
ajlm-2018	115	27	-	-	PUNCT
ajlm-2018	115	28	naïve	naïve	ADJ
ajlm-2018	115	29	groups	group	NOUN
ajlm-2018	115	30	was	be	AUX
ajlm-2018	115	31	statistically	statistically	ADV
ajlm-2018	115	32	significantly	significantly	ADV
ajlm-2018	115	33	higher	high	ADJ
ajlm-2018	115	34	when	when	SCONJ
ajlm-2018	115	35	compared	compare	VERB
ajlm-2018	115	36	to	to	ADP
ajlm-2018	115	37	the	the	DET
ajlm-2018	115	38	hiv	hiv	PROPN
ajlm-2018	115	39	-	-	PUNCT
ajlm-2018	115	40	negative	negative	ADJ
ajlm-2018	115	41	population	population	NOUN
ajlm-2018	115	42	.	.	PUNCT
ajlm-2018	116	1	this	this	PRON
ajlm-2018	116	2	is	be	AUX
ajlm-2018	116	3	similar	similar	ADJ
ajlm-2018	116	4	to	to	ADP
ajlm-2018	116	5	previous	previous	ADJ
ajlm-2018	116	6	studies	study	NOUN
ajlm-2018	116	7	carried	carry	VERB
ajlm-2018	116	8	out	out	ADP
ajlm-2018	116	9	in	in	ADP
ajlm-2018	116	10	a	a	DET
ajlm-2018	116	11	south	south	ADJ
ajlm-2018	116	12	-	-	PUNCT
ajlm-2018	116	13	eastern	eastern	ADJ
ajlm-2018	116	14	state	state	NOUN
ajlm-2018	116	15	of	of	ADP
ajlm-2018	116	16	nigeria	nigeria	PROPN
ajlm-2018	116	17	in	in	ADP
ajlm-2018	116	18	2021	2021	NUM
ajlm-2018	116	19	,	,	PUNCT
ajlm-2018	116	20	which	which	PRON
ajlm-2018	116	21	reported	report	VERB
ajlm-2018	116	22	significantly	significantly	ADV
ajlm-2018	116	23	higher	high	ADJ
ajlm-2018	116	24	ae	ae	PROPN
ajlm-2018	116	25	in	in	ADP
ajlm-2018	116	26	hiv	hiv	PROPN
ajlm-2018	116	27	-	-	PUNCT
ajlm-2018	116	28	positive	positive	ADJ
ajlm-2018	116	29	patients	patient	NOUN
ajlm-2018	116	30	compared	compare	VERB
ajlm-2018	116	31	to	to	ADP
ajlm-2018	116	32	hiv	hiv	PROPN
ajlm-2018	116	33	-	-	PUNCT
ajlm-2018	116	34	negative	negative	ADJ
ajlm-2018	116	35	persons.39	persons.39	NOUN
ajlm-2018	116	36	similar	similar	ADJ
ajlm-2018	116	37	to	to	ADP
ajlm-2018	116	38	our	our	PRON
ajlm-2018	116	39	finding	finding	NOUN
ajlm-2018	116	40	,	,	PUNCT
ajlm-2018	116	41	ezeugwunne	ezeugwunne	AUX
ajlm-2018	116	42	et	et	PROPN
ajlm-2018	116	43	al.40	al.40	PROPN
ajlm-2018	116	44	in	in	ADP
ajlm-2018	116	45	2019	2019	NUM
ajlm-2018	116	46	reported	report	VERB
ajlm-2018	116	47	a	a	DET
ajlm-2018	116	48	reduction	reduction	NOUN
ajlm-2018	116	49	in	in	ADP
ajlm-2018	116	50	serum	serum	NOUN
ajlm-2018	116	51	concentration	concentration	NOUN
ajlm-2018	116	52	of	of	ADP
ajlm-2018	116	53	ae	ae	PROPN
ajlm-2018	116	54	as	as	ADP
ajlm-2018	116	55	the	the	DET
ajlm-2018	116	56	length	length	NOUN
ajlm-2018	116	57	of	of	ADP
ajlm-2018	116	58	art	art	NOUN
ajlm-2018	116	59	treatment	treatment	NOUN
ajlm-2018	116	60	progressed	progress	VERB
ajlm-2018	116	61	among	among	ADP
ajlm-2018	116	62	hiv	hiv	PROPN
ajlm-2018	116	63	-	-	PUNCT
ajlm-2018	116	64	positive	positive	ADJ
ajlm-2018	116	65	patients	patient	NOUN
ajlm-2018	116	66	in	in	ADP
ajlm-2018	116	67	nnawi	nnawi	PROPN
ajlm-2018	116	68	,	,	PUNCT
ajlm-2018	116	69	nigeria	nigeria	PROPN
ajlm-2018	116	70	.	.	PUNCT
ajlm-2018	117	1	the	the	DET
ajlm-2018	117	2	reason	reason	NOUN
ajlm-2018	117	3	for	for	ADP
ajlm-2018	117	4	reduced	reduced	ADJ
ajlm-2018	117	5	ae	ae	PROPN
ajlm-2018	117	6	with	with	ADP
ajlm-2018	117	7	increased	increase	VERB
ajlm-2018	117	8	length	length	NOUN
ajlm-2018	117	9	of	of	ADP
ajlm-2018	117	10	treatment	treatment	NOUN
ajlm-2018	117	11	is	be	AUX
ajlm-2018	117	12	unclear	unclear	ADJ
ajlm-2018	117	13	but	but	CCONJ
ajlm-2018	117	14	may	may	AUX
ajlm-2018	117	15	be	be	AUX
ajlm-2018	117	16	related	relate	VERB
ajlm-2018	117	17	to	to	ADP
ajlm-2018	117	18	the	the	DET
ajlm-2018	117	19	immune	immune	ADJ
ajlm-2018	117	20	system.41	system.41	NOUN
ajlm-2018	117	21	limitations	limitation	NOUN
ajlm-2018	117	22	the	the	DET
ajlm-2018	117	23	small	small	ADJ
ajlm-2018	117	24	sample	sample	NOUN
ajlm-2018	117	25	size	size	NOUN
ajlm-2018	117	26	used	use	VERB
ajlm-2018	117	27	for	for	ADP
ajlm-2018	117	28	the	the	DET
ajlm-2018	117	29	analysis	analysis	NOUN
ajlm-2018	117	30	limited	limit	VERB
ajlm-2018	117	31	the	the	DET
ajlm-2018	117	32	statistical	statistical	ADJ
ajlm-2018	117	33	strength	strength	NOUN
ajlm-2018	117	34	of	of	ADP
ajlm-2018	117	35	the	the	DET
ajlm-2018	117	36	study	study	NOUN
ajlm-2018	117	37	.	.	PUNCT
ajlm-2018	118	1	conclusion	conclusion	NOUN
ajlm-2018	118	2	from	from	ADP
ajlm-2018	118	3	this	this	DET
ajlm-2018	118	4	study	study	NOUN
ajlm-2018	118	5	,	,	PUNCT
ajlm-2018	118	6	dyslipidaemia	dyslipidaemia	PROPN
ajlm-2018	118	7	is	be	AUX
ajlm-2018	118	8	associated	associate	VERB
ajlm-2018	118	9	with	with	ADP
ajlm-2018	118	10	hiv	hiv	PROPN
ajlm-2018	118	11	infection	infection	NOUN
ajlm-2018	118	12	with	with	ADP
ajlm-2018	118	13	or	or	CCONJ
ajlm-2018	118	14	without	without	ADP
ajlm-2018	118	15	art	art	NOUN
ajlm-2018	118	16	,	,	PUNCT
ajlm-2018	118	17	although	although	SCONJ
ajlm-2018	118	18	the	the	DET
ajlm-2018	118	19	pattern	pattern	NOUN
ajlm-2018	118	20	of	of	ADP
ajlm-2018	118	21	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	118	22	may	may	AUX
ajlm-2018	118	23	vary	vary	VERB
ajlm-2018	118	24	.	.	PUNCT
ajlm-2018	119	1	prolonged	prolonged	ADJ
ajlm-2018	119	2	use	use	NOUN
ajlm-2018	119	3	of	of	ADP
ajlm-2018	119	4	art	art	NOUN
ajlm-2018	119	5	is	be	AUX
ajlm-2018	119	6	a	a	DET
ajlm-2018	119	7	significant	significant	ADJ
ajlm-2018	119	8	risk	risk	NOUN
ajlm-2018	119	9	of	of	ADP
ajlm-2018	119	10	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	119	11	among	among	ADP
ajlm-2018	119	12	hiv	hiv	PROPN
ajlm-2018	119	13	-	-	PUNCT
ajlm-2018	119	14	positive	positive	ADJ
ajlm-2018	119	15	patients	patient	NOUN
ajlm-2018	119	16	.	.	PUNCT
ajlm-2018	120	1	patients	patient	NOUN
ajlm-2018	120	2	with	with	ADP
ajlm-2018	120	3	hiv	hiv	PROPN
ajlm-2018	120	4	,	,	PUNCT
ajlm-2018	120	5	therefore	therefore	ADV
ajlm-2018	120	6	,	,	PUNCT
ajlm-2018	120	7	are	be	AUX
ajlm-2018	120	8	at	at	ADP
ajlm-2018	120	9	a	a	DET
ajlm-2018	120	10	high	high	ADJ
ajlm-2018	120	11	risk	risk	NOUN
ajlm-2018	120	12	of	of	ADP
ajlm-2018	120	13	developing	develop	VERB
ajlm-2018	120	14	cardiometabolic	cardiometabolic	NOUN
ajlm-2018	120	15	diseases	disease	NOUN
ajlm-2018	120	16	;	;	PUNCT
ajlm-2018	120	17	hence	hence	ADV
ajlm-2018	120	18	,	,	PUNCT
ajlm-2018	120	19	routine	routine	ADJ
ajlm-2018	120	20	monitoring	monitoring	NOUN
ajlm-2018	120	21	of	of	ADP
ajlm-2018	120	22	these	these	DET
ajlm-2018	120	23	patients	patient	NOUN
ajlm-2018	120	24	’	'	PUNCT
ajlm-2018	120	25	lipid	lipid	NOUN
ajlm-2018	120	26	profiles	profile	NOUN
ajlm-2018	120	27	will	will	AUX
ajlm-2018	120	28	benefit	benefit	VERB
ajlm-2018	120	29	their	their	PRON
ajlm-2018	120	30	management	management	NOUN
ajlm-2018	120	31	.	.	PUNCT
ajlm-2018	121	1	acknowledgements	acknowledgement	NOUN
ajlm-2018	121	2	competing	compete	VERB
ajlm-2018	121	3	interests	interest	NOUN
ajlm-2018	121	4	the	the	DET
ajlm-2018	121	5	authors	author	NOUN
ajlm-2018	121	6	declare	declare	VERB
ajlm-2018	121	7	that	that	SCONJ
ajlm-2018	121	8	they	they	PRON
ajlm-2018	121	9	have	have	VERB
ajlm-2018	121	10	no	no	DET
ajlm-2018	121	11	financial	financial	ADJ
ajlm-2018	121	12	or	or	CCONJ
ajlm-2018	121	13	personal	personal	ADJ
ajlm-2018	121	14	relationships	relationship	NOUN
ajlm-2018	121	15	that	that	PRON
ajlm-2018	121	16	may	may	AUX
ajlm-2018	121	17	have	have	AUX
ajlm-2018	121	18	inappropriately	inappropriately	ADV
ajlm-2018	121	19	influenced	influence	VERB
ajlm-2018	121	20	them	they	PRON
ajlm-2018	121	21	in	in	ADP
ajlm-2018	121	22	writing	write	VERB
ajlm-2018	121	23	this	this	DET
ajlm-2018	121	24	article	article	NOUN
ajlm-2018	121	25	.	.	PUNCT
ajlm-2018	122	1	authors	author	NOUN
ajlm-2018	122	2	’	'	PUNCT
ajlm-2018	122	3	contributions	contribution	NOUN
ajlm-2018	122	4	all	all	DET
ajlm-2018	122	5	listed	list	VERB
ajlm-2018	122	6	authors	author	NOUN
ajlm-2018	122	7	contributed	contribute	VERB
ajlm-2018	122	8	to	to	ADP
ajlm-2018	122	9	the	the	DET
ajlm-2018	122	10	development	development	NOUN
ajlm-2018	122	11	of	of	ADP
ajlm-2018	122	12	this	this	DET
ajlm-2018	122	13	manuscript	manuscript	NOUN
ajlm-2018	122	14	.	.	PUNCT
ajlm-2018	123	1	m.n.o	m.n.o	PROPN
ajlm-2018	123	2	.	.	PROPN
ajlm-2018	123	3	participated	participate	VERB
ajlm-2018	123	4	in	in	ADP
ajlm-2018	123	5	designing	design	VERB
ajlm-2018	123	6	the	the	DET
ajlm-2018	123	7	work	work	NOUN
ajlm-2018	123	8	as	as	ADV
ajlm-2018	123	9	well	well	ADV
ajlm-2018	123	10	as	as	ADP
ajlm-2018	123	11	the	the	DET
ajlm-2018	123	12	data	data	NOUN
ajlm-2018	123	13	collection	collection	NOUN
ajlm-2018	123	14	,	,	PUNCT
ajlm-2018	123	15	investigations	investigation	NOUN
ajlm-2018	123	16	,	,	PUNCT
ajlm-2018	123	17	data	datum	NOUN
ajlm-2018	123	18	curation	curation	NOUN
ajlm-2018	123	19	and	and	CCONJ
ajlm-2018	123	20	writing	writing	NOUN
ajlm-2018	123	21	of	of	ADP
ajlm-2018	123	22	the	the	DET
ajlm-2018	123	23	manuscript	manuscript	NOUN
ajlm-2018	123	24	.	.	PUNCT
ajlm-2018	124	1	n.k.n	n.k.n	PROPN
ajlm-2018	124	2	.	.	PROPN
ajlm-2018	124	3	conceptualised	conceptualise	VERB
ajlm-2018	124	4	and	and	CCONJ
ajlm-2018	124	5	designed	design	VERB
ajlm-2018	124	6	the	the	DET
ajlm-2018	124	7	work	work	NOUN
ajlm-2018	124	8	,	,	PUNCT
ajlm-2018	124	9	and	and	CCONJ
ajlm-2018	124	10	was	be	AUX
ajlm-2018	124	11	involved	involve	VERB
ajlm-2018	124	12	in	in	ADP
ajlm-2018	124	13	supervision	supervision	NOUN
ajlm-2018	124	14	of	of	ADP
ajlm-2018	124	15	data	datum	NOUN
ajlm-2018	124	16	curation	curation	NOUN
ajlm-2018	124	17	and	and	CCONJ
ajlm-2018	124	18	proofreading	proofreading	NOUN
ajlm-2018	124	19	of	of	ADP
ajlm-2018	124	20	the	the	DET
ajlm-2018	124	21	manuscript	manuscript	NOUN
ajlm-2018	124	22	.	.	PUNCT
ajlm-2018	125	1	u.a.u	u.a.u	PROPN
ajlm-2018	125	2	.	.	PROPN
ajlm-2018	126	1	was	be	AUX
ajlm-2018	126	2	involved	involve	VERB
ajlm-2018	126	3	in	in	ADP
ajlm-2018	126	4	the	the	DET
ajlm-2018	126	5	investigatory	investigatory	NOUN
ajlm-2018	126	6	stages	stage	NOUN
ajlm-2018	126	7	of	of	ADP
ajlm-2018	126	8	this	this	DET
ajlm-2018	126	9	study	study	NOUN
ajlm-2018	126	10	,	,	PUNCT
ajlm-2018	126	11	data	data	NOUN
ajlm-2018	126	12	curation	curation	NOUN
ajlm-2018	126	13	and	and	CCONJ
ajlm-2018	126	14	manuscript	manuscript	NOUN
ajlm-2018	126	15	writing	writing	NOUN
ajlm-2018	126	16	.	.	PUNCT
ajlm-2018	127	1	e.a.u	e.a.u	PROPN
ajlm-2018	127	2	.	.	PROPN
ajlm-2018	128	1	participated	participate	VERB
ajlm-2018	128	2	in	in	ADP
ajlm-2018	128	3	designing	design	VERB
ajlm-2018	128	4	the	the	DET
ajlm-2018	128	5	methodology	methodology	NOUN
ajlm-2018	128	6	,	,	PUNCT
ajlm-2018	128	7	data	data	NOUN
ajlm-2018	128	8	curation	curation	NOUN
ajlm-2018	128	9	and	and	CCONJ
ajlm-2018	128	10	manuscript	manuscript	NOUN
ajlm-2018	128	11	writing	writing	NOUN
ajlm-2018	128	12	.	.	PUNCT
ajlm-2018	129	1	sources	source	NOUN
ajlm-2018	129	2	of	of	ADP
ajlm-2018	129	3	support	support	NOUN
ajlm-2018	129	4	this	this	DET
ajlm-2018	129	5	research	research	NOUN
ajlm-2018	129	6	received	receive	VERB
ajlm-2018	129	7	no	no	DET
ajlm-2018	129	8	specific	specific	ADJ
ajlm-2018	129	9	grant	grant	NOUN
ajlm-2018	129	10	from	from	ADP
ajlm-2018	129	11	any	any	DET
ajlm-2018	129	12	funding	funding	NOUN
ajlm-2018	129	13	agency	agency	NOUN
ajlm-2018	129	14	in	in	ADP
ajlm-2018	129	15	the	the	DET
ajlm-2018	129	16	public	public	ADJ
ajlm-2018	129	17	,	,	PUNCT
ajlm-2018	129	18	commercial	commercial	ADJ
ajlm-2018	129	19	or	or	CCONJ
ajlm-2018	129	20	not	not	PART
ajlm-2018	129	21	-	-	PUNCT
ajlm-2018	129	22	for	for	ADP
ajlm-2018	129	23	-	-	PUNCT
ajlm-2018	129	24	profit	profit	NOUN
ajlm-2018	129	25	sectors	sector	NOUN
ajlm-2018	129	26	.	.	PUNCT
ajlm-2018	130	1	data	datum	NOUN
ajlm-2018	130	2	availability	availability	NOUN
ajlm-2018	130	3	the	the	DET
ajlm-2018	130	4	data	datum	NOUN
ajlm-2018	130	5	generated	generate	VERB
ajlm-2018	130	6	and	and	CCONJ
ajlm-2018	130	7	analysed	analyse	VERB
ajlm-2018	130	8	during	during	ADP
ajlm-2018	130	9	this	this	DET
ajlm-2018	130	10	study	study	NOUN
ajlm-2018	130	11	are	be	AUX
ajlm-2018	130	12	not	not	PART
ajlm-2018	130	13	publicly	publicly	ADV
ajlm-2018	130	14	available	available	ADJ
ajlm-2018	130	15	but	but	CCONJ
ajlm-2018	130	16	are	be	AUX
ajlm-2018	130	17	available	available	ADJ
ajlm-2018	130	18	from	from	ADP
ajlm-2018	130	19	the	the	DET
ajlm-2018	130	20	corresponding	corresponding	ADJ
ajlm-2018	130	21	author	author	NOUN
ajlm-2018	130	22	on	on	ADP
ajlm-2018	130	23	reasonable	reasonable	ADJ
ajlm-2018	130	24	request	request	NOUN
ajlm-2018	130	25	.	.	PUNCT
ajlm-2018	131	1	disclaimer	disclaimer	VERB
ajlm-2018	131	2	the	the	DET
ajlm-2018	131	3	views	view	NOUN
ajlm-2018	131	4	and	and	CCONJ
ajlm-2018	131	5	opinions	opinion	NOUN
ajlm-2018	131	6	expressed	express	VERB
ajlm-2018	131	7	in	in	ADP
ajlm-2018	131	8	this	this	DET
ajlm-2018	131	9	article	article	NOUN
ajlm-2018	131	10	are	be	AUX
ajlm-2018	131	11	those	those	PRON
ajlm-2018	131	12	of	of	ADP
ajlm-2018	131	13	the	the	DET
ajlm-2018	131	14	authors	author	NOUN
ajlm-2018	131	15	and	and	CCONJ
ajlm-2018	131	16	do	do	AUX
ajlm-2018	131	17	not	not	PART
ajlm-2018	131	18	necessarily	necessarily	ADV
ajlm-2018	131	19	reflect	reflect	VERB
ajlm-2018	131	20	the	the	DET
ajlm-2018	131	21	official	official	ADJ
ajlm-2018	131	22	policy	policy	NOUN
ajlm-2018	131	23	or	or	CCONJ
ajlm-2018	131	24	position	position	NOUN
ajlm-2018	131	25	of	of	ADP
ajlm-2018	131	26	any	any	DET
ajlm-2018	131	27	affiliated	affiliated	ADJ
ajlm-2018	131	28	agency	agency	NOUN
ajlm-2018	131	29	of	of	ADP
ajlm-2018	131	30	the	the	DET
ajlm-2018	131	31	authors	author	NOUN
ajlm-2018	131	32	.	.	PUNCT
ajlm-2018	132	1	references	reference	NOUN
ajlm-2018	132	2	kumar	kumar	PROPN
ajlm-2018	132	3	a	a	PROPN
ajlm-2018	132	4	,	,	PUNCT
ajlm-2018	132	5	sathian	sathian	PROPN
ajlm-2018	132	6	b.	b.	PROPN
ajlm-2018	132	7	assessment	assessment	NOUN
ajlm-2018	132	8	of	of	ADP
ajlm-2018	132	9	lipid	lipid	NOUN
ajlm-2018	132	10	profile	profile	NOUN
ajlm-2018	132	11	in	in	ADP
ajlm-2018	132	12	patients	patient	NOUN
ajlm-2018	132	13	with	with	ADP
ajlm-2018	132	14	human	human	ADJ
ajlm-2018	132	15	immunodeficiency	immunodeficiency	NOUN
ajlm-2018	132	16	virus	virus	NOUN
ajlm-2018	132	17	(	(	PUNCT
ajlm-2018	132	18	hiv	hiv	PROPN
ajlm-2018	132	19	/	/	SYM
ajlm-2018	132	20	aids	aids	PROPN
ajlm-2018	132	21	)	)	PUNCT
ajlm-2018	132	22	without	without	ADP
ajlm-2018	132	23	antiretroviral	antiretroviral	ADJ
ajlm-2018	132	24	therapy	therapy	NOUN
ajlm-2018	132	25	.	.	PUNCT
ajlm-2018	133	1	asian	asian	PROPN
ajlm-2018	133	2	pacific	pacific	PROPN
ajlm-2018	133	3	j	j	PROPN
ajlm-2018	133	4	trop	trop	X
ajlm-2018	133	5	dis	dis	PROPN
ajlm-2018	133	6	.	.	PUNCT
ajlm-2018	134	1	2011;1808:24–27	2011;1808:24–27	PROPN
ajlm-2018	134	2	.	.	PUNCT
ajlm-2018	135	1	nayyar	nayyar	PROPN
ajlm-2018	135	2	a.	a.	PROPN
ajlm-2018	135	3	dyslipidemia	dyslipidemia	NOUN
ajlm-2018	135	4	in	in	ADP
ajlm-2018	135	5	hiv	hiv	PROPN
ajlm-2018	135	6	infected	infected	ADJ
ajlm-2018	135	7	and	and	CCONJ
ajlm-2018	135	8	aids	aids	PROPN
ajlm-2018	135	9	patients	patient	NOUN
ajlm-2018	135	10	:	:	PUNCT
ajlm-2018	135	11	association	association	NOUN
ajlm-2018	135	12	of	of	ADP
ajlm-2018	135	13	serum	serum	NOUN
ajlm-2018	135	14	lipids	lipid	NOUN
ajlm-2018	135	15	with	with	ADP
ajlm-2018	135	16	hiv	hiv	PROPN
ajlm-2018	135	17	status	status	NOUN
ajlm-2018	135	18	,	,	PUNCT
ajlm-2018	135	19	a	a	DET
ajlm-2018	135	20	cross	cross	ADJ
ajlm-2018	135	21	-	-	ADJ
ajlm-2018	135	22	sectional	sectional	ADJ
ajlm-2018	135	23	study	study	NOUN
ajlm-2018	135	24	.	.	PUNCT
ajlm-2018	136	1	j	j	PROPN
ajlm-2018	136	2	med	med	PROPN
ajlm-2018	136	3	trop	trop	X
ajlm-2018	136	4	.	.	PUNCT
ajlm-2018	137	1	2019;12:20–25	2019;12:20–25	NUM
ajlm-2018	137	2	.	.	PUNCT
ajlm-2018	138	1	national	national	PROPN
ajlm-2018	138	2	association	association	PROPN
ajlm-2018	138	3	for	for	ADP
ajlm-2018	138	4	clean	clean	ADJ
ajlm-2018	138	5	air	air	NOUN
ajlm-2018	138	6	(	(	PUNCT
ajlm-2018	138	7	naca	naca	NOUN
ajlm-2018	138	8	)	)	PUNCT
ajlm-2018	138	9	.	.	PUNCT
ajlm-2018	139	1	south	south	PROPN
ajlm-2018	139	2	south	south	PROPN
ajlm-2018	139	3	zone	zone	PROPN
ajlm-2018	139	4	summary	summary	NOUN
ajlm-2018	139	5	sheet	sheet	NOUN
ajlm-2018	139	6	.	.	PUNCT
ajlm-2018	140	1	nigeria	nigeria	PROPN
ajlm-2018	140	2	hiv	hiv	PROPN
ajlm-2018	140	3	/	/	SYM
ajlm-2018	140	4	aids	aids	PROPN
ajlm-2018	140	5	indicator	indicator	NOUN
ajlm-2018	140	6	and	and	CCONJ
ajlm-2018	140	7	impact	impact	NOUN
ajlm-2018	140	8	survey	survey	NOUN
ajlm-2018	140	9	.	.	PUNCT
ajlm-2018	141	1	naiis	naiis	ADJ
ajlm-2018	141	2	preliminary	preliminary	ADJ
ajlm-2018	141	3	findings	finding	NOUN
ajlm-2018	141	4	,	,	PUNCT
ajlm-2018	141	5	south	south	PROPN
ajlm-2018	141	6	south	south	PROPN
ajlm-2018	141	7	zone	zone	NOUN
ajlm-2018	142	1	[	[	X
ajlm-2018	142	2	homepage	homepage	NOUN
ajlm-2018	142	3	on	on	ADP
ajlm-2018	142	4	the	the	DET
ajlm-2018	142	5	internet	internet	NOUN
ajlm-2018	142	6	]	]	PUNCT
ajlm-2018	142	7	.	.	PUNCT
ajlm-2018	143	1	2019	2019	NUM
ajlm-2018	143	2	;	;	PUNCT
ajlm-2018	144	1	p.	p.	NOUN
ajlm-2018	144	2	1–5	1–5	NUM
ajlm-2018	144	3	.	.	PUNCT
ajlm-2018	145	1	jani	jani	PROPN
ajlm-2018	145	2	c	c	PROPN
ajlm-2018	145	3	,	,	PUNCT
ajlm-2018	145	4	patel	patel	PROPN
ajlm-2018	145	5	k	k	PROPN
ajlm-2018	145	6	,	,	PUNCT
ajlm-2018	145	7	walker	walker	PROPN
ajlm-2018	145	8	a	a	PROPN
ajlm-2018	145	9	,	,	PUNCT
ajlm-2018	145	10	et	et	PROPN
ajlm-2018	145	11	al	al	PROPN
ajlm-2018	145	12	.	.	PUNCT
ajlm-2018	146	1	trends	trend	NOUN
ajlm-2018	146	2	of	of	ADP
ajlm-2018	146	3	hiv	hiv	PROPN
ajlm-2018	146	4	mortality	mortality	NOUN
ajlm-2018	146	5	between	between	ADP
ajlm-2018	146	6	2001	2001	NUM
ajlm-2018	146	7	and	and	CCONJ
ajlm-2018	146	8	2018	2018	NUM
ajlm-2018	146	9	:	:	PUNCT
ajlm-2018	146	10	an	an	DET
ajlm-2018	146	11	observational	observational	ADJ
ajlm-2018	146	12	analysis	analysis	NOUN
ajlm-2018	146	13	.	.	PUNCT
ajlm-2018	147	1	trop	trop	X
ajlm-2018	147	2	med	me	VERB
ajlm-2018	147	3	infect	infect	PROPN
ajlm-2018	147	4	dis	dis	PROPN
ajlm-2018	147	5	.	.	PUNCT
ajlm-2018	148	1	2021;6(173):1–14	2021;6(173):1–14	PROPN
ajlm-2018	148	2	.	.	PUNCT
ajlm-2018	149	1	https://doi.org/10.3390%2ftropicalmed6040173	https://doi.org/10.3390%2ftropicalmed6040173	PROPN
ajlm-2018	149	2	fiseha	fiseha	PROPN
ajlm-2018	149	3	t	t	PROPN
ajlm-2018	149	4	,	,	PUNCT
ajlm-2018	149	5	alemu	alemu	PROPN
ajlm-2018	149	6	w	w	PROPN
ajlm-2018	149	7	,	,	PUNCT
ajlm-2018	149	8	dereje	dereje	ADJ
ajlm-2018	149	9	h	h	NOUN
ajlm-2018	149	10	,	,	PUNCT
ajlm-2018	149	11	i	i	PROPN
ajlm-2018	149	12	d	d	PROPN
ajlm-2018	149	13	zt	zt	PROPN
ajlm-2018	149	14	.	.	PUNCT
ajlm-2018	149	15	prevalence	prevalence	NOUN
ajlm-2018	149	16	of	of	ADP
ajlm-2018	149	17	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2018	149	18	among	among	ADP
ajlm-2018	149	19	hiv	hiv	PROPN
ajlm-2018	149	20	-	-	PUNCT
ajlm-2018	149	21	infected	infect	VERB
ajlm-2018	149	22	patients	patient	NOUN
ajlm-2018	149	23	receiving	receive	VERB
ajlm-2018	149	24	combination	combination	NOUN
ajlm-2018	149	25	antiretroviral	antiretroviral	ADJ
ajlm-2018	149	26	therapy	therapy	NOUN
ajlm-2018	149	27	in	in	ADP
ajlm-2018	149	28	north	north	PROPN
ajlm-2018	149	29	shewa	shewa	PROPN
ajlm-2018	149	30	,	,	PUNCT
ajlm-2018	149	31	ethiopia	ethiopia	PROPN
ajlm-2018	149	32	.	.	PUNCT
ajlm-2018	150	1	plos	plos	PROPN
ajlm-2018	150	2	one	one	NUM
ajlm-2018	150	3	.	.	PUNCT
ajlm-2018	151	1	2021;16(4):e00250328	2021;16(4):e00250328	NUM
ajlm-2018	151	2	.	.	PUNCT
ajlm-2018	152	1	ombeni	ombeni	PROPN
ajlm-2018	152	2	w	w	PROPN
ajlm-2018	152	3	,	,	PUNCT
ajlm-2018	152	4	kamuhabwa	kamuhabwa	PROPN
ajlm-2018	152	5	ar	ar	PROPN
ajlm-2018	152	6	.	.	PROPN
ajlm-2018	152	7	lipid	lipid	PROPN
ajlm-2018	152	8	profile	profile	NOUN
ajlm-2018	152	9	in	in	ADP
ajlm-2018	152	10	hiv	hiv	PROPN
ajlm-2018	152	11	-	-	PUNCT
ajlm-2018	152	12	infected	infect	VERB
ajlm-2018	152	13	patients	patient	NOUN
ajlm-2018	152	14	using	use	VERB
ajlm-2018	152	15	first	first	ADJ
ajlm-2018	152	16	-	-	PUNCT
ajlm-2018	152	17	line	line	NOUN
ajlm-2018	152	18	antiretroviral	antiretroviral	ADJ
ajlm-2018	152	19	drugs	drug	NOUN
ajlm-2018	152	20	.	.	PUNCT
ajlm-2018	153	1	j	j	PROPN
ajlm-2018	153	2	int	int	PROPN
ajlm-2018	153	3	assoc	assoc	PROPN
ajlm-2018	153	4	provid	provid	PROPN
ajlm-2018	153	5	aids	aids	PROPN
ajlm-2018	153	6	care	care	PROPN
ajlm-2018	153	7	.	.	PUNCT
ajlm-2018	154	1	2016;15(2):164–171	2016;15(2):164–171	NUM
ajlm-2018	154	2	.	.	PUNCT
ajlm-2018	155	1	https://doi.org/10.1177/2325957415614642	https://doi.org/10.1177/2325957415614642	NOUN
ajlm-2018	155	2	charakida	charakida	PROPN
ajlm-2018	155	3	m	m	PROPN
ajlm-2018	155	4	,	,	PUNCT
ajlm-2018	155	5	donald	donald	PROPN
ajlm-2018	155	6	ae	ae	PROPN
ajlm-2018	155	7	,	,	PUNCT
ajlm-2018	155	8	green	green	PROPN
ajlm-2018	155	9	h	h	PROPN
ajlm-2018	155	10	,	,	PUNCT
ajlm-2018	155	11	et	et	PROPN
ajlm-2018	155	12	al	al	PROPN
ajlm-2018	155	13	.	.	PUNCT
ajlm-2018	156	1	early	early	ADJ
ajlm-2018	156	2	structural	structural	ADJ
ajlm-2018	156	3	and	and	CCONJ
ajlm-2018	156	4	functional	functional	ADJ
ajlm-2018	156	5	changes	change	NOUN
ajlm-2018	156	6	of	of	ADP
ajlm-2018	156	7	the	the	DET
ajlm-2018	156	8	vasculature	vasculature	NOUN
ajlm-2018	156	9	in	in	ADP
ajlm-2018	156	10	hiv	hiv	PROPN
ajlm-2018	156	11	-	-	PUNCT
ajlm-2018	156	12	infected	infect	VERB
ajlm-2018	156	13	children	child	NOUN
ajlm-2018	156	14	impact	impact	NOUN
ajlm-2018	156	15	of	of	ADP
ajlm-2018	156	16	disease	disease	NOUN
ajlm-2018	156	17	and	and	CCONJ
ajlm-2018	156	18	antiretroviral	antiretroviral	ADJ
ajlm-2018	156	19	therapy	therapy	NOUN
ajlm-2018	156	20	.	.	PUNCT
ajlm-2018	157	1	circulation	circulation	NOUN
ajlm-2018	157	2	.	.	PUNCT
ajlm-2018	158	1	2005;112(1):103–109	2005;112(1):103–109	NUM
ajlm-2018	158	2	.	.	PUNCT
ajlm-2018	159	1	https://doi.org/10.1161/circulationaha.104.517144	https://doi.org/10.1161/circulationaha.104.517144	PROPN
ajlm-2018	159	2	amusa	amusa	VERB
ajlm-2018	159	3	g	g	PROPN
ajlm-2018	159	4	,	,	PUNCT
ajlm-2018	159	5	osaigbovo	osaigbovo	PROPN
ajlm-2018	159	6	g	g	PROPN
ajlm-2018	159	7	,	,	PUNCT
ajlm-2018	159	8	imoh	imoh	PROPN
ajlm-2018	159	9	l	l	NOUN
ajlm-2018	159	10	,	,	PUNCT
ajlm-2018	159	11	awokola	awokola	PROPN
ajlm-2018	159	12	b.	b.	PROPN
ajlm-2018	160	1	cardiovascular	cardiovascular	ADJ
ajlm-2018	160	2	risk	risk	NOUN
ajlm-2018	160	3	factors	factor	NOUN
ajlm-2018	160	4	in	in	ADP
ajlm-2018	160	5	hiv	hiv	PROPN
ajlm-2018	160	6	-	-	PUNCT
ajlm-2018	160	7	infected	infect	VERB
ajlm-2018	160	8	adults	adult	NOUN
ajlm-2018	160	9	in	in	ADP
ajlm-2018	160	10	north	north	NOUN
ajlm-2018	160	11	-	-	PUNCT
ajlm-2018	160	12	central	central	NOUN
ajlm-2018	160	13	nigeria	nigeria	PROPN
ajlm-2018	160	14	:	:	PUNCT
ajlm-2018	161	1	prevalence	prevalence	NOUN
ajlm-2018	161	2	,	,	PUNCT
ajlm-2018	161	3	associated	associate	VERB
ajlm-2018	161	4	factors	factor	NOUN
ajlm-2018	161	5	and	and	CCONJ
ajlm-2018	161	6	assessment	assessment	NOUN
ajlm-2018	161	7	of	of	ADP
ajlm-2018	161	8	risk	risk	NOUN
ajlm-2018	161	9	using	use	VERB
ajlm-2018	161	10	framingham	framingham	PROPN
ajlm-2018	161	11	risk	risk	NOUN
ajlm-2018	161	12	score	score	NOUN
ajlm-2018	161	13	preliminary	preliminary	ADJ
ajlm-2018	161	14	results	result	NOUN
ajlm-2018	161	15	from	from	ADP
ajlm-2018	161	16	a	a	DET
ajlm-2018	161	17	survey	survey	NOUN
ajlm-2018	161	18	.	.	PUNCT
ajlm-2018	162	1	j	j	PROPN
ajlm-2018	162	2	biomed	biome	VERB
ajlm-2018	162	3	res	re	NOUN
ajlm-2018	162	4	clin	clin	PROPN
ajlm-2018	162	5	pract	pract	PROPN
ajlm-2018	162	6	.	.	PUNCT
ajlm-2018	163	1	2021;4(1):71–83	2021;4(1):71–83	NUM
ajlm-2018	163	2	.	.	PUNCT
ajlm-2018	164	1	https://doi.org/10.46912/jbrcp.208	https://doi.org/10.46912/jbrcp.208	VERB
ajlm-2018	164	2	oguejiofor	oguejiofor	ADP
ajlm-2018	164	3	o	o	PROPN
ajlm-2018	164	4	,	,	PUNCT
ajlm-2018	164	5	onwukwe	onwukwe	ADJ
ajlm-2018	164	6	c	c	NOUN
ajlm-2018	164	7	,	,	PUNCT
ajlm-2018	164	8	odenigbo	odenigbo	PROPN
ajlm-2018	164	9	cu	cu	PROPN
ajlm-2018	164	10	.	.	PUNCT
ajlm-2018	165	1	dyslipidemia	dyslipidemia	VERB
ajlm-2018	165	2	in	in	ADP
ajlm-2018	165	3	nigeria	nigeria	PROPN
ajlm-2018	165	4	:	:	PUNCT
ajlm-2018	165	5	prevalence	prevalence	NOUN
ajlm-2018	165	6	and	and	CCONJ
ajlm-2018	165	7	pattern	pattern	NOUN
ajlm-2018	165	8	.	.	PUNCT
ajlm-2018	166	1	ann	ann	PROPN
ajlm-2018	166	2	afr	afr	PROPN
ajlm-2018	166	3	med	med	PROPN
ajlm-2018	166	4	.	.	PUNCT
ajlm-2018	167	1	2012;11(4):197–202	2012;11(4):197–202	NUM
ajlm-2018	167	2	.	.	PUNCT
ajlm-2018	168	1	https://doi.org/10.4103/1596-3519.102846	https://doi.org/10.4103/1596-3519.102846	PROPN
ajlm-2018	168	2	armstrong	armstrong	PROPN
ajlm-2018	168	3	c	c	PROPN
ajlm-2018	168	4	,	,	PUNCT
ajlm-2018	168	5	liu	liu	PROPN
ajlm-2018	168	6	e	e	PROPN
ajlm-2018	168	7	,	,	PUNCT
ajlm-2018	168	8	grinspoon	grinspoon	PROPN
ajlm-2018	168	9	s	s	PROPN
ajlm-2018	168	10	,	,	PUNCT
ajlm-2018	168	11	et	et	PROPN
ajlm-2018	168	12	al	al	PROPN
ajlm-2018	168	13	.	.	PROPN
ajlm-2018	168	14	dyslipidemia	dyslipidemia	NOUN
ajlm-2018	168	15	in	in	ADP
ajlm-2018	168	16	an	an	DET
ajlm-2018	168	17	hiv	hiv	NOUN
ajlm-2018	168	18	-	-	PUNCT
ajlm-2018	168	19	positive	positive	ADJ
ajlm-2018	168	20	,	,	PUNCT
ajlm-2018	168	21	antiretroviral	antiretroviral	ADJ
ajlm-2018	168	22	treatment	treatment	NOUN
ajlm-2018	168	23	-	-	PUNCT
ajlm-2018	168	24	naïve	naïve	ADJ
ajlm-2018	168	25	population	population	NOUN
ajlm-2018	168	26	in	in	ADP
ajlm-2018	168	27	dar	dar	PROPN
ajlm-2018	168	28	es	es	PROPN
ajlm-2018	168	29	salaam	salaam	PROPN
ajlm-2018	168	30	,	,	PUNCT
ajlm-2018	168	31	tanzania	tanzania	PROPN
ajlm-2018	168	32	catharina	catharina	PROPN
ajlm-2018	168	33	.	.	PUNCT
ajlm-2018	169	1	j	j	PROPN
ajlm-2018	169	2	acquir	acquir	PROPN
ajlm-2018	169	3	immune	immune	VERB
ajlm-2018	169	4	defic	defic	ADJ
ajlm-2018	169	5	syndr	syndr	NOUN
ajlm-2018	169	6	.	.	PUNCT
ajlm-2018	170	1	2012;57(2):141–145	2012;57(2):141–145	X
ajlm-2018	170	2	.	.	PUNCT
ajlm-2018	171	1	https://doi.org/10.1097%2fqai.0b013e318219a3d1	https://doi.org/10.1097%2fqai.0b013e318219a3d1	AUX
ajlm-2018	171	2	yusuf	yusuf	PROPN
ajlm-2018	171	3	r	r	PROPN
ajlm-2018	171	4	,	,	PUNCT
ajlm-2018	171	5	sambo	sambo	PROPN
ajlm-2018	171	6	ai	ai	PROPN
ajlm-2018	171	7	,	,	PUNCT
ajlm-2018	171	8	mohammed	mohammed	PROPN
ajlm-2018	171	9	mh	mh	PROPN
ajlm-2018	171	10	,	,	PUNCT
ajlm-2018	171	11	abdulaziz	abdulaziz	PROPN
ajlm-2018	171	12	h.	h.	PROPN
ajlm-2018	171	13	lipid	lipid	PROPN
ajlm-2018	171	14	profile	profile	NOUN
ajlm-2018	171	15	of	of	ADP
ajlm-2018	171	16	hiv	hiv	PROPN
ajlm-2018	171	17	/	/	SYM
ajlm-2018	171	18	aids	aid	NOUN
ajlm-2018	171	19	patients	patient	NOUN
ajlm-2018	171	20	attending	attend	VERB
ajlm-2018	171	21	antiretroviral	antiretroviral	ADJ
ajlm-2018	171	22	clinic	clinic	NOUN
ajlm-2018	171	23	in	in	ADP
ajlm-2018	171	24	zaria	zaria	PROPN
ajlm-2018	171	25	,	,	PUNCT
ajlm-2018	171	26	north	north	NOUN
ajlm-2018	171	27	-	-	PUNCT
ajlm-2018	171	28	western	western	NOUN
ajlm-2018	171	29	nigeria	nigeria	PROPN
ajlm-2018	171	30	.	.	PUNCT
ajlm-2018	172	1	sub	sub	ADJ
ajlm-2018	172	2	-	-	ADJ
ajlm-2018	172	3	saharan	saharan	ADJ
ajlm-2018	172	4	african	african	PROPN
ajlm-2018	172	5	j	j	PROPN
ajlm-2018	172	6	med	med	PROPN
ajlm-2018	172	7	.	.	PUNCT
ajlm-2018	173	1	2014;1(1):31–35	2014;1(1):31–35	PROPN
ajlm-2018	173	2	.	.	PUNCT
ajlm-2018	174	1	talmud	talmud	PROPN
ajlm-2018	174	2	pj	pj	PROPN
ajlm-2018	174	3	,	,	PUNCT
ajlm-2018	174	4	hawe	hawe	PROPN
ajlm-2018	174	5	e	e	PROPN
ajlm-2018	174	6	,	,	PUNCT
ajlm-2018	174	7	miller	miller	PROPN
ajlm-2018	174	8	gj	gj	PROPN
ajlm-2018	174	9	,	,	PUNCT
ajlm-2018	174	10	humphries	humphries	PROPN
ajlm-2018	174	11	se	se	PROPN
ajlm-2018	174	12	.	.	PUNCT
ajlm-2018	175	1	nonfasting	nonfaste	VERB
ajlm-2018	175	2	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	175	3	b	b	PROPN
ajlm-2018	175	4	and	and	CCONJ
ajlm-2018	175	5	triglyceride	triglyceride	ADJ
ajlm-2018	175	6	levels	level	NOUN
ajlm-2018	175	7	as	as	ADP
ajlm-2018	175	8	a	a	DET
ajlm-2018	175	9	useful	useful	ADJ
ajlm-2018	175	10	predictor	predictor	NOUN
ajlm-2018	175	11	of	of	ADP
ajlm-2018	175	12	coronary	coronary	ADJ
ajlm-2018	175	13	heart	heart	NOUN
ajlm-2018	175	14	disease	disease	NOUN
ajlm-2018	175	15	risk	risk	NOUN
ajlm-2018	175	16	in	in	ADP
ajlm-2018	175	17	.	.	PUNCT
ajlm-2018	176	1	arter	arter	NOUN
ajlm-2018	176	2	thromb	thromb	PROPN
ajlm-2018	176	3	vasc	vasc	PROPN
ajlm-2018	176	4	biol	biol	PROPN
ajlm-2018	176	5	.	.	PUNCT
ajlm-2018	177	1	2002;22:1918–1923	2002;22:1918–1923	NUM
ajlm-2018	177	2	.	.	PUNCT
ajlm-2018	178	1	tuech	tuech	PROPN
ajlm-2018	178	2	l	l	NOUN
ajlm-2018	178	3	,	,	PUNCT
ajlm-2018	178	4	ferrie	ferrie	PROPN
ajlm-2018	178	5	j	j	PROPN
ajlm-2018	178	6	,	,	PUNCT
ajlm-2018	178	7	bonnet	bonnet	NOUN
ajlm-2018	178	8	e	e	NOUN
ajlm-2018	178	9	,	,	PUNCT
ajlm-2018	178	10	et	et	PROPN
ajlm-2018	178	11	al	al	PROPN
ajlm-2018	178	12	.	.	PROPN
ajlm-2018	178	13	markedly	markedly	ADV
ajlm-2018	178	14	increased	increase	VERB
ajlm-2018	178	15	in	in	ADP
ajlm-2018	178	16	hiv	hiv	PROPN
ajlm-2018	178	17	-	-	PUNCT
ajlm-2018	178	18	infected	infect	VERB
ajlm-2018	178	19	patients	patient	NOUN
ajlm-2018	178	20	treated	treat	VERB
ajlm-2018	178	21	with	with	ADP
ajlm-2018	178	22	protease	protease	NOUN
ajlm-2018	178	23	inhibitors	inhibitor	NOUN
ajlm-2018	178	24	:	:	PUNCT
ajlm-2018	178	25	association	association	NOUN
ajlm-2018	178	26	with	with	ADP
ajlm-2018	178	27	the	the	DET
ajlm-2018	178	28	development	development	NOUN
ajlm-2018	178	29	of	of	ADP
ajlm-2018	178	30	lipodystrophy	lipodystrophy	NOUN
ajlm-2018	178	31	.	.	PUNCT
ajlm-2018	179	1	2001;86(1):296–302	2001;86(1):296–302	X
ajlm-2018	179	2	.	.	PUNCT
ajlm-2018	180	1	adiels	adiels	PROPN
ajlm-2018	180	2	m	m	PROPN
ajlm-2018	180	3	,	,	PUNCT
ajlm-2018	180	4	taskinen	taskinen	PROPN
ajlm-2018	180	5	m	m	PROPN
ajlm-2018	180	6	-	-	PUNCT
ajlm-2018	180	7	r	r	NOUN
ajlm-2018	180	8	,	,	PUNCT
ajlm-2018	180	9	björnson	björnson	NOUN
ajlm-2018	180	10	e	e	NOUN
ajlm-2018	180	11	,	,	PUNCT
ajlm-2018	180	12	et	et	PROPN
ajlm-2018	180	13	al	al	PROPN
ajlm-2018	180	14	.	.	PROPN
ajlm-2018	180	15	role	role	NOUN
ajlm-2018	180	16	of	of	ADP
ajlm-2018	180	17	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	180	18	c	c	PROPN
ajlm-2018	180	19	-	-	PUNCT
ajlm-2018	180	20	iii	iii	NUM
ajlm-2018	180	21	overproduction	overproduction	NOUN
ajlm-2018	180	22	in	in	ADP
ajlm-2018	180	23	diabetic	diabetic	ADJ
ajlm-2018	180	24	dyslipidaemia	dyslipidaemia	PROPN
ajlm-2018	180	25	.	.	PUNCT
ajlm-2018	181	1	diabetes	diabetes	VERB
ajlm-2018	181	2	obes	obes	PRON
ajlm-2018	181	3	metab	metab	NOUN
ajlm-2018	181	4	.	.	PUNCT
ajlm-2018	182	1	2019;21(8):1861–1870	2019;21(8):1861–1870	NUM
ajlm-2018	182	2	.	.	PUNCT
ajlm-2018	183	1	malavazi	malavazi	PROPN
ajlm-2018	183	2	i	i	PRON
ajlm-2018	183	3	,	,	PUNCT
ajlm-2018	183	4	abrao	abrao	ADP
ajlm-2018	183	5	ep	ep	PROPN
ajlm-2018	183	6	,	,	PUNCT
ajlm-2018	183	7	mikawa	mikawa	PROPN
ajlm-2018	183	8	ay	ay	PROPN
ajlm-2018	183	9	,	,	PUNCT
ajlm-2018	183	10	landgraf	landgraf	PROPN
ajlm-2018	183	11	vo	vo	NOUN
ajlm-2018	183	12	,	,	PUNCT
ajlm-2018	183	13	costa	costa	PROPN
ajlm-2018	183	14	,	,	PUNCT
ajlm-2018	183	15	da	da	PROPN
ajlm-2018	183	16	pi	pi	NOUN
ajlm-2018	183	17	.	.	PUNCT
ajlm-2018	184	1	abnormalities	abnormality	NOUN
ajlm-2018	184	2	in	in	ADP
ajlm-2018	184	3	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	184	4	and	and	CCONJ
ajlm-2018	184	5	lipid	lipid	NOUN
ajlm-2018	184	6	levels	level	NOUN
ajlm-2018	184	7	in	in	ADP
ajlm-2018	184	8	an	an	DET
ajlm-2018	184	9	hiv	hiv	NOUN
ajlm-2018	184	10	-	-	PUNCT
ajlm-2018	184	11	infected	infect	VERB
ajlm-2018	184	12	brazilian	brazilian	ADJ
ajlm-2018	184	13	population	population	NOUN
ajlm-2018	184	14	under	under	ADP
ajlm-2018	184	15	different	different	ADJ
ajlm-2018	184	16	treatment	treatment	NOUN
ajlm-2018	184	17	profiles	profile	NOUN
ajlm-2018	184	18	:	:	PUNCT
ajlm-2018	184	19	the	the	DET
ajlm-2018	184	20	relevance	relevance	NOUN
ajlm-2018	184	21	of	of	ADP
ajlm-2018	184	22	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	184	23	e	e	NOUN
ajlm-2018	184	24	genotypes	genotype	NOUN
ajlm-2018	184	25	and	and	CCONJ
ajlm-2018	184	26	immunol	immunol	NOUN
ajlm-2018	184	27	.	.	PUNCT
ajlm-2018	185	1	clin	clin	PROPN
ajlm-2018	185	2	chem	chem	NOUN
ajlm-2018	185	3	lab	lab	NOUN
ajlm-2018	185	4	med	me	VERB
ajlm-2018	185	5	.	.	PUNCT
ajlm-2018	186	1	2004;42(5):525–532	2004;42(5):525–532	X
ajlm-2018	186	2	.	.	PUNCT
ajlm-2018	186	3	harchaoui	harchaoui	PROPN
ajlm-2018	186	4	kel	kel	PROPN
ajlm-2018	186	5	,	,	PUNCT
ajlm-2018	186	6	visser	visser	PROPN
ajlm-2018	186	7	me	i	PRON
ajlm-2018	186	8	,	,	PUNCT
ajlm-2018	186	9	kastelein	kastelein	PROPN
ajlm-2018	186	10	jjp	jjp	PROPN
ajlm-2018	186	11	,	,	PUNCT
ajlm-2018	186	12	stroes	stroe	NOUN
ajlm-2018	186	13	es	es	NOUN
ajlm-2018	186	14	,	,	PUNCT
ajlm-2018	186	15	dallinga	dallinga	NOUN
ajlm-2018	186	16	-	-	PUNCT
ajlm-2018	186	17	thie	thie	NOUN
ajlm-2018	186	18	gm	gm	PROPN
ajlm-2018	186	19	.	.	PUNCT
ajlm-2018	186	20	triglycerides	triglyceride	NOUN
ajlm-2018	186	21	and	and	CCONJ
ajlm-2018	186	22	cardiovascular	cardiovascular	ADJ
ajlm-2018	186	23	risk	risk	NOUN
ajlm-2018	186	24	.	.	PUNCT
ajlm-2018	187	1	curr	curr	PROPN
ajlm-2018	187	2	cardiol	cardiol	PROPN
ajlm-2018	187	3	rev	rev	PROPN
ajlm-2018	187	4	.	.	PROPN
ajlm-2018	187	5	2009;5:216–222	2009;5:216–222	NUM
ajlm-2018	187	6	.	.	PUNCT
ajlm-2018	188	1	kuhlmann	kuhlmann	PROPN
ajlm-2018	188	2	i	i	PRON
ajlm-2018	188	3	,	,	PUNCT
ajlm-2018	188	4	minihane	minihane	PROPN
ajlm-2018	188	5	am	am	NOUN
ajlm-2018	188	6	,	,	PUNCT
ajlm-2018	188	7	huebbe	huebbe	NOUN
ajlm-2018	188	8	p	p	X
ajlm-2018	188	9	,	,	PUNCT
ajlm-2018	188	10	nebel	nebel	PROPN
ajlm-2018	188	11	a	a	PROPN
ajlm-2018	188	12	,	,	PUNCT
ajlm-2018	188	13	rimbach	rimbach	PROPN
ajlm-2018	188	14	g.	g.	PROPN
ajlm-2018	188	15	apolipoprotein	apolipoprotein	VERB
ajlm-2018	188	16	e	e	PROPN
ajlm-2018	188	17	genotype	genotype	NOUN
ajlm-2018	188	18	and	and	CCONJ
ajlm-2018	188	19	hepatitis	hepatitis	NOUN
ajlm-2018	188	20	c	c	NOUN
ajlm-2018	188	21	,	,	PUNCT
ajlm-2018	188	22	hiv	hiv	PROPN
ajlm-2018	188	23	and	and	CCONJ
ajlm-2018	188	24	herpes	herpe	NOUN
ajlm-2018	188	25	simplex	simplex	NOUN
ajlm-2018	188	26	disease	disease	NOUN
ajlm-2018	188	27	risk	risk	NOUN
ajlm-2018	188	28	:	:	PUNCT
ajlm-2018	188	29	a	a	DET
ajlm-2018	188	30	literature	literature	NOUN
ajlm-2018	188	31	review	review	NOUN
ajlm-2018	188	32	.	.	PUNCT
ajlm-2018	189	1	lipids	lipids	ADP
ajlm-2018	189	2	health	health	NOUN
ajlm-2018	189	3	dis	dis	PROPN
ajlm-2018	189	4	.	.	PUNCT
ajlm-2018	190	1	2010;9(8):1–14	2010;9(8):1–14	X
ajlm-2018	190	2	.	.	PUNCT
ajlm-2018	190	3	agiresaasi	agiresaasi	PROPN
ajlm-2018	190	4	a	a	PRON
ajlm-2018	190	5	,	,	PUNCT
ajlm-2018	190	6	nassanga	nassanga	ADV
ajlm-2018	190	7	g	g	PROPN
ajlm-2018	190	8	,	,	PUNCT
ajlm-2018	190	9	tumwesigye	tumwesigye	NOUN
ajlm-2018	190	10	nm	nm	NOUN
ajlm-2018	190	11	.	.	PUNCT
ajlm-2018	190	12	excessive	excessive	ADJ
ajlm-2018	190	13	alcohol	alcohol	NOUN
ajlm-2018	190	14	use	use	NOUN
ajlm-2018	190	15	and	and	CCONJ
ajlm-2018	190	16	its	its	PRON
ajlm-2018	190	17	negative	negative	ADJ
ajlm-2018	190	18	consequences	consequence	NOUN
ajlm-2018	190	19	among	among	ADP
ajlm-2018	190	20	women	woman	NOUN
ajlm-2018	190	21	of	of	ADP
ajlm-2018	190	22	child	child	NOUN
ajlm-2018	190	23	-	-	PUNCT
ajlm-2018	190	24	bearing	bear	VERB
ajlm-2018	190	25	age	age	NOUN
ajlm-2018	190	26	in	in	ADP
ajlm-2018	190	27	africa	africa	PROPN
ajlm-2018	190	28	:	:	PUNCT
ajlm-2018	190	29	a	a	DET
ajlm-2018	190	30	systematic	systematic	ADJ
ajlm-2018	190	31	review	review	NOUN
ajlm-2018	190	32	.	.	PUNCT
ajlm-2018	191	1	hsoa	hsoa	PROPN
ajlm-2018	192	1	j	j	PROPN
ajlm-2018	192	2	alcohol	alcohol	PROPN
ajlm-2018	192	3	drug	drug	NOUN
ajlm-2018	192	4	abus	abus	NOUN
ajlm-2018	192	5	subst	subst	NOUN
ajlm-2018	192	6	depend	depend	VERB
ajlm-2018	192	7	.	.	PUNCT
ajlm-2018	193	1	2021;7(25):2–8	2021;7(25):2–8	X
ajlm-2018	193	2	.	.	PUNCT
ajlm-2018	194	1	https://doi.org/10.24966/adsd-9594/100025	https://doi.org/10.24966/adsd-9594/100025	PROPN
ajlm-2018	194	2	federal	federal	PROPN
ajlm-2018	194	3	ministry	ministry	PROPN
ajlm-2018	194	4	of	of	ADP
ajlm-2018	194	5	health	health	PROPN
ajlm-2018	194	6	(	(	PUNCT
ajlm-2018	194	7	fmoh	fmoh	NOUN
ajlm-2018	194	8	)	)	PUNCT
ajlm-2018	194	9	,	,	PUNCT
ajlm-2018	194	10	nigeria	nigeria	PROPN
ajlm-2018	194	11	.	.	PUNCT
ajlm-2018	195	1	national	national	PROPN
ajlm-2018	195	2	aids	aids	PROPN
ajlm-2018	195	3	,	,	PUNCT
ajlm-2018	195	4	viral	viral	ADJ
ajlm-2018	195	5	hepatitis	hepatitis	NOUN
ajlm-2018	195	6	and	and	CCONJ
ajlm-2018	195	7	stis	stis	PROPN
ajlm-2018	195	8	control	control	NOUN
ajlm-2018	195	9	programme	programme	NOUN
ajlm-2018	195	10	(	(	PUNCT
ajlm-2018	195	11	nascp	nascp	ADJ
ajlm-2018	195	12	)	)	PUNCT
ajlm-2018	195	13	,	,	PUNCT
ajlm-2018	195	14	nigeria	nigeria	PROPN
ajlm-2018	195	15	:	:	PUNCT
ajlm-2018	195	16	national	national	ADJ
ajlm-2018	195	17	guidelines	guideline	NOUN
ajlm-2018	195	18	for	for	ADP
ajlm-2018	195	19	hiv	hiv	PROPN
ajlm-2018	195	20	testing	testing	NOUN
ajlm-2018	195	21	services	service	NOUN
ajlm-2018	195	22	,	,	PUNCT
ajlm-2018	195	23	2017	2017	NUM
ajlm-2018	195	24	;	;	PUNCT
ajlm-2018	195	25	p.	p.	NOUN
ajlm-2018	195	26	1–84	1–84	PROPN
ajlm-2018	195	27	.	.	PUNCT
ajlm-2018	196	1	allan	allan	PROPN
ajlm-2018	196	2	cc	cc	PROPN
ajlm-2018	196	3	,	,	PUNCT
ajlm-2018	196	4	poon	poon	NOUN
ajlm-2018	196	5	ls	ls	PROPN
ajlm-2018	196	6	,	,	PUNCT
ajlm-2018	196	7	chan	chan	PROPN
ajlm-2018	196	8	csg	csg	PROPN
ajlm-2018	196	9	,	,	PUNCT
ajlm-2018	196	10	richmond	richmond	PROPN
ajlm-2018	196	11	w	w	PROPN
ajlm-2018	196	12	,	,	PUNCT
ajlm-2018	196	13	fu	fu	ADJ
ajlm-2018	196	14	pc	pc	NOUN
ajlm-2018	196	15	.	.	PUNCT
ajlm-2018	197	1	enzymatic	enzymatic	ADJ
ajlm-2018	197	2	determination	determination	NOUN
ajlm-2018	197	3	of	of	ADP
ajlm-2018	197	4	total	total	ADJ
ajlm-2018	197	5	serum	serum	NOUN
ajlm-2018	197	6	cholesterol	cholesterol	PROPN
ajlm-2018	197	7	.	.	PUNCT
ajlm-2018	198	1	clin	clin	PROPN
ajlm-2018	198	2	chem	chem	NOUN
ajlm-2018	198	3	.	.	PUNCT
ajlm-2018	199	1	1974;20(4):470–475	1974;20(4):470–475	NUM
ajlm-2018	199	2	.	.	PUNCT
ajlm-2018	200	1	bucolo	bucolo	PROPN
ajlm-2018	200	2	g	g	PROPN
ajlm-2018	200	3	,	,	PUNCT
ajlm-2018	200	4	david	david	PROPN
ajlm-2018	200	5	h.	h.	PROPN
ajlm-2018	200	6	quantitative	quantitative	ADJ
ajlm-2018	200	7	determination	determination	NOUN
ajlm-2018	200	8	of	of	ADP
ajlm-2018	200	9	serum	serum	NOUN
ajlm-2018	200	10	triglycerides	triglyceride	NOUN
ajlm-2018	200	11	by	by	ADP
ajlm-2018	200	12	the	the	DET
ajlm-2018	200	13	use	use	NOUN
ajlm-2018	200	14	of	of	ADP
ajlm-2018	200	15	enzymes	enzyme	NOUN
ajlm-2018	200	16	.	.	PUNCT
ajlm-2018	201	1	clin	clin	PROPN
ajlm-2018	201	2	chem	chem	PROPN
ajlm-2018	201	3	.	.	PUNCT
ajlm-2018	202	1	1973;19(5):476–482	1973;19(5):476–482	X
ajlm-2018	202	2	.	.	PROPN
ajlm-2018	202	3	friedewald	friedewald	PROPN
ajlm-2018	202	4	w	w	PROPN
ajlm-2018	202	5	,	,	PUNCT
ajlm-2018	202	6	levy	levy	NOUN
ajlm-2018	202	7	r	r	NOUN
ajlm-2018	202	8	,	,	PUNCT
ajlm-2018	202	9	fredrickson	fredrickson	PROPN
ajlm-2018	202	10	d.	d.	PROPN
ajlm-2018	202	11	estimation	estimation	NOUN
ajlm-2018	202	12	of	of	ADP
ajlm-2018	202	13	the	the	DET
ajlm-2018	202	14	concentration	concentration	NOUN
ajlm-2018	202	15	of	of	ADP
ajlm-2018	202	16	low	low	ADJ
ajlm-2018	202	17	-	-	PUNCT
ajlm-2018	202	18	density	density	NOUN
ajlm-2018	202	19	lipoprotein	lipoprotein	ADJ
ajlm-2018	202	20	cholesterol	cholesterol	NOUN
ajlm-2018	202	21	in	in	ADP
ajlm-2018	202	22	plasma	plasma	NOUN
ajlm-2018	202	23	,	,	PUNCT
ajlm-2018	202	24	without	without	ADP
ajlm-2018	202	25	the	the	DET
ajlm-2018	202	26	use	use	NOUN
ajlm-2018	202	27	of	of	ADP
ajlm-2018	202	28	the	the	DET
ajlm-2018	202	29	preparative	preparative	ADJ
ajlm-2018	202	30	ultracentrifuge	ultracentrifuge	NOUN
ajlm-2018	202	31	.	.	PUNCT
ajlm-2018	203	1	clin	clin	PROPN
ajlm-2018	203	2	chem	chem	PROPN
ajlm-2018	203	3	.	.	PUNCT
ajlm-2018	204	1	1972;18(6):499–502	1972;18(6):499–502	NUM
ajlm-2018	204	2	.	.	PUNCT
ajlm-2018	204	3	zoest	zoest	PROPN
ajlm-2018	205	1	ra	ra	PROPN
ajlm-2018	205	2	van	van	PROPN
ajlm-2018	205	3	,	,	PUNCT
ajlm-2018	205	4	born	bear	VERB
ajlm-2018	205	5	bh	bh	PROPN
ajlm-2018	205	6	van	van	PROPN
ajlm-2018	205	7	den	den	PROPN
ajlm-2018	205	8	,	,	PUNCT
ajlm-2018	205	9	reiss	reiss	ADJ
ajlm-2018	205	10	p.	p.	NOUN
ajlm-2018	205	11	hypertension	hypertension	NOUN
ajlm-2018	205	12	in	in	ADP
ajlm-2018	205	13	people	people	NOUN
ajlm-2018	205	14	living	live	VERB
ajlm-2018	205	15	with	with	ADP
ajlm-2018	205	16	hiv	hiv	PROPN
ajlm-2018	205	17	.	.	PUNCT
ajlm-2018	206	1	curr	curr	PROPN
ajlm-2018	206	2	opin	opin	PROPN
ajlm-2018	206	3	hiv	hiv	PROPN
ajlm-2018	206	4	aids	aids	PROPN
ajlm-2018	206	5	.	.	PUNCT
ajlm-2018	207	1	2017;12(6):513–522	2017;12(6):513–522	NUM
ajlm-2018	207	2	.	.	PUNCT
ajlm-2018	207	3	fiseha	fiseha	PROPN
ajlm-2018	207	4	t	t	PROPN
ajlm-2018	207	5	,	,	PUNCT
ajlm-2018	207	6	belete	belete	PROPN
ajlm-2018	207	7	ag	ag	PROPN
ajlm-2018	207	8	,	,	PUNCT
ajlm-2018	207	9	dereje	dereje	ADJ
ajlm-2018	207	10	h	h	NOUN
ajlm-2018	207	11	,	,	PUNCT
ajlm-2018	207	12	dires	dires	PROPN
ajlm-2018	207	13	a.	a.	NOUN
ajlm-2018	207	14	hypertension	hypertension	NOUN
ajlm-2018	207	15	in	in	ADP
ajlm-2018	207	16	hiv	hiv	PROPN
ajlm-2018	207	17	-	-	PUNCT
ajlm-2018	207	18	infected	infect	VERB
ajlm-2018	207	19	patients	patient	NOUN
ajlm-2018	207	20	receiving	receive	VERB
ajlm-2018	207	21	antiretroviral	antiretroviral	ADJ
ajlm-2018	207	22	therapy	therapy	NOUN
ajlm-2018	207	23	in	in	ADP
ajlm-2018	207	24	northeast	northeast	ADJ
ajlm-2018	207	25	ethiopia	ethiopia	PROPN
ajlm-2018	207	26	.	.	PUNCT
ajlm-2018	208	1	int	int	PROPN
ajlm-2018	208	2	j	j	PROPN
ajlm-2018	208	3	hypertens	hyperten	NOUN
ajlm-2018	208	4	.	.	PUNCT
ajlm-2018	209	1	2019;2019:4103604	2019;2019:4103604	NUM
ajlm-2018	209	2	.	.	PUNCT
ajlm-2018	210	1	https://doi.org/10.1155/2019/4103604	https://doi.org/10.1155/2019/4103604	PROPN
ajlm-2018	210	2	lubega	lubega	PROPN
ajlm-2018	210	3	g	g	PROPN
ajlm-2018	210	4	,	,	PUNCT
ajlm-2018	210	5	mayanja	mayanja	PROPN
ajlm-2018	210	6	b	b	NUM
ajlm-2018	210	7	,	,	PUNCT
ajlm-2018	210	8	lutaakome	lutaakome	PROPN
ajlm-2018	210	9	j	j	PROPN
ajlm-2018	210	10	,	,	PUNCT
ajlm-2018	210	11	et	et	PROPN
ajlm-2018	210	12	al	al	PROPN
ajlm-2018	210	13	.	.	PUNCT
ajlm-2018	211	1	prevalence	prevalence	NOUN
ajlm-2018	211	2	and	and	CCONJ
ajlm-2018	211	3	factors	factor	NOUN
ajlm-2018	211	4	associated	associate	VERB
ajlm-2018	211	5	with	with	ADP
ajlm-2018	211	6	hypertension	hypertension	NOUN
ajlm-2018	211	7	among	among	ADP
ajlm-2018	211	8	people	people	NOUN
ajlm-2018	211	9	living	live	VERB
ajlm-2018	211	10	with	with	ADP
ajlm-2018	211	11	hiv	hiv	PROPN
ajlm-2018	211	12	/	/	SYM
ajlm-2018	211	13	aids	aids	PROPN
ajlm-2018	211	14	on	on	ADP
ajlm-2018	211	15	antiretroviral	antiretroviral	ADJ
ajlm-2018	211	16	therapy	therapy	NOUN
ajlm-2018	211	17	in	in	ADP
ajlm-2018	211	18	uganda	uganda	PROPN
ajlm-2018	211	19	.	.	PUNCT
ajlm-2018	212	1	pan	pan	PROPN
ajlm-2018	212	2	afr	afr	PROPN
ajlm-2018	212	3	med	med	PROPN
ajlm-2018	212	4	j.	j.	PROPN
ajlm-2018	212	5	2021;38:216	2021;38:216	PROPN
ajlm-2018	212	6	.	.	PUNCT
ajlm-2018	213	1	https://doi.org/10.11604/pamj.2021.38.216.28034	https://doi.org/10.11604/pamj.2021.38.216.28034	NOUN
ajlm-2018	213	2	masenga	masenga	NOUN
ajlm-2018	213	3	sk	sk	PROPN
ajlm-2018	213	4	,	,	PUNCT
ajlm-2018	213	5	hamooya	hamooya	PROPN
ajlm-2018	213	6	bm	bm	PROPN
ajlm-2018	213	7	,	,	PUNCT
ajlm-2018	213	8	nzala	nzala	PROPN
ajlm-2018	213	9	s	s	PROPN
ajlm-2018	213	10	,	,	PUNCT
ajlm-2018	213	11	et	et	PROPN
ajlm-2018	213	12	al	al	PROPN
ajlm-2018	213	13	.	.	PUNCT
ajlm-2018	213	14	patho	patho	PROPN
ajlm-2018	213	15	-	-	PUNCT
ajlm-2018	213	16	immune	immune	ADJ
ajlm-2018	213	17	mechanisms	mechanism	NOUN
ajlm-2018	213	18	of	of	ADP
ajlm-2018	213	19	hypertension	hypertension	NOUN
ajlm-2018	213	20	in	in	ADP
ajlm-2018	213	21	hiv	hiv	PROPN
ajlm-2018	213	22	:	:	PUNCT
ajlm-2018	213	23	a	a	DET
ajlm-2018	213	24	systematic	systematic	ADJ
ajlm-2018	213	25	and	and	CCONJ
ajlm-2018	213	26	thematic	thematic	ADJ
ajlm-2018	213	27	review	review	NOUN
ajlm-2018	213	28	.	.	PUNCT
ajlm-2018	214	1	curr	curr	PROPN
ajlm-2018	214	2	hypertens	hypertens	PROPN
ajlm-2018	214	3	rep	rep	PROPN
ajlm-2018	214	4	.	.	PROPN
ajlm-2018	214	5	2019;21:56	2019;21:56	NUM
ajlm-2018	214	6	.	.	PUNCT
ajlm-2018	215	1	https://doi.org/10.1007/s11906-019-0956-5	https://doi.org/10.1007/s11906-019-0956-5	PROPN
ajlm-2018	215	2	yano	yano	PROPN
ajlm-2018	215	3	y	y	PROPN
ajlm-2018	215	4	,	,	PUNCT
ajlm-2018	215	5	stamler	stamler	PROPN
ajlm-2018	215	6	j	j	PROPN
ajlm-2018	215	7	,	,	PUNCT
ajlm-2018	215	8	garside	garside	PROPN
ajlm-2018	215	9	db	db	PROPN
ajlm-2018	215	10	,	,	PUNCT
ajlm-2018	215	11	et	et	PROPN
ajlm-2018	215	12	al	al	PROPN
ajlm-2018	215	13	.	.	PROPN
ajlm-2018	215	14	isolated	isolate	VERB
ajlm-2018	215	15	systolic	systolic	ADJ
ajlm-2018	215	16	hypertension	hypertension	NOUN
ajlm-2018	215	17	in	in	ADP
ajlm-2018	215	18	young	young	ADJ
ajlm-2018	215	19	and	and	CCONJ
ajlm-2018	215	20	middle	middle	ADJ
ajlm-2018	215	21	-	-	PUNCT
ajlm-2018	215	22	aged	aged	ADJ
ajlm-2018	215	23	adults	adult	NOUN
ajlm-2018	215	24	and	and	CCONJ
ajlm-2018	215	25	31	31	NUM
ajlm-2018	215	26	-	-	PUNCT
ajlm-2018	215	27	year	year	NOUN
ajlm-2018	215	28	risk	risk	NOUN
ajlm-2018	215	29	for	for	ADP
ajlm-2018	215	30	cardiovascular	cardiovascular	ADJ
ajlm-2018	215	31	mortality	mortality	NOUN
ajlm-2018	215	32	:	:	PUNCT
ajlm-2018	215	33	the	the	DET
ajlm-2018	215	34	chicago	chicago	PROPN
ajlm-2018	215	35	heart	heart	PROPN
ajlm-2018	215	36	association	association	PROPN
ajlm-2018	215	37	detection	detection	NOUN
ajlm-2018	215	38	project	project	NOUN
ajlm-2018	215	39	in	in	ADP
ajlm-2018	215	40	industry	industry	NOUN
ajlm-2018	215	41	study	study	NOUN
ajlm-2018	215	42	.	.	PUNCT
ajlm-2018	216	1	j	j	PROPN
ajlm-2018	216	2	am	be	AUX
ajlm-2018	216	3	coll	coll	PROPN
ajlm-2018	216	4	cardiol	cardiol	PROPN
ajlm-2018	216	5	2015;65(4):327–335	2015;65(4):327–335	PROPN
ajlm-2018	216	6	.	.	PUNCT
ajlm-2018	216	7	https://doi.org/10.1016/j.jacc.2014.10.060	https://doi.org/10.1016/j.jacc.2014.10.060	PROPN
ajlm-2018	217	1	xu	xu	PROPN
ajlm-2018	217	2	c	c	X
ajlm-2018	217	3	,	,	PUNCT
ajlm-2018	217	4	sun	sun	PROPN
ajlm-2018	217	5	z	z	PROPN
ajlm-2018	217	6	,	,	PUNCT
ajlm-2018	217	7	zheng	zheng	PROPN
ajlm-2018	217	8	l.	l.	PROPN
ajlm-2018	217	9	prevalence	prevalence	PROPN
ajlm-2018	217	10	of	of	ADP
ajlm-2018	217	11	and	and	CCONJ
ajlm-2018	217	12	risk	risk	NOUN
ajlm-2018	217	13	factors	factor	NOUN
ajlm-2018	217	14	for	for	ADP
ajlm-2018	217	15	isolated	isolated	ADJ
ajlm-2018	217	16	systolic	systolic	ADJ
ajlm-2018	217	17	hypertension	hypertension	NOUN
ajlm-2018	217	18	in	in	ADP
ajlm-2018	217	19	the	the	DET
ajlm-2018	217	20	rural	rural	ADJ
ajlm-2018	217	21	adult	adult	NOUN
ajlm-2018	217	22	population	population	NOUN
ajlm-2018	217	23	of	of	ADP
ajlm-2018	217	24	liaoning	liaoning	PROPN
ajlm-2018	217	25	province	province	PROPN
ajlm-2018	217	26	,	,	PUNCT
ajlm-2018	217	27	china	china	PROPN
ajlm-2018	217	28	.	.	PUNCT
ajlm-2018	218	1	j	j	PROPN
ajlm-2018	218	2	int	int	PROPN
ajlm-2018	218	3	med	med	PROPN
ajlm-2018	218	4	res	re	NOUN
ajlm-2018	218	5	.	.	PUNCT
ajlm-2018	219	1	2008;36(2):353–356	2008;36(2):353–356	X
ajlm-2018	219	2	.	.	PUNCT
ajlm-2018	219	3	bonnet	bonnet	NOUN
ajlm-2018	219	4	e	e	PROPN
ajlm-2018	219	5	,	,	PUNCT
ajlm-2018	219	6	ruidavets	ruidavets	PROPN
ajlm-2018	219	7	j	j	PROPN
ajlm-2018	219	8	,	,	PUNCT
ajlm-2018	219	9	tuech	tuech	PROPN
ajlm-2018	219	10	j	j	PROPN
ajlm-2018	219	11	,	,	PUNCT
ajlm-2018	219	12	et	et	PROPN
ajlm-2018	219	13	al	al	PROPN
ajlm-2018	219	14	.	.	PROPN
ajlm-2018	220	1	apolipoprotein	apolipoprotein	VERB
ajlm-2018	220	2	c	c	X
ajlm-2018	220	3	-	-	PUNCT
ajlm-2018	220	4	iii	iii	NOUN
ajlm-2018	220	5	and	and	CCONJ
ajlm-2018	220	6	e	e	NOUN
ajlm-2018	220	7	-	-	ADJ
ajlm-2018	220	8	containing	contain	VERB
ajlm-2018	220	9	lipoparticles	lipoparticle	NOUN
ajlm-2018	221	1	are	be	AUX
ajlm-2018	221	2	markedly	markedly	ADV
ajlm-2018	221	3	increased	increase	VERB
ajlm-2018	221	4	in	in	ADP
ajlm-2018	221	5	hiv	hiv	PROPN
ajlm-2018	221	6	-	-	PUNCT
ajlm-2018	221	7	infected	infect	VERB
ajlm-2018	221	8	patients	patient	NOUN
ajlm-2018	221	9	treated	treat	VERB
ajlm-2018	221	10	with	with	ADP
ajlm-2018	221	11	protease	protease	NOUN
ajlm-2018	221	12	inhibitors	inhibitor	NOUN
ajlm-2018	221	13	:	:	PUNCT
ajlm-2018	221	14	association	association	NOUN
ajlm-2018	221	15	with	with	ADP
ajlm-2018	221	16	the	the	DET
ajlm-2018	221	17	development	development	NOUN
ajlm-2018	221	18	of	of	ADP
ajlm-2018	221	19	lipodystrophy	lipodystrophy	NOUN
ajlm-2018	221	20	.	.	PUNCT
ajlm-2018	222	1	j	j	PROPN
ajlm-2018	222	2	clin	clin	PROPN
ajlm-2018	222	3	endocrinol	endocrinol	PROPN
ajlm-2018	222	4	metab	metab	NOUN
ajlm-2018	222	5	.	.	PUNCT
ajlm-2018	223	1	2001;86(1):296–302	2001;86(1):296–302	NUM
ajlm-2018	223	2	.	.	PROPN
ajlm-2018	223	3	luo	luo	PROPN
ajlm-2018	223	4	m	m	PROPN
ajlm-2018	223	5	,	,	PUNCT
ajlm-2018	223	6	peng	peng	PROPN
ajlm-2018	223	7	d.	d.	PROPN
ajlm-2018	223	8	the	the	DET
ajlm-2018	223	9	emerging	emerge	VERB
ajlm-2018	223	10	role	role	NOUN
ajlm-2018	223	11	of	of	ADP
ajlm-2018	223	12	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	223	13	c	c	NOUN
ajlm-2018	223	14	-	-	PUNCT
ajlm-2018	223	15	iii	iii	NOUN
ajlm-2018	223	16	:	:	PUNCT
ajlm-2018	223	17	beyond	beyond	ADP
ajlm-2018	223	18	effects	effect	NOUN
ajlm-2018	223	19	on	on	ADP
ajlm-2018	223	20	triglyceride	triglyceride	ADJ
ajlm-2018	223	21	metabolism	metabolism	NOUN
ajlm-2018	223	22	.	.	PUNCT
ajlm-2018	224	1	lipids	lipids	ADP
ajlm-2018	224	2	health	health	NOUN
ajlm-2018	224	3	dis	dis	PROPN
ajlm-2018	224	4	.	.	PUNCT
ajlm-2018	225	1	2016;15:184	2016;15:184	X
ajlm-2018	225	2	.	.	PUNCT
ajlm-2018	226	1	https://doi.org/10.1186/s12944-016-0352-y	https://doi.org/10.1186/s12944-016-0352-y	VERB
ajlm-2018	226	2	daniyam	daniyam	NOUN
ajlm-2018	226	3	c	c	NOUN
ajlm-2018	226	4	,	,	PUNCT
ajlm-2018	226	5	iroezindu	iroezindu	NOUN
ajlm-2018	226	6	m.	m.	NOUN
ajlm-2018	226	7	lipid	lipid	PROPN
ajlm-2018	226	8	profile	profile	NOUN
ajlm-2018	226	9	of	of	ADP
ajlm-2018	226	10	anti	anti	ADJ
ajlm-2018	226	11	-	-	ADJ
ajlm-2018	226	12	retroviral	retroviral	ADJ
ajlm-2018	226	13	treatment‑naïve	treatment‑naïve	NUM
ajlm-2018	226	14	hiv	hiv	PROPN
ajlm-2018	226	15	-	-	PUNCT
ajlm-2018	226	16	infected	infect	VERB
ajlm-2018	226	17	patients	patient	NOUN
ajlm-2018	226	18	in	in	ADP
ajlm-2018	226	19	jos	jos	PROPN
ajlm-2018	226	20	,	,	PUNCT
ajlm-2018	226	21	nigeria	nigeria	PROPN
ajlm-2018	226	22	.	.	PUNCT
ajlm-2018	227	1	ann	ann	PROPN
ajlm-2018	227	2	med	med	PROPN
ajlm-2018	227	3	heal	heal	PROPN
ajlm-2018	227	4	sci	sci	PROPN
ajlm-2018	227	5	res	re	NOUN
ajlm-2018	227	6	.	.	PUNCT
ajlm-2018	228	1	2013;3(1):26–30	2013;3(1):26–30	NUM
ajlm-2018	228	2	.	.	PUNCT
ajlm-2018	229	1	https://doi.org/10.4103%2f2141-9248.109468	https://doi.org/10.4103%2f2141-9248.109468	PROPN
ajlm-2018	229	2	singh	singh	PROPN
ajlm-2018	229	3	j	j	PROPN
ajlm-2018	229	4	,	,	PUNCT
ajlm-2018	229	5	verma	verma	PROPN
ajlm-2018	229	6	m	m	PROPN
ajlm-2018	229	7	,	,	PUNCT
ajlm-2018	229	8	ghalaut	ghalaut	PROPN
ajlm-2018	229	9	ps	ps	PROPN
ajlm-2018	229	10	,	,	PUNCT
ajlm-2018	229	11	verma	verma	PROPN
ajlm-2018	229	12	r	r	PROPN
ajlm-2018	229	13	,	,	PUNCT
ajlm-2018	229	14	soni	soni	PROPN
ajlm-2018	229	15	a	a	X
ajlm-2018	229	16	,	,	PUNCT
ajlm-2018	229	17	ghalaut	ghalaut	PROPN
ajlm-2018	229	18	vs.	vs.	ADP
ajlm-2018	229	19	alteration	alteration	NOUN
ajlm-2018	229	20	in	in	ADP
ajlm-2018	229	21	lipid	lipid	NOUN
ajlm-2018	229	22	profile	profile	NOUN
ajlm-2018	229	23	in	in	ADP
ajlm-2018	229	24	treatment	treatment	NOUN
ajlm-2018	229	25	-	-	PUNCT
ajlm-2018	229	26	naive	naive	ADJ
ajlm-2018	229	27	hiv	hiv	NOUN
ajlm-2018	229	28	-	-	PUNCT
ajlm-2018	229	29	infected	infect	VERB
ajlm-2018	229	30	patients	patient	NOUN
ajlm-2018	229	31	and	and	CCONJ
ajlm-2018	229	32	changes	change	NOUN
ajlm-2018	229	33	following	follow	VERB
ajlm-2018	229	34	haart	haart	PROPN
ajlm-2018	229	35	initiation	initiation	NOUN
ajlm-2018	229	36	in	in	ADP
ajlm-2018	229	37	haryana	haryana	PROPN
ajlm-2018	229	38	.	.	PUNCT
ajlm-2018	230	1	j	j	PROPN
ajlm-2018	230	2	endocrinol	endocrinol	NOUN
ajlm-2018	230	3	metab	metab	NOUN
ajlm-2018	230	4	.	.	PUNCT
ajlm-2018	231	1	2014;4(1–2):25–31	2014;4(1–2):25–31	NUM
ajlm-2018	231	2	.	.	PUNCT
ajlm-2018	232	1	https://doi.org/10.14740/jem207w	https://doi.org/10.14740/jem207w	PROPN
ajlm-2018	232	2	banerjee	banerjee	PROPN
ajlm-2018	232	3	s	s	PROPN
ajlm-2018	232	4	,	,	PUNCT
ajlm-2018	232	5	mccutchan	mccutchan	PROPN
ajlm-2018	232	6	ja	ja	PROPN
ajlm-2018	232	7	,	,	PUNCT
ajlm-2018	232	8	ances	ance	VERB
ajlm-2018	232	9	bm	bm	PROPN
ajlm-2018	232	10	,	,	PUNCT
ajlm-2018	233	1	et	et	PROPN
ajlm-2018	233	2	al	al	PROPN
ajlm-2018	233	3	.	.	PROPN
ajlm-2018	233	4	hypertriglyceridemia	hypertriglyceridemia	PROPN
ajlm-2018	233	5	in	in	ADP
ajlm-2018	233	6	combination	combination	NOUN
ajlm-2018	233	7	antiretroviral	antiretroviral	ADJ
ajlm-2018	233	8	-	-	PUNCT
ajlm-2018	233	9	treated	treat	VERB
ajlm-2018	233	10	hiv	hiv	PROPN
ajlm-2018	233	11	-	-	PUNCT
ajlm-2018	233	12	positive	positive	ADJ
ajlm-2018	233	13	individuals	individual	NOUN
ajlm-2018	233	14	:	:	PUNCT
ajlm-2018	233	15	potential	potential	ADJ
ajlm-2018	233	16	impact	impact	NOUN
ajlm-2018	233	17	on	on	ADP
ajlm-2018	233	18	hiv	hiv	PROPN
ajlm-2018	233	19	sensory	sensory	ADJ
ajlm-2018	233	20	polyneuropathy	polyneuropathy	NOUN
ajlm-2018	233	21	.	.	PUNCT
ajlm-2018	234	1	aids	aids	PROPN
ajlm-2018	234	2	.	.	PUNCT
ajlm-2018	235	1	2011;25(2):f1	2011;25(2):f1	NUM
ajlm-2018	235	2	–	–	PUNCT
ajlm-2018	235	3	f6	f6	NUM
ajlm-2018	235	4	.	.	PUNCT
ajlm-2018	236	1	https://doi.org/10.1097/qad.0b013e328341dd68	https://doi.org/10.1097/qad.0b013e328341dd68	PRON
ajlm-2018	236	2	limas	lima	NOUN
ajlm-2018	236	3	tg	tg	PROPN
ajlm-2018	236	4	de	de	PROPN
ajlm-2018	236	5	,	,	PUNCT
ajlm-2018	236	6	pinto	pinto	NOUN
ajlm-2018	236	7	gda	gda	PROPN
ajlm-2018	236	8	,	,	PUNCT
ajlm-2018	236	9	marcato	marcato	PROPN
ajlm-2018	236	10	lm	lm	PROPN
ajlm-2018	236	11	,	,	PUNCT
ajlm-2018	236	12	coelho	coelho	PROPN
ajlm-2018	236	13	dr	dr	PROPN
ajlm-2018	236	14	.	.	PROPN
ajlm-2018	236	15	analysis	analysis	NOUN
ajlm-2018	236	16	of	of	ADP
ajlm-2018	236	17	the	the	DET
ajlm-2018	236	18	prevalence	prevalence	NOUN
ajlm-2018	236	19	of	of	ADP
ajlm-2018	236	20	dyslipidemia	dyslipidemia	NOUN
ajlm-2018	236	21	in	in	ADP
ajlm-2018	236	22	individuals	individual	NOUN
ajlm-2018	236	23	with	with	ADP
ajlm-2018	236	24	hiv	hiv	PROPN
ajlm-2018	236	25	and	and	CCONJ
ajlm-2018	236	26	its	its	PRON
ajlm-2018	236	27	association	association	NOUN
ajlm-2018	236	28	with	with	ADP
ajlm-2018	236	29	antiretroviral	antiretroviral	ADJ
ajlm-2018	236	30	therapy	therapy	NOUN
ajlm-2018	236	31	.	.	PUNCT
ajlm-2018	237	1	rev	rev	PROPN
ajlm-2018	237	2	soc	soc	PROPN
ajlm-2018	237	3	bras	bras	PROPN
ajlm-2018	237	4	med	med	ADJ
ajlm-2018	237	5	trop	trop	X
ajlm-2018	237	6	.	.	PUNCT
ajlm-2018	238	1	2014;47(5):547–551	2014;47(5):547–551	NUM
ajlm-2018	238	2	.	.	PUNCT
ajlm-2018	239	1	https://doi.org/10.1590/0037-8682-0128-2014%0amajor	https://doi.org/10.1590/0037-8682-0128-2014%0amajor	PROPN
ajlm-2018	239	2	ude	ude	PROPN
ajlm-2018	239	3	ua	ua	PROPN
ajlm-2018	239	4	,	,	PUNCT
ajlm-2018	239	5	nnamah	nnamah	PROPN
ajlm-2018	239	6	nk	nk	PROPN
ajlm-2018	239	7	,	,	PUNCT
ajlm-2018	239	8	igwe	igwe	PROPN
ajlm-2018	239	9	mn	mn	PROPN
ajlm-2018	239	10	,	,	PUNCT
ajlm-2018	239	11	okonorobo	okonorobo	PROPN
ajlm-2018	239	12	mn	mn	PROPN
ajlm-2018	239	13	,	,	PUNCT
ajlm-2018	239	14	ude	ude	NOUN
ajlm-2018	239	15	ea	ea	NOUN
ajlm-2018	239	16	.	.	PUNCT
ajlm-2018	240	1	fasting	fast	VERB
ajlm-2018	240	2	plasma	plasma	NOUN
ajlm-2018	240	3	glucose	glucose	NOUN
ajlm-2018	240	4	and	and	CCONJ
ajlm-2018	240	5	lipid	lipid	NOUN
ajlm-2018	240	6	profile	profile	NOUN
ajlm-2018	240	7	of	of	ADP
ajlm-2018	240	8	patients	patient	NOUN
ajlm-2018	240	9	with	with	ADP
ajlm-2018	240	10	schizophrenia	schizophrenia	NOUN
ajlm-2018	240	11	and	and	CCONJ
ajlm-2018	240	12	bipolar	bipolar	ADJ
ajlm-2018	240	13	disorder	disorder	NOUN
ajlm-2018	240	14	in	in	ADP
ajlm-2018	240	15	abakaliki	abakaliki	ADJ
ajlm-2018	240	16	,	,	PUNCT
ajlm-2018	240	17	ebonyi	ebonyi	PROPN
ajlm-2018	240	18	state	state	PROPN
ajlm-2018	240	19	nigeria	nigeria	PROPN
ajlm-2018	240	20	:	:	PUNCT
ajlm-2018	240	21	a	a	DET
ajlm-2018	240	22	controlled	control	VERB
ajlm-2018	240	23	study	study	NOUN
ajlm-2018	240	24	.	.	PUNCT
ajlm-2018	241	1	world	world	PROPN
ajlm-2018	241	2	j	j	PROPN
ajlm-2018	241	3	med	med	PROPN
ajlm-2018	241	4	sci	sci	PROPN
ajlm-2018	241	5	.	.	PUNCT
ajlm-2018	242	1	2021;18(4):122–129	2021;18(4):122–129	PROPN
ajlm-2018	242	2	.	.	PUNCT
ajlm-2018	242	3	suastika	suastika	PROPN
ajlm-2018	242	4	k	k	PROPN
ajlm-2018	242	5	,	,	PUNCT
ajlm-2018	242	6	dwipayana	dwipayana	PROPN
ajlm-2018	242	7	p	p	PROPN
ajlm-2018	242	8	,	,	PUNCT
ajlm-2018	242	9	saraswati	saraswati	PROPN
ajlm-2018	242	10	imr	imr	PROPN
ajlm-2018	242	11	,	,	PUNCT
ajlm-2018	242	12	et	et	PROPN
ajlm-2018	242	13	al	al	PROPN
ajlm-2018	242	14	.	.	PROPN
ajlm-2018	242	15	relationship	relationship	NOUN
ajlm-2018	242	16	between	between	ADP
ajlm-2018	242	17	age	age	NOUN
ajlm-2018	242	18	and	and	CCONJ
ajlm-2018	242	19	metabolic	metabolic	NOUN
ajlm-2018	242	20	disorders	disorder	NOUN
ajlm-2018	242	21	in	in	ADP
ajlm-2018	242	22	the	the	DET
ajlm-2018	242	23	population	population	NOUN
ajlm-2018	242	24	of	of	ADP
ajlm-2018	242	25	bali	bali	PROPN
ajlm-2018	242	26	.	.	PUNCT
ajlm-2018	243	1	j	j	PROPN
ajlm-2018	243	2	clin	clin	PROPN
ajlm-2018	243	3	gerontol	gerontol	PROPN
ajlm-2018	243	4	geriatr	geriatr	PROPN
ajlm-2018	243	5	.	.	PUNCT
ajlm-2018	244	1	2011;2(2):47–52	2011;2(2):47–52	NUM
ajlm-2018	244	2	.	.	PUNCT
ajlm-2018	245	1	https://doi.org/10.1016/j.jcgg.2011.03.001	https://doi.org/10.1016/j.jcgg.2011.03.001	PROPN
ajlm-2018	245	2	saito	saito	PROPN
ajlm-2018	245	3	t	t	PROPN
ajlm-2018	245	4	,	,	PUNCT
ajlm-2018	245	5	matsunaga	matsunaga	NOUN
ajlm-2018	245	6	a	a	X
ajlm-2018	245	7	,	,	PUNCT
ajlm-2018	245	8	fukunaga	fukunaga	PROPN
ajlm-2018	245	9	m	m	PRON
ajlm-2018	245	10	,	,	PUNCT
ajlm-2018	245	11	nagahama	nagahama	PROPN
ajlm-2018	245	12	k	k	PROPN
ajlm-2018	245	13	,	,	PUNCT
ajlm-2018	245	14	hara	hara	PROPN
ajlm-2018	245	15	s	s	PROPN
ajlm-2018	245	16	,	,	PUNCT
ajlm-2018	245	17	muso	muso	PROPN
ajlm-2018	245	18	e.	e.	PROPN
ajlm-2018	245	19	apolipoprotein	apolipoprotein	VERB
ajlm-2018	245	20	e	e	VERB
ajlm-2018	245	21	-	-	VERB
ajlm-2018	245	22	related	relate	VERB
ajlm-2018	245	23	glomerular	glomerular	ADJ
ajlm-2018	245	24	disorders	disorder	NOUN
ajlm-2018	245	25	.	.	PUNCT
ajlm-2018	246	1	kidney	kidney	NOUN
ajlm-2018	246	2	int	int	NOUN
ajlm-2018	246	3	.	.	PUNCT
ajlm-2018	247	1	2020;97(2):279–88	2020;97(2):279–88	X
ajlm-2018	247	2	.	.	X
ajlm-2018	247	3	mooijaart	mooijaart	PROPN
ajlm-2018	247	4	sp	sp	PROPN
ajlm-2018	247	5	,	,	PUNCT
ajlm-2018	247	6	berbe´e	berbe´e	PROPN
ajlm-2018	247	7	jfp	jfp	PROPN
ajlm-2018	247	8	,	,	PUNCT
ajlm-2018	247	9	heemst	heemst	PROPN
ajlm-2018	247	10	d	d	PROPN
ajlm-2018	247	11	van	van	PROPN
ajlm-2018	247	12	,	,	PUNCT
ajlm-2018	247	13	et	et	PROPN
ajlm-2018	247	14	al	al	PROPN
ajlm-2018	247	15	.	.	PROPN
ajlm-2018	248	1	apoe	apoe	ADJ
ajlm-2018	248	2	plasma	plasma	NOUN
ajlm-2018	248	3	levels	level	NOUN
ajlm-2018	248	4	and	and	CCONJ
ajlm-2018	248	5	risk	risk	NOUN
ajlm-2018	248	6	of	of	ADP
ajlm-2018	248	7	cardiovascular	cardiovascular	ADJ
ajlm-2018	248	8	mortality	mortality	NOUN
ajlm-2018	248	9	in	in	ADP
ajlm-2018	248	10	old	old	ADJ
ajlm-2018	248	11	age	age	NOUN
ajlm-2018	248	12	.	.	PUNCT
ajlm-2018	249	1	plos	plos	PROPN
ajlm-2018	249	2	med	med	PROPN
ajlm-2018	249	3	.	.	PUNCT
ajlm-2018	249	4	2006;3(6):e176	2006;3(6):e176	NOUN
ajlm-2018	249	5	.	.	PUNCT
ajlm-2018	250	1	https://doi.org/10.1371/journal.pmed.0030176	https://doi.org/10.1371/journal.pmed.0030176	NOUN
ajlm-2018	250	2	ezeugwunne	ezeugwunne	NOUN
ajlm-2018	250	3	ip	ip	NOUN
ajlm-2018	250	4	,	,	PUNCT
ajlm-2018	250	5	chibueze	chibueze	VERB
ajlm-2018	250	6	i	i	PRON
ajlm-2018	250	7	,	,	PUNCT
ajlm-2018	250	8	victor	victor	PROPN
ajlm-2018	250	9	e	e	PROPN
ajlm-2018	250	10	,	,	PUNCT
ajlm-2018	250	11	et	et	PROPN
ajlm-2018	250	12	al	al	PROPN
ajlm-2018	250	13	.	.	PROPN
ajlm-2018	251	1	gender	gender	PROPN
ajlm-2018	251	2	comparison	comparison	NOUN
ajlm-2018	251	3	of	of	ADP
ajlm-2018	251	4	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	251	5	and	and	CCONJ
ajlm-2018	251	6	lipid	lipid	NOUN
ajlm-2018	251	7	profiles	profile	NOUN
ajlm-2018	251	8	in	in	ADP
ajlm-2018	251	9	hiv	hiv	PROPN
ajlm-2018	251	10	seropositives	seropositive	NOUN
ajlm-2018	251	11	in	in	ADP
ajlm-2018	251	12	nauth	nauth	ADJ
ajlm-2018	251	13	nnewi	nnewi	PROPN
ajlm-2018	251	14	,	,	PUNCT
ajlm-2018	251	15	south	south	PROPN
ajlm-2018	251	16	eastern	eastern	PROPN
ajlm-2018	251	17	.	.	PUNCT
ajlm-2018	252	1	j	j	PROPN
ajlm-2018	252	2	biotechnol	biotechnol	PROPN
ajlm-2018	252	3	biochem	biochem	PROPN
ajlm-2018	252	4	.	.	PUNCT
ajlm-2018	253	1	2021;7(5):55–61	2021;7(5):55–61	NUM
ajlm-2018	253	2	.	.	NOUN
ajlm-2018	253	3	ezeugwunne	ezeugwunne	AUX
ajlm-2018	253	4	ip	ip	PROPN
ajlm-2018	253	5	,	,	PUNCT
ajlm-2018	253	6	ogbodo	ogbodo	ADP
ajlm-2018	253	7	ec	ec	PROPN
ajlm-2018	253	8	,	,	PUNCT
ajlm-2018	253	9	analike	analike	ADP
ajlm-2018	253	10	ra	ra	PROPN
ajlm-2018	253	11	,	,	PUNCT
ajlm-2018	253	12	et	et	PROPN
ajlm-2018	253	13	al	al	PROPN
ajlm-2018	253	14	.	.	PUNCT
ajlm-2018	253	15	evaluation	evaluation	NOUN
ajlm-2018	253	16	of	of	ADP
ajlm-2018	253	17	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	253	18	and	and	CCONJ
ajlm-2018	253	19	lipid	lipid	NOUN
ajlm-2018	253	20	profiles	profile	NOUN
ajlm-2018	253	21	in	in	ADP
ajlm-2018	253	22	hiv	hiv	PROPN
ajlm-2018	253	23	symptomatic	symptomatic	ADJ
ajlm-2018	253	24	subjects	subject	NOUN
ajlm-2018	253	25	before	before	ADP
ajlm-2018	253	26	and	and	CCONJ
ajlm-2018	253	27	after	after	ADP
ajlm-2018	253	28	12	12	NUM
ajlm-2018	253	29	months	month	NOUN
ajlm-2018	253	30	antiretroviral	antiretroviral	ADJ
ajlm-2018	253	31	therapy	therapy	NOUN
ajlm-2018	253	32	in	in	ADP
ajlm-2018	253	33	nauth	nauth	NOUN
ajlm-2018	253	34	.	.	PUNCT
ajlm-2018	254	1	j	j	PROPN
ajlm-2018	254	2	med	med	PROPN
ajlm-2018	254	3	lab	lab	PROPN
ajlm-2018	254	4	sci	sci	PROPN
ajlm-2018	254	5	.	.	PUNCT
ajlm-2018	255	1	2019;29(1):52–60	2019;29(1):52–60	X
ajlm-2018	255	2	.	.	PUNCT
ajlm-2018	256	1	https://doi.org/10.5281/zenodo.4010837	https://doi.org/10.5281/zenodo.4010837	PROPN
ajlm-2018	256	2	leeman	leeman	PROPN
ajlm-2018	256	3	h	h	PROPN
ajlm-2018	256	4	,	,	PUNCT
ajlm-2018	256	5	kaminska	kaminska	PROPN
ajlm-2018	256	6	e	e	PROPN
ajlm-2018	256	7	,	,	PUNCT
ajlm-2018	256	8	green	green	PROPN
ajlm-2018	256	9	d	d	PROPN
ajlm-2018	256	10	,	,	PUNCT
ajlm-2018	257	1	et	et	PROPN
ajlm-2018	257	2	al	al	PROPN
ajlm-2018	257	3	.	.	PROPN
ajlm-2018	257	4	serum	serum	PROPN
ajlm-2018	257	5	apolipoprotein	apolipoprotein	ADJ
ajlm-2018	257	6	e	e	PROPN
ajlm-2018	257	7	and	and	CCONJ
ajlm-2018	257	8	other	other	ADJ
ajlm-2018	257	9	inflammatory	inflammatory	ADJ
ajlm-2018	257	10	markers	marker	NOUN
ajlm-2018	257	11	can	can	AUX
ajlm-2018	257	12	identify	identify	VERB
ajlm-2018	257	13	non	non	ADJ
ajlm-2018	257	14	-	-	ADJ
ajlm-2018	257	15	responding	respond	VERB
ajlm-2018	257	16	patients	patient	NOUN
ajlm-2018	257	17	to	to	ADP
ajlm-2018	257	18	a	a	DET
ajlm-2018	257	19	dendritic	dendritic	ADJ
ajlm-2018	257	20	cell	cell	NOUN
ajlm-2018	257	21	.	.	PUNCT
ajlm-2018	258	1	transl	transl	PROPN
ajlm-2018	258	2	oncol	oncol	PROPN
ajlm-2018	258	3	.	.	PUNCT
ajlm-2018	259	1	2019;12(3):397–403	2019;12(3):397–403	X
ajlm-2018	259	2	.	.	X
ajlm-2018	259	3	https://doi.org/10.1016/j.tranon.2018.11.002	https://doi.org/10.1016/j.tranon.2018.11.002	NOUN